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  Lentiviruses can infect postmitotic cells, indicative of a role for the nucleocytoplasmic 
transport machinery. Genome-wide RNA interference screens identified transportin 3 (TNPO3) 
that may regulate human immunodeficiency virus type 1 (HIV-1) preintegration complex (PIC) 
nuclear import but plays no role during murine leukemia virus (MLV) infection. Independently, 
TNPO3  was  shown  to  bind  HIV-1  integrase  (IN),  a  PIC  component,  suggesting  a  potential 
mechanism for nuclear import. We demonstrated direct binding between TNPO3 and several 
retroviral  INs,  which  did  not  correlate  with  TNPO3  dependency  profiles  of  the  respective 
retroviruses.  Infectivity  assays  employing  HIV-1/MLV  chimeric  viruses  ascertained  that  the 
capsid  (CA)  domain,  but  not  IN,  was  the  functional  determinant  of  TNPO3  dependence.  A 
carboxy-terminal  truncation  mutant  of  the  serine-arginine  rich  (SR)  protein  family  member, 
cleavage and polyadenylation specific factor 6 (CPSF6), CPSF6-358, which lacks its RS domain, 
was shown to restrict HIV-1 PIC nuclear import. We demonstrated that CPSF6 interacts with 
HIV-1 CA, and a single point mutation in CA, Asn74Asp (N74D), abolished this interaction. 
N74D also rendered HIV-1 TNPO3-independent and impaired cyclophilin A (CypA) binding to 
CA. The CA:CPSF6 binding interface, as described in a partial co-crystal structure, defined a 
surface  pocket  on  CA  that  faces  the  CA  hexamer:hexamer  interspace.  Infectivities  and  CA 
binding profiles of CA mutants within this pocket or with aberrant CypA-related phenotypes 
were assessed to compare their CPSF6-358 sensitivity and TNPO3 dependence, which largely   iv 
correlated. We showed an overall correlation between the CPSF6/CPSF6-358 binding profiles of 
these HIV-1 CA mutants and their CPSF6-358 sensitivity, whereas TNPO3 binding and TNPO3 
dependence did not correlate. Based on similar infectivity profiles of CA mutants and the loss of 
the RS domain from CPSF6-358 we tested for a direct interaction between CPSF6 and TNPO3. 
We demonstrated specific binding between recombinant TNPO3 and the CPSF6.RS domain. 
Mutagenesis  experiments  suggested  a  multicontact  binding  interface.  The  interaction  was 
downmodulated by Ras-related nuclear protein (Ran)-GTP, indicating that CPSF6 is a bona fide 
import substrate of TNPO3. Our results support a model where TNPO3 regulates nuclear CPSF6 
localization and that in its absence CPSF6 may restrict infection by directly interacting with 
HIV-1 CA at the hexamer:hexamer interface.  
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 A.  Epidemiology and evolutionary origins of HIV/AIDS  
 
Acquired  immunodeficiency  syndrome  (AIDS),  caused  by  the  retrovirus  human 
immunodeficiency virus (HIV), was first described in 1981 when the Center for Disease Control 
reported 5 individual cases of Pneumocystis carinii pneumonia, an opportunistic infection that 
only leads to disease occurrence in immunosuppressed patients. In about 2 years HIV particles 
were isolated from AIDS patients and declared the causative agent of the disease (Gallo et al., 
1983, Barre-Sinousi et al., 1983; Levy et al., 1984). HIV is transmitted via mucosal exposure 
during  sex,  direct  blood-to-blood  contact,  and  also  breastfeeding.  AIDS  progresses  by 
debilitating the adaptive immune defenses of the body by targeted killing of CD4 (cluster of 
differentiation  4  glycoprotein)+  T  lymphocytes,  macrophages  and  dendritic  cells,  and  by 
inflicting  irreversible  damage  to  lymphoid  tissues,  which  leave  immunodeficient  patients 
vulnerable to otherwise benign infections that may become life-threatening if left untreated.  
There are two types of HIV (HIV-1 and HIV-2) identified so far that circulate in the 
human  population.  Molecular  epidemiology  and  viral  phylogeny  analyses  on  viral  genetic 
sequences map the evolutionary roots of the globally circulating virulent HIV-1 group M to Old 
World Pan troglodytes troglodytes populations in West Africa about 100 years ago (Korber et 
al,. 2000), where the related parental primate retrovirus, chimpanzee simian immunodeficiency 
virus (SIVcpz), is believed to have made a zoonotic jump into humans by means of bush meat 
consumption (Gao et al., 1999; Hahn et al,. 2000). HIV-1 subgroups N and O are thought to have 
derived from SIVcpz via independent zoonotic jumps, though HIV-1 Group O also bears some 
resemblance to SIVgor that infects gorillas (Sharp et al., 2011). The more recently discovered 
HIV-1 Group P has a clear independent evolutionary history that can be traced back to SIVgor 
sequences (Sharp et al., 2011). In the case of the less virulent HIV-2 epidemic that is mainly   3 
contained to West Africa, the parental simian virus is believed to be SIVsmm that is endemic to 
sooty mangabees (Figure 1.1) (Hirsch et al; 1989; Sharp et al., 2011). 
 
Figure 1.1 Evolutionary origin of HIV. A simplified schematic of the phylogenetic origins of HIV-1 and 
HIV-2 strains is shown (Adapted from Sharp et al., 2011). 
 
Today, AIDS is a major pandemic associated with high morbidity and mortality. In 2012, 
the  World  Health  Organization  (WHO)  and  United  Nations  AIDS  Programme  (UNAIDS) 
estimated that there were 35.3 million people worldwide infected with HIV-1, of which ~29 
million  live  in  Sub-Saharan  Africa  and  East  and  South  Asia  (WHO/UNAIDS,  2013).  Most 
(95%)  of  the  affected  population  resides  in  low-  and  middle-income  countries  with  limited 
access to medication. It was estimated that AIDS has caused ~1.6 million deaths in 2012, still a 
significant decrease from ~2.3 million in 2005, thanks to the continuous development of post-
exposure prophylactic strategies in the past ~20 years that culminated in a multiple drug regimen 
called highly active antiretroviral therapy (HAART). A high mutation rate of the virus enables 
quick generation of diverse HIV-1 quasispecies within an infected host. This in turn increases the   4 
probability of viral resistance arising against antiretrovirals if they are not administered in a 
timely  fashion  and  in  combination  to  curb  viral  replication  at  independent  stages,  thereby 
limiting the occurrence of multiple resistance mutations. The continuous depletion of immune 
cells upon HIV-1 infection renders patients with a weakened immunity to fight back both HIV-1 
itself and other associated opportunistic infections. HAART, however, has been successful in 
suppressing active viral replication and spread (OARAC, 2014), but AIDS still is practically an 
incurable disease due to non-replicating latent infections in HIV-1 reservoirs in the body that 
cannot be targeted by currently available drugs. This in turn enables HIV-1 to bounce back if the 
patients  are  taken  off  of  HAART  (Chun  et  al.,  1997),  requiring  a  life-long  dependence  on 
potentially high-cost medication and medical care.  
Seminal  recent  reports,  however,  have  shown  that  aggressive  HAART  in  infected 
newborns may cure HIV-1 infection, possibly because the virus did not have the chance to form 
latent  infection  reservoirs  yet  (Persaud  et  al.,  2013;  Persaud  et al.,  2014).  Additionally,  the 
exceptional proof-of-principle case of “the Berlin Patient” showed that practical eradication of 
HIV-1 in a chronically infected individual may be possible (Yukl et al., 2013; Symons et al., 
2014):  Timothy  Ray  Brown,  an  HIV+  patient  of  11  years  on  HAART,  who  concomitantly 
developed  acute  myeloid  leukemia,  was  given  two  bone  marrow  transplants  bearing 
hematopoietic stem cells from a donor who was selected for natural resistance to HIV-1 (Huetter 
et al., 2009). These HIV-1 resistant individuals have a nonfunctional CCR5 (Cys-Cys chemokine 
receptor  type  5)  protein  with  a  32  amino  acid  (aa)  deletion  (CCR5  Δ32)  due  to  a  rare 
homozygous mutation (Liu et al., 1996). CXCR4 (Cys-X-Cys chemokine receptor type 4), which 
is the coreceptor on CD4+ T cells required for HIV-1 attachment and entry (Feng et al., 1996) 
whereas another coreceptor, CCR5, is more abundantly found on macrophages (Deng et al.,   5 
1996; Alkhatib et al., 1996) and microglial cells (He et al., 1997), a critical late target of HIV-1 
during the course of systemic pathogenesis and progression to  AIDS (Gartner  et al., 1986). 
Following the repopulation of transplanted CCR5 Δ32 T cells (Huetter et al., 2009), Brown’s 
viral load decreased to undetectable levels and even after discontinuation of HAART remained 
as such, prompting him to be declared the first person to be cured of chronic HIV-1 infection in 
2006. Currently, several gene therapy strategies are being developed based on the success of the 
Berlin Patient that involve autologous hematopoietic stem cell transplantation (HSCT) combined 
with  ex vivo CCR5 Δ32 genomic engineering  (Li et al., 2013). They utilize  the  zinc finger 
nuclease  (ZFN)  and  more  recently  the  CRISPR/Cas9  (clustered  regularly  interspaced  short 
palindromic  repeats/CRISPR  associated  nuclease  9)  technology  (Cradick  et  al.,  2013). 
Alternative approaches such as excision of the provirus from an infected cell are also being 
pursued with the goal of eradicating the disease (Hauber et al., 2013). With these experimental 
therapies still in the pipelines waiting to be optimized for both efficacy and safety (Manjunath et 
al., 2013; Zou et al., 2013), the search for further pharmacological prophylaxes to expand our 
arsenal of antiretrovirals targeting HIV-1 in its early phases of infection is of utmost importance. 
 
     6 
B.   HIV-1 virion structure 
B.i.  Genomic composition 
Among the seven genera within the family of exogenous  Retroviridae; α- through ε-, 
spumaviruses  and  lentiviruses,  HIV-1  is  the  prototypical  primate  lentivirus  (Figure  1.2). 
Exogenous retroviruses are found to infect both invertebrate insects and vertebrate animals from 
fishes to mammals, and evolutionarily they have a shared history with endogenous retroviruses, 
which  are  established  upon  extant  retroviral  infection  of  germline  cells,  are  derivatives  of 
retrotransposons bearing long terminal repeats (LTRs). The signature evolutionary adaptation 
from  LTR-retrotransposons  to  retroviruses  is  that  the latter  acquired an  open  reading  frame 
coding for an envelope (env) gene granting them the ability to jump from one cell to another 
(Malik et al., 2000, Kim et al., 2004). HIV-1 is believed to have evolved from chimpanzee SIV 
(SIVcpz; Figure 1.1) around the turn of the 20th century. Molecular clock analyses based on viral 
sequence comparisons claimed lentiviral SIVs to be at least about 32,000 years old (Worobey et 
al., 2010; Worobey et al., 2008). This finding, however, is probably a gross underestimate, as 
evidenced by the evolutionary history of anti-lentiviral host restriction factors that have to co-
evolve with lentiviruses (Duggal and Emerman et al., 2012) and can be traced back to 10 Mya 
(Compton et al., 2013). 
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Figure 1.2 Evolutionary tree of Retroviridae. The seven genera of Retroviridae and related endogenous 
retroviruses based on an alignment of the amino acid residues of the RT domain of the pol gene. SFVcpz, 
simian foamy virus isolated from chimpanzee; SFVagm, simian foamy virus isolated from African green 
monkey; BFV, bovine foamy virus; FFV, feline foamy virus, FeLV, feline leukemia virus; MuLV/MLV, 
murine  leukemia  virus;  GALV,  gibbon  ape  leukemia  virus;  PERV,  porcine  endogenous  retrovirus; 
HERV-W, human endogenous retrovirus W; SnRV, snake retrovirus; WDSV, walleye dermal sarcoma 
virus;  BLV,  bovine  leukemia  virus;  HTLV,  human  T-lymphotropic  virus;  EIAV,  equine  infectious 
anemia virus; Visna, maedi-visna ovine lentivirus; RSV, Rous sarcoma virus; HRV-5, human retrovirus 
5;  SRV,  simian  retrovirus;  MMTV,  mouse  mammary  tumor  virus,  HERV-K,  human  endogenous 
retrovirus K; IAP, intracisternal A type particle of mouse. Adapted and modified from Weiss, 2006. 
 
HIV-1, like all retroviruses, contains a positive-strand RNA genome, and once inside the 
target cells it needs to be reverse-transcribed into a double-stranded DNA genome by the viral 
reverse  transcriptase  (RT),  a  hallmark  enzyme  of  all  retroviruses.  The  viral  DNA  (vDNA) 
eventually gains access to host chromatin and with the aid of another retroviral hallmark enzyme, 
integrase  (IN)  (Panganiban  et  al.,  1984),  it  gets  integrated  into  the  host  genome.  The 
distinguishing characteristics of HIV-1 and lentiviruses is that they can efficiently infect non-
dividing  cells  such  as  resting  CD4+  T  cells  (Zack  et  al.,  1990)  and  differentiated  tissue   8 
macrophages (Von Schwedler et al., 1994), where the host chromatin would be inaccessible to 
most other retroviruses (Konstantoulas et al., 2014) within the post-mitotic nuclear envelope. 
This  lentiviral  property  is  readily  taken  advantage  of  by  gene  delivery  vector  development 
(Follenzi et al., 2000). More recently, the β-retrovirus MMTV was also shown to be able to 
transduce non-dividing dendritic cells (Konstantoulas et al., 2014). 
HIV-1 virions carry two identical copies of an approximately 9.2 kilobase (kb) single-
stranded, positive-sense genomic RNA (gRNA) that bears terminal repeat (R) elements abutting 
unique 5’- and 3’-end sequences named U5 and U3, respectively. The vDNA genome bears three 
structural and six regulatory/accessory genes flanked by a 5’- and a 3’- end LTR region, a result 
of  U5  and  U3  sequence  duplication  while  reverse  transcribing  the  gRNA;  i.e.  each  LTR  is 
composed of U3-R-U5 sequences. The primary genes, group-specific antigen (gag), polymerase 
(pol),  and  env  encode  protein  products  that  are  initially  synthesized  as  polyproteins.  Upon 
posttranslational  modifications  by  viral or  cellular  proteases,  respective  polyprotein  products 
Gag  (55  kD),  Gag-Pol  (160  kD;  resulting  from  a  controlled  translational  frameshift),  and 
glycoprotein  (gp)  Env  (gp160,  160  kD)  are  processed  into mature  viral  proteins  that  either 
become structural components of progeny virions (Gag; matrix (MA), capsid (CA), nucleocapsid 
(NC), protein (p) 6, and Env; surface gp120 (SU, 120 kD), transmembrane gp41 (TM, 41 kD), 
which remain noncovalently associated on the viral membrane after maturation) (Kowalski et al., 
1987) or catalyze key enzymatic reactions of the viral life cycle (Gag-Pol: protease (PR), RT, 
IN).  The  other  six  HIV-1  regulatory  and  accessory  genes,  however,  are  primary  translation 
products of alternatively spliced mRNAs: viral infectivity factor (Vif), viral protein R (Vpr), 
trans-activator  of  transcription  (Tat),  regulator  of  expression  of  virion  proteins  (Rev),  viral 
protein unique (Vpu), and negative regulatory factor (Nef) that perform both cell-type specific   9 
and non-specific functions to aid with HIV-1 infection and counteract innate host restriction 
mechanisms (Figure 1.3) (Coffin et al., 1997). 
 
 
Figure 1.3 Genomic organization of HIV-1. The ~9.7 kb DNA genome harbors three structural genes; 
gag, pol,  and  env,  which  are  flanked  by  identical  5’-  and  3’-end  LTR  regions.  Alternatively  spliced 
transcripts  from  all  three  reading  frames  collectively  encode  two  regulatory;  tat  and  rev,  and  four 
accessory genes; vif, vpu, vpr and nef. The sequence of the HXB2 strain is taken  as a reference for 
numbering. Adapted from Los Alamos National Laboratory HIV Sequence Compendium, 2013. 
 
The  HIV-1  RNA  genome  is  generated  by  cellular  RNA  polymerase  II  and  host 
transcriptional  machinery  and  thus  bears  hallmarks  of  cellular  mRNAs,  such  as  the  7-
methylguanosine cap at the 5’ end and an approximately 200 nucleotide (nt) long poly(A) tail at 
the  3’  end.  There  is  an  18  nt  long  primer  binding  sequence  (PBS)  abutting  the  5’  LTR, 
complementary to the 3’ terminal sequence of the cellular lysine transfer RNA (tRNALys,3) 
where reverse transcription is initiated upon tRNALys,3 binding. Downstream of the PBS is the 
cis-acting Psi (Ψ) packaging signal, composed of four stem loop structures, required for physical 
association with Gag and incorporation of the viral gRNA into assembling virions. Other critical 
secondary and tertiary structural motifs, named trans-activator response element (TAR) and Rev 
response element (RRE), are regulatory binding sites for viral accessory proteins Tat and Rev, 
respectively.  The  TAR  element  is  a  hairpin  structure  that  serves  as  a  negative  regulator  of 
transcriptional initiation and read-through elongation, unless bound by Tat (Kao et al., 1987). 
RRE is an approximately 350 nt long RNA secondary structure within the env-coding region of 
the vRNA and Rev to RRE binding is required for unspliced viral mRNAs to utilize the CRM1   10 
(chromosome  region  maintenance  1)-dependent  mRNA  nucleocytoplasmic  export  pathway 
(Emerman et al., 1989). 
 
B.ii.  Structural components 
 
Figure  1.4  HIV-1  virion  structure.  On  the  left,  3D  reconstruction  and  a  reference  cryoelectron 
tomography section of mature HIV-1 particles. Viral envelope is depicted in blue, matrix in yellow and 
capsid core in red (Briggs et al., 2006). On the right, schematic representation of a mature HIV-1 particle. 
Adapted from National Institute of Allergy and Infectious Diseases, 2013.  
 
Mature HIV-1 particles are enveloped in a spherical lipid bilayer (∅ ~145 nm) that is 
formed upon budding from specialized membrane microdomains. The viral envelope membrane 
is  enriched  in  ‘raft  lipids’,  i.e.  sphingomyelin,  cholesterol,  and  plasmalogen-phosphatidyl 
ethanol; and saturated fatty acids are also more abundant than in the producer cell membrane 
(Waheed  et  al.,  2009).  The  viral  envelope  is  studded  with  the  envelope  glycoprotein  (Env) 
formed  by  the  noncovalently  bonded  TM  gp41  and  the  SU  attachment  glycoprotein  gp120 
(Figure 1.4).  
The proteolytically cleaved Gag polyprotein product (Figure 1.3) MA (17 kD, p17) forms 
a discontinuous submembrane layer that encloses the mature capsid core particle in the shape of 
a Fullerene cone composed of ~1100 copies of CA (24 kD, p24) (Figure 1.4). The core houses   11 
the  diploid  gRNA  in  a  dense  ribonucleoprotein complex  with  NC  (7  kD,  p7),  p6,  and also 
cellular  tRNALys,3,  which  is  packaged  into  assembling  virions  via  Lysyl-tRNA  synthetase 
(KARS):Gag interactions (Guo et al., 2003; Kovaleski et al., 2006), to  subsequently serve as the 
primer  of  reverse  transcription  in  target  cells.  Other  major  components  are  the  Gag-Pol 
polyprotein products responsible for key enzymatic reactions in the viral life cycle, namely RT 
for reverse transcribing the vRNA into vDNA and IN for eventually integrating the vDNA into 
the host genome (Figure 1.4, right).  
When expressed by itself in absence of other viral proteins, unprocessed Gag is capable 
of generating immature virus like particles (VLPs) that do not form the conical core (Gheysen et 
al., 1989). The formation of these structures relies on the CA domain of the Gag polyprotein. 
VLPs will spontaneously bud off from producer cells and can also be non-specifically taken up 
by target cells, yet are replication-incompetent. 
 
B.ii.1.  Gag and the capsid core 
MA spans the first 132 amino acid residues of the unprocessed Gag polyprotein, that 
upon myristoylation at its N-terminus and thanks to a highly basic domain between residues 17 
and  31  targets  Gag  to  viral  assembly  sites  at  the  cell  membrane  (Hill  et  al,  1996).  In  the 
assembling virion it serves to bridge membrane-bound Env (specifically gp41) proteins with Gag 
proteins lining up under the membrane. Upon maturation initiated by PR proteolytic cleavage of 
Gag, MA forms trimeric and hexameric structures that act as protective barriers beneath the viral 
envelope around the capsid core. It is also reported to be associated with the reverse transcription 
complex (RTC) that forms upon delivery of the capsid core to the target cell cytoplasm and later 
co-purifies with cytoplasmic fractions that contain in vitro integration activity, suggesting it may   12 
also be associated with the pre-integration complex (PIC) in infected cells (Fassati et al., 2001). 
Accordingly MA was proposed to play a role in the early phase post-entry events such as nuclear 
import of the PIC, but such a function has been subsequently contested (Yamashita et al., 2005).  
In a mature HIV-1 particle, the conical capsid core serves as a protective vehicle that 
delivers the viral replication machinery to the host nucleus (Figure 1.4). It is made up of mature 
CA, a 231 aa long post-cleavage product of the Gag polyprotein. Each single CA molecule is 
composed of two independently folded domains; an amino-terminal domain (NTD) comprising 
seven  ʱ-helices  and  a  β-hairpin  (Mortuza  et  al.,  2004),  a  carboxy-terminal  domain  (CTD) 
comprising four ʱ-helices (Gamble et al., 1997), and a flexible linker with a 310-helix connecting 
the two structural domains (Figure 1.5D, E) (Berthet-Colominas et al., 1999).  Upon maturation, 
approximately 1200 copies of CA, about half the number of the Gag proteins that make up the 
immature virion, multimerize into a conical shell that measures approximately 119 x 60 nM 
(Briggs et al., 2003; Pornillos et al., 2011; Figure 1.5A). The conical capsid structure results 
from  the  assembly  of  self-associating  CA  hexamers  into  a  hexagonal  lattice  (Figure  1.5B) 
interspersed with an exact number of 12 CA pentamers (5 at the narrow and 7 at the broader end 
of  the  cone)  that  enable  surface  declinations  and  closure  of  an  otherwise  quasi-cylindrical 
topology  with  variable  curvature  (Figure  1.5A).  Original  calculations  estimated  the  core  to 
contain ~ 1500 CA molecules (Ganser et al., 1999). Higher resolution structures and structural 
modeling efforts corrected this number to be ~ 1200 (Briggs et al., 2003, Ganser-Pornillos et al., 
2004) and then to ~ 1200 (Briggs et al., 2011; Pornillos et al., 2011; Zhao et al., 2013).   13 
 
Figure 1.5. Atomic-level modeling of the HIV-1 capsid core. (A) Atomic structures of around 250 CA 
hexamers (orange NTDs, blue CTDs) and 12 CA pentamers (yellow NTDs, blue CTDs) are modelled 
together  to  render  the  conical  capsid  core  (Adapted  and  modified  from  Pornillos  et  al.,  2011).  (B) 
Expanded view of a central CA hexamer and six neighboring CA hexamers within a planar capsid lattice; 
resolved experimentally (Adapted from Pornillos et al., 2009). (C) Expanded view of the CA CTD-CTD 
dimer interface between two neighboring CA hexamers. CTD ʱ-helix (H) 9 mediates intermultimeric 
interactions (Adapted from Pornillos et al., 2009). (D) Side view of a ribbon diagram of a single CA 
hexamer. Each CA subunit is colored differently (Adapted from Pornillos et al., 2011). (E) Detailed view 
of the interaction surface between two neighboring capsid subunits within a hexamer. One full length CA 
(blue), and the NTD of an adjacent CA (orange) are depicted. Intermolecular NTD-NTD and NTD-CTD 
interfaces are highlighted (Adapted from Pornillos et al., 2009).  
 
While the hexameric symmetric rings of NTDs and their outward emanating flexible 
loops create the cytoplasmically exposed facade of the viral core available for interaction with 
cellular  factors  (Figure  1.5B),  the  inner-facing  CTDs,  and  specifically  ʱ-helices  9  (H9s)  of 
neighboring  multimers  are  responsible  for  intermultimeric  contacts  at  2-fold  symmetry  axes 
enabling the formation of the conical capsid lattice (Figure 1.5A-C). Additional hydrophobic 
residues on CTD H10s at the hexameric three-fold symmetry centers contribute further critical 
interactions required for lattice formation. Intermolecular interactions between contiguous CAs 
within  a  multimer  (Figure15.D)  are  mediated  by  intermolecular  NTD-NTD  and  NTD-CTD   14 
contacts of adjoining molecules (Figure 1.5E). Within each CA multimer, every CTD is packed 
against the NTD of the adjacent CA molecule where amino acid residues of the helix 4 in the 
NTD line up against a groove in the CTD formed by helices 8, 9 and 11 (Figure 1.5E) (Pornillos 
et al., 2009).  
Extensive  intrahexameric  and  intrapentameric  packing  ensures  multimeric  stability, 
whereas rather flexible intermultimeric interactions serve to enable modulation of capsid core 
stability.  Such  flexibility  is  essential  (Forshey  et  al.,  2002)  as  the  viral  core  is  slated  for 
conformational and compositional changes upon its entry into the cytoplasm: The intact capsid 
shell is supposed to disassemble in a controlled fashion, i.e. ‘uncoat’, in order to allow sufficient 
shielding and timely delivery of the subviral RTC. 
CA  alone  has  self-assembling  properties  that  enable  mature  lattice  formation.  This 
phenomenon  can  be  utilized  to  reconstitute  topologically  closed  (spherical)  and  open 
(cylindrical) CA assemblies in vitro that display native capsid surface architecture and thus can 
be used as a surrogate quaternary substrate in biochemical and structural studies (Gross et al., 
1997; Gross et al., 1998). In a similar vein, the CA domain, when present within the context of 
unprocessed Gag polyprotein, is responsible for self-association of Gag at the inner surface of 
the cellular membrane during viral assembly. 
Inside the capsid core, the viral RNA genome is complexed with the 55 aa residue long 
basic nucleic acid-binding protein NC. The hallmark feature of NC is two 14 aa residue long 
Cys-X2-Cys-X4-His-X4-Cys (CCHC) ‘Gag-knuckle’ zinc finger domains (Morellet et al., 1992). 
Zn2+ coordination induces conformational changes in these knuckles within the central globular 
domain of NC that allows it to act as a critical molecular chaperone in the early stages of viral 
replication  (Buckman  et  al.,  2003),  mainly  reverse  transcription  (Levin  et  al.,  2010).  It   15 
chaperones  tRNALys,3  binding  to  the  complementary  PBS,  aids  with  initiation  and  strand 
transfer of reverse transcription (Tsuchihashi et al., 1994), increases the efficiency of reverse 
transcription by destabilizing the secondary structure of TAR, and thereby relieves a structural 
block to minus-strand transfer during reverse transcription, adding to the stability of RTC and 
PIC by shielding the viral genome from cellular nucleases. NC, within the context of Gag, bears 
the major responsibility in mediating contact with ψ, which is crucial for gRNA encapsidation 
during viral assembly (Berkowitz et al., 1995). Multimerization of NC contributes to Gag self-
assembly (Burniston et al., 1999) and plays a role in plasma membrane targeting of Gag during 
viral egress. NC may also be partially important during viral budding due to its limited ability to 
recruit components of the cellular membrane budding and scission machinery, which will be 
described below (Bieniasz, 2006). 
P6, the carboxy-terminal protein domain of Gag, is a 52 aa residue long, proline-rich 
sequence that is responsible for budding at assembly sites on the plasma membrane (Goettlinger 
et al., 1991; Huang et al., 1995). Two distinct late assembly (L) domains within p6, namely the 
major  Pro-Thr-Ala-Pro-Pro  (PTAP),  and  the Tyr-Pro-Xn-Leu  (YPXnL)  motifs,  carry  out  this 
function (Strack et al., 2003; Von Schwedler et al., 2003). The PTAP motif is responsible for 
recruiting tumor susceptibility gene 101 (Tsg101), which then brings in other members of the 
cellular endosomal sorting complex required for transport (ESCRT) machinery to viral assembly 
sites (Garrus et al., 2001). ESCRT machinery coordinates outward plasma membrane budding at 
viral assembly sites and membrane scission by a complex set of molecular steps. The  YPXnL 
motif, on the other hand, binds another ESCRT component; apoptosis-linked gene 2-interacting 
protein X (ALIX), which itself can bind TSG101 and again recruit the full complement of the 
ESCRT machinery (Strack et al., 2003; Von Schwedler et al., 2003). Mutations in these two   16 
domains result in a ‘late’ block to viral budding, where progeny viral particles fail to sever the 
membrane neck connecting them to cellular membranes; hence the  ‘L-domain’ nomenclature. 
Besides  its  crucial  role  in  budding,  the  p6  domain  of  Gag  is  also  responsible  for  Vpr 
incorporation into viral particles (Kondo et al., 1996). 
 
B.ii.2.  Gag-Pol and the replication machinery 
Gag-Pol  expression  results  from  a  translational  frameshift  event  (due  to  a  single 
nucleotide backsliding of the ribosome) at the junction of gag and pol coding regions on the viral 
mRNA (Jacks et al., 1988). The frequency of this frameshift event determines the amount of Gag 
vs.  Gag-Pol  expression,  and  thus  yields  a  critical  10-20:1  ratio  required  for  efficient  viral 
assembly (Jacks et al., 1988).  
PR is responsible for maturational cleavage of both Gag and Gag-Pol (in the case of Gag-
Pol in an autocatalytic fashion) upon viral budding, which yields mature Gag (MA, CA, NC, p6) 
and Pol (PR, RT, IN) proteins. In the absence of a functional PR or PR cleavage sites within Gag 
and Gag-Pol, progeny virions cannot undergo maturation and are rendered non-infectious (Kohl 
et al., 1988). HIV-1 PR is a homodimeric aspartyl protease, where each subunit contributes one 
catalytic aspartic acid residue (Asp25) to the active site (Wlodawer et al., 1989). PR activation 
and viral maturation is coupled to viral budding, presumably due to the high local concentration 
of Gag-Pol in assembling virions. Transient overexpression of Gag-Pol in virion producing cells 
leads  to  premature  intracellular  protease  activity  that  is  detrimental  to  viral  assembly  and 
budding (Karacostas et al., 1993).   
HIV-1 gRNA undergoes reverse transcription to generate the double-stranded (ds) vDNA 
genome (Temin et al., 1970; Baltimore, 1970) that can be integrated into host chromatin. This   17 
signature  step  of  the  retroviral life  cycle,  which  originally  challenged  the  central  dogma  of 
molecular biology, is catalyzed by the viral RT holoenzyme, a post-cleavage product of the Pol 
domain in Gag-Pol. The three enzymatic reactions  that RT catalyzes are (i) RNA-dependent 
DNA polymerization (required for minus-strand synthesis), (ii) RNA degradation as a result of 
the  non-specific  endonuclease  activity  of  the  C-terminal  RNase  H  domain,  and  (iii)  DNA-
dependent DNA polymerization, which is required for plus-strand synthesis and completion of 
reverse transcription (Hu and Hughes., 2012).  
The RT holoenzyme is a heterodimer consisting of one p66 and one p51 subunit, where 
p51 is a PR post-cleavage product of a single RT molecule (p66) with the C-terminal RNase H 
domain removed (Di Marzo Veronese et al., 1996). As a result, p51 and p66 share identical 
amino acid sequences, yet within the context of the RT holoenzyme, the subdomains of each 
molecule adopt different conformations - to the extent that p51 lacks a functional nucleic acid 
binding cleft and a polymerase active site, and rather serves a structural role within the p66/p51 
heterodimer (Kohlstaedt et al., 1992).  
HIV-1 IN comprises three separate functional domains (Engelman et al. 1993): an NTD 
with a zing finger motif that serves a structural role; a catalytic core domain (CCD) that harbors 
DNA-binding sites and the catalytic DDE triad (D64, D116 and E152) (Engelman et al., 1992; 
Dyda  et  al.,  1994)  required  for  divalent  cation  (Mg2+  in  vivo)  coordination  and  enzymatic 
function (Goldgur et al., 1998); and finally a CTD with nonspecific DNA-binding properties 
(Dar et al,. 2009). The 3D structure of the full length HIV-1 IN, the active IN-tetramer, and the 
active  IN-tetramer:vDNA  complex;  namely  the  intasome,  have  been  elusive.  Breakthrough 
structural studies with the prototype foamy virus (PFV) intasome yielded valuable insight into   18 
the molecular underpinnings of the integration reaction (Hare et al., 2010; Maertens et al., 2010), 
which was later utilized to model the HIV-1 intasome (Krishnan et al., 2010b). 
Upon completion of vDNA synthesis, the HIV-1 genome is slated for integration into the 
host chromatin to generate a provirus (Li et al., 2006). HIV-1 IN, encoded at the 3’ end of the the 
pol gene, forms a nucleoproteinacious PIC together with the vDNA and other viral and cellular 
accessory proteins, and mediates two separate enzymatic reactions in vivo that enable integration 
(Figure 1.6; Engelman et al., 1991).  
 
 
Figure 1.6 Mechanism of HIV-1 integration. The two enzymatic reactions carried out by IN in vivo, 
namely 3’ processing of vDNA ends and strand transfer into host chromatin, are followed by nick repair 
by host DNA repair machinery. This in turn yields an integrated viral genome. Formation of a provirus is 
accompanied by a 5 bp duplication at the DNA target site, a signature of HIV-1 integration. Adapted and 
modified from Knipe and Howley, 2006. 
 
During the initial ‘3’ processing’, IN removes a dinucleotide from both 3’ termini of the 
ds vDNA in a specific endonucleolytic cleavage reaction, exposing a pair of palindromic CA 
dinucleotides and their 3-hydroxyl groups (Fujiwara et al., 1988). Upon gaining access to the 
host chromatin, IN catalyzes the insertion of the exposed 3’-OH ends into opposing strands of 
the host genomic DNA via a nucleophilic attack, which is dubbed “DNA strand transfer”, a step   19 
subject to pharmacological inhibition (Koh et al., 2011). The resulting nicked proviral ends are 
eventually repaired by host DNA repair machinery, and are flanked by a 5 bp long host DNA 
duplication (Figure 1.6) (Brown et al., 1989). 
 
B.ii.3.  Env and the viral envelope glycoprotein complex  
Each HIV-1 Env trimer subunit is composed of a surface gp120 and a transmembrane 
gp41 that are post-cleavage products of the env-encoded polyprotein. Gp120 and gp41 are non-
covalently attached to each other in a metastable state on the mature virion surface (Figure 1.4). 
Specifically, gp120 is responsible for initial attachment to the viral receptor CD4 (Dalgleish et 
al., 1984; McDougal et al 1986) and major coreceptors CCR5 or CXCR4 on target cells, whereas 
gp41  plays  a  crucial  role  during  membrane  fusion  by  juxtaposing  the  cellular  and  viral 
membranes  upon  major  conformational  changes  (Vishwanathan  et  al.,  2008).  Sequential 
gp120/CD4/coreceptor interactions  (Lasky  et  al.,  1987)  license  gp41  to  expose a  previously 
buried fusion peptide (Buzon et al., 2010) that gets inserted into the target membrane akin to a 
spring loaded mechanism. This is immediately followed by additional conformational changes 
leading to parts of gp41 to snap back unto itself and form stable six helix bundles along the 
trimeric axis that pull the two membranes upon each other and initiate fusion (Melikyan et al., 
2000). 
 The cytoplasmic tail of gp41, on the other hand, is necessary for contacting the MA 
domain of self-assembling Gag proteins at the plasma membrane allowing their incorporation 
into  progeny  virions  (Freed  et  al.,  1996).  The  ability  of  gp120  to  recognize  different  viral 
coreceptors determines HIV-1 tropism; e.g. R5 isolates refer to viruses that bear a gp120 capable 
of binding to CCR5, whereas X4 isolates bind to CXCR4.    20 
The  metastable  structure  of  the  gp120/gp41  trimer,  flexible  surface  regions  called 
variable loops (V1-V5), heavy glycosylation and masking of the native Env trimer have all been 
confounding factors in structural efforts and, thus, solving the full length atomic structure of a 
native Env trimer has been formidable. Gradual progress was achieved by studies that utilized 
stable substructures (Furuta et al., 1998) and partial ligand:receptor complexes (Kwong et al., 
1998),  and  more  recently  state-of-the-art  technological  advancements  in  3D  structure 
determination such as single particle cryo-electron microscopy coupled with traditional X-Ray 
crystallography  yielded the first ever atomic resolution structural information about the Env 
trimer (Mao et al., 2013; Julien et al., 2013; Khayat et al., 2013; Lyumkis et., 2013). Env proteins 
mediate the first physical contact with the host and display immunogenic epitopes to the host 
adaptive immune system (Popovic et al., 1984; Wyatt et al., 1998). As a result, structural and 
biochemical details into their functioning are absolutely essential to our understanding of their 
mechanism of action and to our vaccine development efforts, which have to involve generating 
neutralizing antibodies, however difficult it may be. 
 
B.ii.4.  Regulatory proteins  
Following provirus formation,  the cellular transcription machinery expresses the viral 
genome. Host RNA polymerase II drives the transcription of the HIV-1 genome; however only 
abortive  short  viral  transcripts  are  made  initially.  These  transcripts  allow  expression  of  the 
regulatory Tat and Rev proteins. By binding to the TAR element within the 5’ LTR of nascent 
viral transcripts, Tat recruits Cyclin T1 and cyclin-dependent kinase (CDK) 9 (Gaynor et al., 
1992) that phosphorylates the CTD of RNA polymerase II (Ping et al., 2001), enabling increased 
processivity and transcriptional elongation (Laspia et al., 1989; Zhu et al., 1997; Mancebo et al., 
1997). The Tat:TAR interaction thus acts as a switch from abortive to productive transcription of   21 
the full complement of viral RNAs, including the unspliced gRNA (Feinberg et al., 1986). Lack 
of splicing poses a block to nuclear export of viral long RNAs, however this is relieved by Rev 
recruitment to RRE within the env on the viral gRNA that allows the utilization of the cellular 
CRM1-mediated mRNA nuclear export pathway even in absence of coupled splicing (Malim et 
al., 1989).This is critical for the late stage expression of viral structural polyproteins and for 
eventual gRNA incorporation into progeny virions.  
 
B.ii.5.  Accessory proteins 
A characteristic feature of HIV-1, among other primate lentiviruses, is the expression of 
accessory proteins that aid in the evasion from host adaptive and innate immune defenses (Neil 
and  Bieniasz,  2009).  Vif,  Vpu  and  Vpr  each  antagonize  a  separate  intracellular  intrinsic 
resistance  factor  (Malim  et  al.,  2008)  by  inducing  their  polyubiquitination  and  proteasomal 
degradation  via  joint  recruitment  of  the  members  of  the  modular  Cullin–RING  finger  E3 
ubiquitin ligases (CRLs). In otherwise non-permissive cells, Vif binds and targets (Marin et al., 
2003; Sheehy et al., 2003) the restriction factor APOBEC3G (apolipoprotein B mRNA-editing, 
enzyme-catalytic,  polypeptide-like  3G)  in  hematopoietic  cells  that  induce  hypermutations  in 
vDNA by cytosine deamination (Sheehy et al., 2002; Harris et al., 2003; Bishop et al., 2004). 
Vpu counteracts the type II transmembrane protein tetherin (Van damme et al., 2008; Neil et al., 
2008)  that  blocks  viral  release  via  membrane  anchoring  of  budding  virions.  Vpr/Vpx  (Vpr-
related  viral  protein  x  of  SIV;  Lim  et  al.,  2012)  targets  SAMHD1  (SAM  domain  and  HD 
domain-containing protein 1), which poses an interferon-induced intracellular block to HIV-1 
reverse  transcription  (Laguette  et  al.,  2011,  Hrecka  et  al.,  2011).  By  its  phosphohydrolytic 
activity (Powell et al., 2011; Goldstone et al., 2011), SAMHD1 depletes cytoplasmic nucleotide 
pools in monocytes, macrophages and dendritic cells (Laguette et al., 2011). Nef, on the other   22 
hand,  plays  a  critical  role  in  suppressing  the    adaptive  immune  response  against  HIV-1  by 
downregulating  the  surface  availability  and  exposure  of  Env,  but  also  CD4,  TCR  (T-cell 
receptor)-CD3 and MHC-I (major histocompatibility complex class I) (Swigut et al., 2001). By 
limiting the availability of viral epitopes and mediators of adaptive immunity, Nef thus acts as a 
stealth factor, benefiting long-term systemic viral infectivity. Additionally, Vpr has been shown 
to induce G2 arrest in infected monocyte derived macrophages (MDMs), which increases HIV-1 
transcription activity and efficiency (Goh et al., 1998; Hrecka et al., 2007). Vpr, incorporated 
into progeny virions via its interactions with the p6 domain within Gag during viral assembly, is 
also found to be associated with the PIC in the early phase of the HIV-1 infection and there have 
been reports assigning it a role in PIC nuclear import in macrophages (Vodicka et al., 1998; 
Popov et al., 1998)      23 
C.   HIV-1 replication cycle 
 
Figure 1.7 HIV-1 replication cycle. HIV-1 infection starts when the envelope (Env) proteins on mature 
viral particles attach to receptor (CD4) and coreceptor molecules (CCR5 or CXCR4) on a target cell 
(Figure 1.7A). Attachment triggers conformational changes in the envelope:receptor complex resulting in 
the juxtaposition of the viral and cellular membranes. This, in turn, leads to fusion of the membranes and 
the viral capsid core is released into the cytosol (Figure 1.7B). Upon entry, the protective capsid shell 
uncoats in a controlled fashion (Figure 1.7C), unless it is restricted by human TRIM5ʱ that recognizes the 
mature capsid lattice and targets it for destruction. Concomitant with uncoating, viral RNA genome is 
reverse transcribed into a double-stranded  DNA species by viral RT  using  cellular resources (Figure 
1.7D). The viral life cycle can be inhibited at this stage by host restriction factor APOBEC3G that induces 
hypermutations in the viral genome; or SAMHD1, which depletes cytosolic nucleotide pools required for 
DNA synthesis. Upon successful completion of reverse transcription, the viral DNA is complexed with 
IN and other viral and cellular accessory factors, which are now dubbed the preintegration complex (PIC). 
This nucleoprotein complex is subsequently imported through nuclear pores into the nucleus allowing it 
access  to  host  chromatin  (Figure  1.7E).  With  the  aid  of  the  cellular  LEDGF,  the  PIC  is  targeted  to 
preferred genomic sites where viral IN catalyzes the integration of the two LTR ends of the viral DNA 
into the host DNA (Figure 1.7F), successfully generating a provirus. In the second half of the replication 
cycle, recruitment of cellular transcription factors such as P-TEFb mediate transcription of viral genes by 
host RNA polymerase II (Figure 1.7G). Alternatively spliced and subspliced viral transcripts are then 
exported  into  the  cytosol  via  CRM1-mediated  export  pathway  (Figure  1.7H),  where  the  host  protein 
translation  machinery  utilizes  them  to  produce  viral  proteins  (Figure  1.7I).  Unspliced  viral  genomic 
RNAs, together with viral structural proteins, are then trafficked to viral assembly sites at the plasma 
membrane (Figure 1.7J), where they form immature particles that bud off from the cell with the help of 
the  cellular  ESCRT  machinery  (Figure  1.7K).  Fully  formed  virions  can  then  be  released  into  the 
extracellular  space,  at  which  stage  the  host  restriction  factor  tetherin  can  block  them  by  membrane 
anchoring  (Figure  1.7L).  Viral  budding  and  release  trigger  the  nascent  HIV-1  particle  to  undergo 
maturation that generates fully infectious particles (Figure 1.7M). Once this newly formed HIV-1 virion 
finds  another  target  cell,  a  new  round  of  the  replication  cycle  can  begin  (Figure  1.7A-M).  NRTI, 
nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; INSTI, 
integrase strand transfer inhibitor. Adapted and modified from Engelman and Cherepanov, 2012.   24 
C.i.   Early phase events leading up to provirus formation 
C.i.1.   Attachment and Entry  
As an enveloped virus, HIV-1 enters target cells via specific cell surface receptor (CD4) 
attachment followed by viral and plasma membrane fusion, which mediates entry. There has also 
been recent incidental evidence pointing to endocytic vesicles as the actual site of fusion upon 
viral  uptake,  though  this  observation  awaits  confirmation  by  independent  research  groups 
(Miyauchi et al., 2009). The globular envelope protein is a trimeric heterodimer composed of the 
SU  gp120  subunit,  which  mediates  initial  binding,  and  TM  gp41,  which  is  responsible  for 
triggering membrane fusion (B.ii.3). Upon binding to CD4 on target cells, gp120 undergoes 
conformational changes allowing critical recognition of specific coreceptors (CCR5 or CXCR4) 
(Figure 1.7A). This is followed by further conformational changes triggering gp41 (Finzi et al., 
2010)  to  expose  and  insert  its  fusion  peptide  stably  into  the  plasma  membrane  enabling 
juxtaposition of the two membranes. Finally gp41 subdomains snap unto themselves, pulling the 
two membranes together. Membrane fusion ensues and the viral capsid core is released into the 
cytosol  (Figure  1.7B).  This  initial  stage  of  the  viral  life  cycle  is  successfully  targeted  by 
fusion/entry inhibitors in the clinic. 
 
C.i.2.   Uncoating  
Upon entry into the cytosol the viral capsid core is believed to uncoat by losing its CA 
shell on its way to the nucleus, while the vRNA genome is reverse transcribed within. This leads 
to the maturation into a  functional  RTC  (Iordansky et al., 2006).  HIV-1 is believed to take 
advantage  of  cellular  factors  such  as  cyclophilin  A  (CypA)  and  PDZ  domain  containing 8 
(PDZD8) (Guth et al., 2014) to regulate both viral core stability and disassembly allowing timely   25 
progression into RTCs (Figure 1.7C). Uncoating and reverse transcription are tightly coordinated 
processes as evidenced by impediments to each brought forward by disabling the other: Family 
members  of the  host  antiviral  factor TRIM5  (Tripartite motif-containing  Motif  5)  recognize 
intact viral cores (Figure 1.5A) and lead to their accelerated uncoating, which in turn inhibits 
reverse transcription and subsequent formation of the PIC and nuclear entry (Stremlau et al., 
2006).  There  are  CA  mutants  with  aberrant  stability  and  disassembly  kinetics  that  are  also 
defective for reverse transcription. Similarly, inhibitors of reverse transcription have been shown 
to delay the kinetics of uncoating, pointing to a two-way regulatory mechanism (Hulme et al., 
2011; Yang et al., 2013). 
When  exactly  uncoating  initiates,  and  whether  it  goes  to  completion  while  the  core 
traverses the cytoplasm on its way to the nucleus, are still poorly understood. Whereas there is 
some  evidence  in  support  of  gradual  CA  disassembly  during  reverse  transcription  up  until 
nuclear entry, others have proposed that intact cores can reach the nuclear membrane and dock at 
the nuclear pore complexes (NPCs; Di Nunzio et al., 2012), and may only disassemble with the 
aid of nucleoporins (NUPs) like Nup358 (Bichel et al., 2013). Alternative models emphasize that 
uncoating may not strip the RTC/PIC of all the CA molecules attached, and some CA may even 
make its way into the nucleus along with the PIC (Zhou et al., 2011). 
 
 
C.i.3.   Reverse Transcription 
Once in the cytosol, exposure to abundant levels of deoxyribonucleotides is hypothesized 
to trigger reverse transcription. This hypothesis garnered support by the recent discovery of a 
cellular restriction factor, SAMHD1, which blocks HIV-1 at the stage of reverse transcription by   26 
depleting cytosolic nucleotide pools. Viral Vpr/Vpx has been shown to antagonize SAMHD1 
activity by targeting it to proteosomal degradation (Lim et al., 2012). 
In the core, vRNA is packaged together with tRNALys,3. Once the tertiary clover leaf 
structure of tRNALys,3 is chaperoned by NC to open up, it serves as a primer for RT thanks to 
its 3’ end 18 nt sequence being complementary to the PBS on the vRNA.  
The RT holoenzyme is solely responsible for all steps of reverse transcription (B.ii.2, 
Figure  1.7D);  thus  it  serves  as  an  RNA-dependent  DNA  polymerase  (i),  a  nonspecific 
riboendonuclease (ii), and a DNA-dependent DNA polymerase (iii). The viral RT holoenzyme is 
responsible for (i) reverse transcribing the positive-sense single-stranded vRNA genome into a 
negative-sense  single-stranded  DNA  (minus-strand).  This  is  followed  by  (ii)  the  RNase  H 
subdomain  of  RT  degrading  the  original  RNA  template  within  this  RNA/DNA  genomic 
intermediate, except for two purine-rich sequences known as the polypurine tract (PPT) and the 
central PPT (cPPT). The PPT and the cPPT then prime the synthesis of the complementary 
positive-sense  DNA  strand (positive-strand)  yielding  a double-stranded genomic vDNA  (iii). 
Mechanical intricacies during positive-strand DNA synthesis at the cPPT generate a temporary 
DNA triplex, the ‘DNA flap’, which is proposed to enhance viral infectivity in nondividing 
target cells (Zennou et al., 2000, Arhel et al., 2007) (possibly by kinetic enhancement of reverse 
transcription; Skasko et al., 2008) and which also possibly antagonizes host restriction factor 
APOBEC3G (Wurtzer et al., 2006; Hu et al., 2010). 
APOBEC3G is incorporated into assempling virions in producer cells (Svarovskaia et al., 
2004), only to restrict reverse transcription in target cells by inducing C  U mutations in the 
minus-strand, which result in G  A hypermutations in progeny gRNAs and thus destroy the 
coding and replicative capacity of the virus (Suspène et al., 2006). Viral protein Vif evolved to   27 
counteract APOBEC3G by directing it to the ubiquitin-proteasome proteolytic pathway (B.ii.5, 
Figure 1.7D) (Marin et al., 2003; Sheehy et al., 2003; Newman et al., 2005). 
Reverse transcription ultimately results in a double-stranded vDNA with two homologous 
LTRs at both the 3’ and the 5’ ends, which is then used as a substrate for IN to form an intasome 
(an IN–tetramer holding together the two LTR ends of a vDNA).  
 
C.i.4.   Nuclear import of the PIC 
HIV-1, the prototypical lentivirus, can efficiently infect non-dividing cells (Lewis et al., 
1992).  It  can  import  into  the  postmitotic  nuclei  of  cells  via  active  transport  mechanisms 
(Bukrinsky et al., 1992)  -  a distinguishing property  generally  not shared by other genera of 
Retroviridae,  such  as  the  γ-retroviral  MLV  -  rendering  its  infection  cell  cycle-independent 
(Lewis et al., 1994). Another exception is the β-retrovirus MMTV, which was recently shown to 
be able to transduce non-dividing dendritic cells (Konstantoulas et al., 2014).  
Many viral RTC/PIC components and cellular nucleocytoplasmic shuttling proteins have 
been proposed to play a role in HIV-1  nuclear import, yet detailed investigations have been 
unable to definitively support these data (Suzuki et al., 2007). Studies involving partial gag-pol 
chimeras  generated  between  cell  cycle-dependent  MLV  (Roe  et  al.,  1993)  and  cell  cycle-
independent HIV-1 (Katz et al., 2003) revealed CA to be the major determinant of this ability 
(Figure 1.7E; Yamashita and Emerman., 2004). Originally, biochemical characterization efforts 
failed to detect CA as a major constituent of HIV-1 RTC (Karageorgos et al., 1993; Miller et al., 
1997; Fassati et al., 2001), the precursor of the PIC; and hence a potential functional role of CA 
in PIC nuclear import was unsupported. The MLV RTC, however, contained high levels of CA 
(Fassati et al., 1999), suggesting that a more stable and less uncoated MLV was being prevented 
from nuclear entry as opposed to a more extensively uncoated HIV-1. The viral determinant of   28 
nuclear import and cellular factors that facilitate this step are of major interest, because some of 
the physiologically relevant targets of infection, such as differentiated macrophages and resting 
T lymphocytes (Weinberg et al., 1991), are non-dividing cells where HIV-1 exclusively relies on 
this  pathway  and  may  utilize  it  in  other  cycling  target  cells,  as  well.  For  a  more  detailed 
description of our current understanding of HIV-1 PIC nuclear import, please refer to section 
D.ii. 
 
C.i.5.   Integration 
Once inside the nucleus, the HIV-1 PIC is ready to integrate the vDNA into the host 
chromatin in a reaction catalyzed by IN (B.ii.2), thus forming the provirus and completing the 
first phase of the viral replication cycle (Figure 1.7F). Integration site selection, however, is not a 
random process but rather favors weak palindromic sequences (Wu et al., 2005; Delelis et al., 
2007) within regions of high transcriptional activity (Mitchell et al., 2004; Wang et al., 2007; 
Santoni et al., 2010). PIC targeting (Marshall et al., 2007; Shun et al., 2007b) and chromatin 
tethering (Llano et al., 2006) to these preferred sites is mediated by the lens epithelium-derived 
growth factor (LEDGF/p75) via direct interaction with IN (Ciuffi et al., 2005; Cherepanov et al., 
2003; Cherepanov et al., 2004). More recently there has been accumulating evidence in favor of 
aditional cellular proteins playing roles in integration target site selection. Even though a direct 
binding to IN has been observed and thus a hypothetical mechanical explanation is available for 
some  of  these  factors  like  for  the  more  recently  discovered  transportin  3  (TNPO3/TRN-
SR2/importin 12; Christ et al., 2008; Krishnan et al., 2010a; Larue et al., 2012; Taltynov et al., 
2013)  and  Nup153  (Woodward  et  al.,  2009;  Matreyek  et  al,.  2011),  a  similar  biochemical 
explanation is missing for CypA, Nup358, and the cleavage and polyadenylation specific factor 6   29 
(CPSF6; mammalian cleavage factor I 68 kD subunit, CFIm68), which have also been shown to 
play regulatory roles in uncoating, nuclear import and integration site targeting. It is an attractive 
model that all these events are functionally linked to each other, where licensing or alternative 
path commitment  in steps prior to nuclear import and integration may play critical roles in 
integration target site selection itself (Pryciak et al, 1992; Lewinski et al., 2006; Koh et al., 
2013). 
 
C.ii.   Late phase events     
C.ii.1.  Gene expression 
Following provirus formation, HIV-1 utilizes host transcription factors and host RNA Pol 
II to express its genome from the 5’ LTR (Figure 1.3). The viral accessory protein Tat serves a 
crucial  role  at  this  step  triggering  transcriptional  initiation  via  recruitment  of  the  positive 
transcription  elongation  factor  b  (P-TEFb),  which  enhances  RNA  Pol  II  processivity  and 
stimulates long vRNA synthesis (B.ii.4, Figure 1.7G). HIV-1 mRNAs are then transported into 
the  cytoplasm  using  the  CRM1  dependent  nuclear  mRNA  export  pathway.  In  the  case  of 
unspliced long vRNAs, the viral accessory protein Rev enables utilization of the same export 
pathway, which normally promotes export only if coupled to mRNA splicing (B.ii.4, Figure 
1.7H). Viral structural proteins are expressed as polyproteins (Figure 1.7I) that rely on a post-
release maturational step to yield functional particles. Viral accessory and regulatory proteins are 
expressed as final protein products (Figure 1.7I; Frankel et al., 1998). 
     30 
C.ii.2.  Production of progeny virions  
Once  viral  proteins  and  genomic  vRNA  are  expressed,  they  traffic  to  the  plasma 
membrane to initiate the assembly process (Figure 1.7J). Gag is targeted to the membrane via its 
N-terminal  myristoylated  MA  domain  (Ono  et  al.,  2000),  while  the  NC  domain  of  the 
polyprotein enables Gag self-assembly and also mediates viral gRNA encapsidation via direct 
interaction  with  the  ψ  signal.  CA-CTD  also  serves  a  critical  role  in  immature  Gag 
multimerization  (B.ii.1).  HIV-1  glycoprotein  precursor  gp160  is  synthesized  on  the  rough 
endoplasmic reticulum (ER), where it is  threaded into the ER-lumen accessing the secretory 
pathway to reach the cell surface. En route to the cell surface  the gp120 domain is heavily 
glycosylated within the trans-Golgi network before getting cleaved by furin or a related host 
protease into gp120 and gp41 to yield mature Env glycoprotein trimers (B.ii.3) (Vollenweider et 
al., 1996; Moulard et al., 2000). Embedded in the plasma membrane, the cytoplasmic tail of gp41 
interacts with the MA domain of Gag, enabling its own incorporation into assembling virions 
(Figure  1.7J)  (Checkley  et  al.,  2011).  Viral  budding  is  then  facilitated  by  the  host  ESCRT 
machinery that is recruited to assembly sites with the aid of the p6 protein (B.ii.5, Figure 1.7K). 
Virion  release  into  the  surroundings,  however,  may  not  necessarily  ensue  freely,  as  budded 
virions can still be trapped by the host restriction factor tetherin via membrane anchoring (Van 
Damme et al., 2008) (Figure 1.7L). The viral accessory factor Vpu counteracts tetherin function 
by  inducing  its  proteosomal  degradation  by  targeting  it  for  polyubiquitination  (B.ii.5)  (Van 
damme et al., 2008; Neil et al., 2008). 
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C.ii.3.  Virion maturation 
Presumably  mediated  by  an  increase  in  its  local  concentration  within  an  assembled 
virion, the activation of the PR domain of Gag-Pol initiates autocleavage of Gag-Pol molecules 
and cleavage of Gag polyproteins (Figure 1.7M). The series of these maturational cleavages 
result in an infectious progeny virion, thus completing the viral life cycle (B.ii.1-2, Figure 1.7A-
M). 
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D.   HIV-1 PIC nuclear import 
D.i.   Nucleocytoplasmic transport and the Ran-GTP cycle 
HIV-1 is believed to gain access to the nucleoplasm by passing through aqueous channels 
created by NPCs on the nuclear envelope, which act as selective passageways actively regulating 
bidirectional nucleocytoplasmic shuttling of molecules in eukaryotic cells (Stewart et al., 2007). 
NPCs are multiprotein complexes built from both permanent and dynamic structural components 
named  NUPs  (Paulillo  et  al.,  2005;  Strambio-De-Castillia  et  al.,  2010).  They  coordinate 
molecular trafficking together with members of the ancient solenoid HEAT repeat containing 
soluble karyopherin β (KPN β) superfamily of nuclear transport receptors (Figure 1.8A; O’Reilly 
et al., 2011) that transiently associate with NPCs (O’Reilly et al., 2011).  
Size  limitations  of  NPCs  allow  passive  diffusion  of  small enough  molecules  (with a 
diameter less than ~ 9 nm), whereas large cargo (with a diameter up to ~ 39 nm; Pante et al., 
2002) require facilitated active transport that is mediated by members of the KPN β superfamily. 
Importins  are  KPN  β  proteins  responsible  for  transport  into  the  nucleus,  whereas  exportins 
enable nucleocytoplasmic export (Figure 1.8A, B). Accordingly, the quest for NUPs and soluble 
importins playing a role in HIV-1 PIC nuclear import has been a subject of much research.  
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Figure 1.8 Nucleocytoplasmic transport and the Ran cycle. (A) Importins and exportins differ from each 
other  in  their  ability  to  bind  RanGTP  and  their  cargo  either  competitively  or  cooperatively.  (B)  A 
schematic showing the maintenance mechanism of the Ran gradient across the nuclear barrier and the 
regulation of Ran-dependent nuclear transport of both import and export cargoes. Please refer to the main 
text for a detailed description. Adapted and modified from Petosa, 2012.  
 
Cargo binding to KPN β proteins is regulated by the small Ras-related nuclear protein 
(Ran)  GTPase.  Directionality  of  nucleocytoplasmic  shuttling  is  established  by  actively 
maintaining  an  asymmetric  gradient  of  the  guanosine  diphosphate  (GDP)-  or  guanosine 
triphosphate (GTP)-bound Ran across the nuclear barrier (Figure 1.8B). Two Ran co-factors, 
situated  on  opposite  sides  of  the  nuclear  envelope  enable  this:  Regulator  of  chromosome 
condensation  1  (RCC1,  Ran  guanine  nucleotide  exchange  factor,  RanGEF)  resides  in  the   34 
nucleus, is associated with nucleosomes (Nemergut et al.,  2001), promotes the conversion of 
RanGDP to RanGTP; Ran GTPase-activating protein (RanGAP) is located on the cytoplasmic 
side of NPCs, is associated with Nup358 filaments (Wilken et al., 1995), and stimulates the 
GTPase activity of Ran in cooperation with the Ran binding protein 1/2 (RanBP1/2), inducing 
RanGTP to RanGDP catalysis (Bischoff et al., 1994). RanGTP is the predominant form inside 
the nucleus, whereas RanGDP is more abundant in the cytosol (Figure 1.8B). 
Ran preferentially binds KPN β proteins in its GTP-bound state (inside the nucleus), and 
GTP to GDP hydrolysis by Ran causes its dissociation from KPN β proteins (on the cytoplasmic 
side of NPCs; Melchior et al., 1995). By means of nuclear localization signal (NLS) sequences 
nuclear-bound cargoes preferentially bind importins (Fontes et al., 2000) in their Ran-free state 
in the cytosol, and are then ferried inward through the NPCs with the aid of the phenylalanine-
glycine (FG)-repeat containing NUPs, that line the NPC (Terry et al., 2009). Cargo and RanGTP 
binding to importins is competitive due to steric hindrance caused by overlapping binding sites 
(Figure 1.8A), and, thus, once at the nucleoplasmic side of the NPCs the high concentration of 
RanGTP enables cargo release. Importins, now complexed with RanGTP, are ferried back to the 
cytoplasmic  side  of  NPCs,  where  Nup358  associated  RanGAP  and  RanBP1/2  stimulate  the 
conversion  of  RanGTP  to  RanGDP  and  induce  Ran  dissociation,  successfully  recycling  the 
karyopherin (Figure 1.8B).  
In the case of exportins such as exportin 1 (CRM1, XPO1), cargo and RanGTP binding is 
cooperative (Figure 1.8A), allowing cargo to preferentially bind the transport protein inside the 
nucleus.  This  binding  is  mediated  by  nuclear export  signal  (NES)  sequences  present  within 
export cargo. Following outward transit through the NPC, this ternary complex again dissociates 
upon RanGAP/RanBP1-stimulated Ran GTPase activity (Kehlenbach et al., 1999). This releases   35 
both the cargo protein and hydrolyzed RanGDP into the cytosol, at which point the free exportin 
can  transit  back  into  the  nucleus  (Figure  1.8B).  Nuclear  transport  factor  2  (NTF2)  then 
selectively imports free RanGDP into the nucleus, where RanGEF can exchange the GDP with 
GTP,  thereby  replenishing  the  nuclear  RanGTP  pools.  This  allows  the  maintenance  of  the 
original Ran gradient (Figure 1.8B). Biochemical studies frequently employ a point mutant of 
Ran, i.e. RanQ69L, which is deficient in GTPase activity, and thus cannot hydrolyze the bound 
GTP. This enables stable karyopherin:RanGTP complex formation aiding characterization in 
binding studies, especially.  
 
D.ii.   Viral and cellular components of RTC/PIC mediating HIV-1 nuclear import 
The RTC and the PIC are believed to be dynamic nucleoprotein complexes, with viral 
and cellular proteins associating with and dissociating from them en route to the chromatin to 
regulate uncoating, reverse transcription and nuclear import. RTCs and intact capsid cores are 
100-200 nm long and have a 50-60 nm diameter across their narrow ends (Miller et al., 1997; 
Zhao et al., 2013), which exceed the 39 nm size limit of transport through NPCs. Accordingly, 
during their maturation into PICs, RTCs must undergo conformational changes such as capsid 
uncoating, and a reduction in their contents, in order to allow the nuclear entry of the intasome 
(vDNA and the active IN-tetramer) as part of a functional PIC with other associated proteins 
(Figure 1.7E). The PIC is estimated to have a diameter of 56 nm at this stage (Miller et al., 
1997). 
Many studies employed coordinated biochemical and functional assays to identify the 
protein components of these complexes at various stages of the infection, as monitored by the 
progress of bulk reverse transcription, nuclear import and in vitro integration activity. RTCs are   36 
more suitable for characterization thanks to their cytoplasmic abundance and specific enzymatic 
activity. When measuring RT activity, the functional readout, namely the amount of early/late 
stage reverse transcripts (ERT/LRT) formed, is already established inside cells before carrying 
out quantification, which minimizes experimental manipulations and increases the accuracy of 
the assay. 
Biochemical identification of viral and cellular components of RTC/PICs before and after 
nuclear import, however, poses a formidable task. Due to low retroviral titers, at physiologically 
relevant experimental conditions with a multiplicity of infection (MOI) of ≤1, as per definition, 
only  ≤1  functional  RTC/PIC  per  cell  will  form,  restricting  biochemical  resources.  Also 
confounding is the fact that PIC activity is tracked by in vitro integration assays (Farnet et al., 
1990), where IN alone will also score positive (Bushman et al., 1991), rendering the presence of 
PIC cofactors practically redundant. In vitro PIC integration assay requires partial purification of 
cytoplasmic and nuclear PICs prior to the assay (Engelman et al., 2009), which may be intrusive 
to structural PIC integrity, and thus skew the assay towards false negatives. This latter concern 
applies to biochemical characterization efforts of RTCs and PICs alike. 
A second approach to monitor PIC-specific activity entails reconstituted nuclear import 
experiments, where isolated cellular fractions or purified cofactors can be added back to PICs 
and isolated nuclei to be assayed for their competence in inducing in vitro nuclear import. Use of 
cell  extracts  depleted  of  candidate  cofactors  provides  a  complementary  approach.  A  third 
approach takes advantage of the phenomenon that vDNA and duplicate terminal LTR’s (Figure 
1.6), once inside the nucleus, can be used as a substrate by the DNA damage repair machinery. 
The homologous DNA recombination (Kilzer et al., 2003) and the non-homologous end-joining 
(NHEJ) pathways give rise to non-infectious, dead-end (albeit limited episomal transcription has   37 
been observed) vDNA structures called 1-LTR and 2-LTR circles (Fritsch et al., 1977; Farnet et 
al., 1991), respectively, which can serve as surrogate markers for vDNA nuclear entry (Li et al., 
2001). Yet another non-productive circular vDNA species is autointegrants, which may form as a 
result of prematurely activated IN that integrates the vDNA into itself (Yan et al., 2009), giving 
rise to circular forms that harbor two LTR sequences. Careful selection of qPCR primers is 
needed to properly distinguish these species from actual 2-LTR circles with defined junctions 
(De Iaco et al., 2013).  
Similarly,  following  adequate  and  validated  subcellular  fractionation,  cytoplasmic  vs. 
nuclear distribution of LRTs can be measured, though a limited ability to distinguish between 
nucleoplasmic (truly inside the nucleus) vs. nuclear membrane associated (technically outside the 
nucleus) vDNA can make such an analysis difficult. Lastly, real-time confocal microscopy of 
fluorescently labeled RTC/PICs (Jun et al., 2011; Lelek et al., 2012; Pereira et al., 2012) and 
immunofluorescent labeling of fixed samples have been developed with the aim of quantitatively 
monitoring RTC/PIC trafficking (McDonald et al., 2002; Arhel et al., 2007) and even ultimate 
integration  target  site  visualization  (Di  Primio  et  al.,  2013).  The  inability  to  match  labeled 
complexes  with  active,  integration-competent  PICs,  however,  puts  some  limitation  on  the 
interpretability of these assays.   
These complications aside, and despite the lack of more direct methods, past research 
efforts  consistently  observed  the  copurification  of  MA,  RT,  and  Vpr  with  active  viral 
nucleoprotein complexes in fractionation experiments (Bukrinsky et al., 1993; Miller et al., 1997; 
Fassati et al, 2001). CA, the major structural constituent  of the  core upon delivery into the 
cytosol,  was,  however,  either  completely  absent  or  only  minimally  present  in  the 
cytoplasmic/nuclear fractions that displayed reverse transcription activity – a striking difference   38 
from MLV RTCs – even though there has been incidental detection of CA in actively reverse 
transcribing  HIV-1  RTCs  in  immunofluorescence  based  assays  (McDonald  et  al.,  2002). 
Disregarding the possibility that loosely attached components like CA may have been stripped 
off of RTC/PICs during purification, the absence of CA in biochemical characterization efforts 
was interpreted as HIV-1 cores uncoating to completion prior to PIC formation. Later efforts, 
however, managed to detect CA both in cytoplasmic RTCs (McDonald et al., 2002; Albanese et 
al., 2008), in association with NPCs (Arhel et al., 2007), in crude biochemical nuclear fractions 
(Zhou et al., 2011) and even inside the nucleus (Di Nunzio et al., 2012), though it is hard to 
comment whether there is any functionality to its presence in these settings due to the limitations 
of the assays discussed before.  
Many of the viral elements identified as PIC components have transferable karyophilic 
signals dubbed NLSs, as determined in ectopic expression assays (Haffar et al., 2000; Bouyac-
Bertoia  et  al.,  2001).  Even  though  the  isolated  expression  separate  from  a  PIC  may  not 
necessarily recapitulate the conditions a functional PIC encounters during infection, each of 
these viral elements (MA; IN; Vpr) have each been proposed to be responsible for PIC nuclear 
import to some extent (Bukrinsky et al., 1993a; Heinzinger et al., 1994; Freed et al., 1995; Gallay 
et al., 1995; Gallay et al., 1997; Bouyac-Bertoia et al., 2001). This is mediated by recruiting 
members of the nuclear transport machinery: Basic type NLSs within IN can bind to importin ʱ 
adaptors and KPN β members themselves, e.g. importin 7 (Fassati et al., 2003), importin ʱ3 (Ao 
et al., 2010) and TNPO3 (Christ et al., 2008; Krishnan et al., 2010a; Larue et al., 2012). IN and 
Vpr have been shown to bind  NUPs directly (Fouchier et al., 1998;  Le Rouzic et al.; 2002; 
Woodward et al., 2009), which would allow them to by-pass a need for soluble KPN β import 
receptors (Jenkins et al., 1998). Point mutations to IN are known to have pleiotropic effects   39 
including defects in PIC nuclear import (Limón et al., 2002a; Lu et al,. 2004); and finally a non-
proteinacious PIC component, namely the genomic triple-stranded DNA flap element generated 
by the cPPT and the central termination signal (CTS), has been proposed to facilitate HIV-1 PIC 
nuclear  import  by  an  unknown  mechanism  (DeRijk  et  al.,  2006).  However,  none  of  these 
individual elements are indispensable to PIC nuclear import during the course of a successful 
infection as shown by subsequent studies (Freed et al., 1997; Fouchier et al., 1997; Limón et al., 
2002b; Dvorin et al., 2002; Zielske et al., 2005., Yamashita et al., 2005; Marsden et al., 2007; 
Rivière et al., 2010) - and in the case of IN, it has been impossible to distinguish specific nuclear 
import defects from indirect ones due to the pleiotropic nature of IN mutations. 
As far as the cellular machinery that HIV-1 exploits on its way into the nucleus goes, 
many nuclear-associated factors including importin-β, importin-7, TNPO3, importin-ʱ (Kamata 
et al., 2005; Hearps et al., 2006), importin-ʱ3 (Ao et al., 2010; Jayappa et al., 2011); Nup98 
(Ebina et al., 2004), Nup153 (DiNunzio et al., 2013; Matreyek et al., 2011), Nup358 (RanBP2; 
with a C-terminal cyclophilin domain; Zhang et al., 2010; Ocwieja et al., 2011) have come into 
the spotlight. Even tRNAs with defective 3' CCA ends have been implicated  in PIC nuclear 
transport (Zaitseva et al., 2006), though many of these factors and their potential functional roles 
in HIV-1 biology await confirmation (Figure 1.7E).  
 
D.ii.1.  The role of HIV-1 CA in PIC nuclear import  
In a rather ingenious experiment, growth-arrested, non-dividing cells were infected with 
chimeric  viruses  that  were  generated  by  swapping  partial  gag/pol  domains  between  nuclear 
import capable HIV-1 and nuclear import deficient MLV (Yamashita et al 2004; Yamashita et 
al., 2005). The experiment pinpointed CA as the viral determinant of efficient transport of vDNA   40 
across the nuclear barrier (as assayed indirectly via 2-LTR circle formation) before proceeding 
with integration. The presence of MLV CA rendered chimeric viruses cell cycle-dependent in all 
genomic contexts, mirroring the parental MLV. Follow up studies identified point mutations in 
CA facing the interhexameric space that resulted in low-titer, cell cycle dependent defective 
viruses  with  aberrant  core  stability;  e.g.  T54A/N57A  and  Q63A/Q67A  (Figure  1.9A-C) 
(Dismuke et al., 2006., Yang et al., 2007; Qi et al., 2008). T54A/N57A virus displayed a rather 
unique post-nuclear entry, pre-integration defect. Q63A/Q67A had both poor core stability and 
restricted  nuclear  import,  although  there  are  confounding  studies  claiming  extended  core 
integrity. While the cell cycle dependence of these two mutants have been observed in all cell 
lines tested, other studies identified additional CA mutants with growth arrest phenotypes in a 
cell type dependent fashion.    41 
 
Figure 1.9 CA mutants with defective core stability, PIC nuclear import and growth arrest phenotypes 
define a novel CA surface pocket at the hexamer:hexamer interface. (A) 3D structure of the A92E HIV-1 
core determined by single particle cryo-EM tomography reveals the interface between two CA hexamers. 
Two CA molecules, each on an adjoining hexamer facing each other at the interhexameric space, are 
highlighted in this series of surface renderings. Top view. (B) Side view with highlighted CA secondary 
structures. (C) Individual amino acid residues with uncoating, nuclear import growth arrest phenotypes 
are highlighted on two CAs facing each other at the hexamer interface. CA-NTDs, orange; CA-CTDs, 
blue; CA-NTD1, green; CA-NTD2, red. PDB: 1VU5 (Zhao et al., 2013)   42 
Two  such  mutations  are  A92E  and  G94D,  where  both  residues  extend  over  to  the 
interhexameric space on a mature core (Figure 1.9A-C). They lie on a surface-exposed flexible 
loop that mediates binding to CypA (PPIA), an 18 kD prolyl isomerase (Bosco et al., 2002) that 
recognizes the 89GP90 dipeptide within the CypA binding loop (Braaten et al., 1996; Gamble et 
al.,  1996;  Yoo  et  al.,  1997),  85PVHAGPIAPG94  of  HIV-1  CA  (Figure  1.9A-C),  and  gets 
incorporated into the virion via this interaction (Thali et al., 1994; Franke et al., 1994). The 
initial interaction between CypA and HIV CA takes place at the stage of viral assembly where 
CypA gets incorporated into assembling virions during Gag multimerization at a Gag:CypA ratio 
of 10:1 (Gross et al., 1998). It was later shown, however, that CypA plays a functional role 
during the early phase of infection in the target cell (Sokolskaja et al., 2004). The CA:CypA 
interaction can be inhibited by cyclosporine A (CsA), a small molecule drug that competitively 
binds  and  blocks  the  CypA  active  site  (Handschumacher  et  al.,  1984),  which  curbs  HIV-1 
infectivity  in  many  natural  target  cell  lines  (Wainberg  et  al.,  1998).  A92E  and  G94D  are 
mutations within the CypA-loop of CA that evolved under suboptimal CsA selection (Aberham 
et al., 1996), rendering mutant viruses not only CsA-resistant but also CsA-dependent in some 
cell lines. A series of studies have extensively characterized A92E and G94D viruses from a 
functional perspective. They display a growth arrest phenotype with a reversible post-nuclear 
import block to infection and may also affect capsid core stability. A CsA-dependent infection 
profile is suggestive of a CypA-dependent restriction in untreated non-permissive cell lines with 
high CypA content (Yin et al., 1998; Ylinen et al., 2009). The infectivity defect of these mutants 
observed in the absence of CsA can similarly be relieved upon combining A92E or G94D with 
CypA binding mutants G89V or P90A. Yet even after the atomic structure of the CypA:CA-
NTD complex was solved, the underlying mechanistic details of how A92E or G94D function   43 
have eluded investigators, because the mutations do not seem to affect CA-NTD binding to the 
attached CypA molecule (In Appendix A, a novel hypothetical superstructural model will be 
discussed  that  bears  a  potential  to  explain  these  opposing  CypA  phenotypes,  thanks  to  a 
proposed  noncanonical  interaction  surface  between  CypA  and  the  CA  hexameric  lattice).  A 
recently  identified  mutant  CA  N121K  also  bears  similar  CsA-dependent  phenotypes,  even 
though N121 does not lie on the CypA loop of CA (Takemura et al,. 2013). 
 
D.ii.2  Other cellular factors modulating HIV-1 CA and PIC nuclear import  
Until recently the only other CA-interacting family of host factors with effects on HIV-1 
core stability and downstream steps was the species-specific TRIM5ʱ innate restriction proteins 
that act as barriers to cross-species transmission of primate lentiviruses (Hofmann et al., 1999). 
Upon the release of the viral core into the cytoplasm, TRIM5ʱ acts by recognizing the hexagonal 
capsid lattice at a macroconformational rather than a residue-specific level (Ohkura et al., 2011; 
McCarthy et al., 2013) and by targeting it for proteasomal degradation in a series of not fully 
delineated steps that involve potential  polyubiquitination  (Danielson et al., 2012)  and innate 
immune signaling mediated by unattached K63-linked ubiquitin chains (Pertel et al., 2011). This 
cellular block prevents the core from maturing into functional RTCs, which can be relieved upon 
MG132 proteasomal inhibitor treatment, allowing reverse transcription to ensue only to form 
nuclear import-deficient RTCs (Anderson et al., 2006; Wu et al., 2006). Similary, several natural 
(TRIMCyp; Yap et al., 2006) and engineered (Friend virus susceptibility 1 (Fv1)-Cyp; Schaller 
et al., 2007) CypA fusion constructs (facilitating CA recognition via CypA:CA interactions) have 
been shown to result in post-reverse transcription and post-nuclear import infectivity defects. 
The recently identified HIV-1 restriction factor myxovirus resistance 2 (Mx2, MxB) (Goujon et   44 
al., 2013; Kane 2013; Liu et al., 2013) seems to target the incoming core at this stage as well, 
also evidenced by the presence of Mx2-resistant CA-CTD mutants (Busnadiego et al., 2014). 
These observations suggest that the HIV-1 core disassembles in a regulated fashion both in a 
positive and negative way and facilitates a functional connection between reverse transcription, 
nuclear trafficking and possibly beyond as evidenced by post-nuclear import blocks encountered 
by several capsid core mutants with aberrant stability/uncoating phenotypes, which may stem 
from a decreased ability to interact with regulatory host factors. 
The importance of cellular factors in mediating HIV-1 infection has most recently been 
explored further by employing human RNAi screens (Brass et al., 2008; Koenig et al., 2008; 
Zhou et al., 2008; Yeung et al., 2009). These screens identified hundreds of potential new HIV-1 
dependency  factors,  one  of  which,  a  nucleo-cytoplasmic  shuttling  protein,  the  importin-β 
TNPO3/TRN-SR2, sparked great interest.  Depleting TNPO3 resulted in an HIV-1 infectivity 
defect in two of these screens (Brass et al., 2008; Koenig et al., 2008) and this infectivity defect 
was mapped to a step in the viral life cycle post-reverse transcription and pre- or at integration. 
As a nucleo-cytoplasmic SR protein transporter, whose depletion resulted in an infectivity defect 
that is compatible with a hypothetical role in HIV-1 nuclear import, TNPO3 has quickly become 
a popular research subject.  
Independent research efforts identified CPSF6/CFIm68, a pre-mRNA splicing factor that 
is a member of the SR protein family (Ruegsegger et al., 1996), to potentially play a role in HIV-
1 PIC nuclear import in a CA-dependent way. Overexpression and cytoplasmic localization of a 
truncation  mutant  of  CPSF6,  CPSF6-358,  which  lacks  the  original  C-terminal  domain,  was 
shown to cause a novel, CA-targeting restriction of HIV-1 PIC nuclear import in mammalian 
cells (Lee et al., 2010). It was noteworthy that the truncation removed the C-terminal RS domain   45 
of CPSF6, which pointed to a hypothetical model that CPSF6 might be a potential cargo of 
TNPO3, and the restriction caused by CPSF6-358 may have stemmed from its potential inability 
to interact with and to be shuttled into the nucleus by TNPO3.  
The discovery of these two novel host factors, TNPO3 and CPSF6, which exerted CA-
dependent phenotypes in core uncoating, nuclear import and integration site targeting piqued our 
interest to study their function, leading to this dissertation. 
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A.  Abstract                     
 
Recent genome-wide screens have highlighted an important role for TNPO3 in HIV-1 
infection and PIC nuclear import. Moreover,  HIV-1  IN interacted with recombinant TNPO3 
under conditions whereby MLV IN failed to do so, suggesting that IN:TNPO3 interactions might 
underscore active retroviral PIC nuclear import. Here we compared infectivity defects in TNPO3 
knockdown (KD) cells with in vitro TNPO3 binding affinities to INs of an expanded set of 
retroviruses. Our results fail to support the hypothesis that TNPO3:IN interactions play a critical 
role  in  TNPO3  dependency  of  retroviral  infection.  In  addition  to  IN,  CA  has  also  been 
highlighted as a retroviral nuclear import determinant. By utilizing MLV/HIV-1 chimera viruses 
we pinpointed the genetic determinant of sensitization to TNPO3 knockdown to the HIV-1 CA 
protein. We therefore conclude that CA, not IN, is the dominant viral factor that dictates TNPO3 
dependency  during  HIV-1  infection.  Under  conditions  where  the  expression  of  CPSF6  is 
enriched in the cytoplasm, be it by overexpression or mutation, we discovered a block to HIV-1 
PIC nuclear import. We gathered evidence that the underlying mechanism is direct binding of 
CPSF6 to CA. The Asn74Asp (N74D) mutation of HIV-1 CA led to a loss of interaction with 
CPSF6 and evasion of the nuclear import restriction. The same mutation rendered HIV-1 TNPO3 
independent, pointing to a functional link between TNPO3 and CPSF6. We show that compared 
to  wild-type  (WT)  HIV-1,  N74D  HIV-1  is  more  sensitive  to  cyclosporine,  and  this  is 
accompanied with a reduced affinity for ectopically expressed CypA, suggesting an indirect 
functional interplay between CPSF6 action and CypA as well. 
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B.   Introduction                     
   
B.i.  TNPO3 has a positive functional role in HIV-1 infection at a post reverse  
transcription / preintegration step   
The importance of cellular interactors in mediating HIV-1 infection has been extensively 
described by human RNAi screens (Brass et al., 2008; Koenig et al., 2008; Zhou et al., 2008; 
Yeung  et  al.,  2009)  that  identified  hundreds  of  potential  new  HIV-1  dependency  factors. 
Although  there  was  little  overlap  between  these  studies  (Bushman  et  al.,  2009),  a  nucleo-
cytoplasmic shuttling protein, the importin-β TNPO3/TRN-SR2 resulted in a HIV-1 infectivity 
defect upon its knockdown in two of these screens (Brass et al., 2008; Koenig et al., 2008). The 
requirement for TNPO3 for  efficient HIV-1 infection was also confirmed in an independent 
study, where it was identified in a yeast-2-hybrid screen as an HIV-1 IN interactor. The same 
study proposed that TNPO3 may be responsible for mediating the nuclear import of HIV-1 PICs, 
as TNPO3 was not seen to bind the IN of MLV that lacks the ability for nuclear import. Even 
though it was uniformly established in all these studies that TNPO3 knockdown did not affect 
reverse transcription, assays looking for the nuclear presence of HIV-1 DNA products, either by 
quantifying total vDNA in nuclear vs cytoplasmic fractions or by assessing the levels of 2-LTR 
circles, failed to agree whether there was a nuclear import defect. As described in Chapter 1; 
D.ii, 2-LTR circles are accepted as a surrogate marker for nuclear import of HIV-1 PICs because 
their formation depends on the host nuclear NHEJ machinery, which joins the two viral terminal 
LTRs together.      49 
 
Figure 2.1 Overview of the crystal structures of unliganded TNPO3 (A), TNPO3:RanQ69L-GTP (B), and 
TNPO3:ASF/SF2 RRM2-RS (C) complexes. TNPO3 is shown as a cartoon, and the RRM2-RS domain of 
ASF/SF2 and Ran are depicted in space-filling surface rendering mode. TNPO3 is colored green except 
for the orange arginine rich R-helix responsible for cargo binding; Ran is colored yellow; and RRM2 and 
RS domains of ASF/SF2 are blue and magenta, respectively. H; helix. (Maertens et al., 2014). 
 
TNPO3 is a transporter of serine-arginine rich (SR) protein family of splicing factors 
(Kataoka et al., 1999; Allemand et al., 2002) that mediates energy-dependent nuclear import of 
cargo  molecules  containing  arginine-serine/arginine-aspartate/arginine-glutamate  (RS/RD/RE) 
rich  domains  (Maertens  et  al.,  2014).  The  Ran  cycle  responsible  for  energy  generation  is 
described in Chapter 1; D.i.  
The  recently  solved  X-Ray  structures  of  TNPO3,  TNPO3:RanQ69L-GTP  and 
TNPO3:ASF/SF2 RRM2 (serine-arginine rich splicing factor 1 / pre-mRNA splicing factor 2 
RNA recognition motif 2)-RS (arginine-serine rich) domain revealed atomic level mechanistic 
insight into (i) how cargo binding is established by pulling in the solenoid karyopherin TNPO3 
(Figure  2.1A)  unto  itself  via  multiple  interactions  (Figure  2.1C)  and  into  (ii)  how  cargo  is   50 
released upon RanQ69L-GTP binding via steric hindrance (Figure 2.1B). This particular study 
highlighted  the  importance  of  an  arginine  rich  R-helix  (specifically  R661,  R664,  R667  and 
R671) and additional residues (R620, R754, R758) in TNPO3 for mediating critical interactions 
with phosphorylated serine residues on ASF/SF2, a canonical SR protein. 
TNPO3-mediated import had been shown to be dependent on the cellular kinase mediated 
phosphorylation of serine residues within RS-domains, as exemplified in the case of the splicing 
factor  ASF/SF2  (Colwill  et  al.,  1996;  Lai  et  al.,  2000;  Lai  et  al.,  2001).  However, 
phosphorylation-independent cargo binding has also been observed (Lai et al., 2003; Yun et al., 
2003).  The  observation  that  TNPO3,  a  nucleocytoplasmic  shuttling  protein  that  may  play  a 
functional role at the step of PIC nuclear import or beyond in integration site targeting (Ocwieja 
et  al.,  2011)  and  its  initial  identification  as  an  HIV-1  and  lentiviral-specific  IN  -  a  PIC 
component - interacting protein garnered interest due to a potential interaction with the PIC in 
infected cells. This observation was, however, at odds with the finding that CA rather than IN is 
the functional determinant of PIC nuclear import (Chapter 1; D.ii) and thus prompted further 
study. 
 
B.ii.  Identification of a novel HIV-1 restriction factor, CPSF6-358     
Additional laboratory evidence supporting a functional role of CA in PIC nuclear import 
came  from  a  study  in  which  we  participated.  The  discovery  of  a  novel,  yet  artificial,  CA-
mediated  restriction  of  HIV-1  PIC  nuclear  import  in  mammalian  cells,  induced  upon 
overexpression and cytoplasmic localization of a C-terminally truncated form of the SR protein, 
CPSF6-358, was noteworthy due to the loss of its RS domain and its potential ability to be 
recognized by TNPO3, the SR protein transporter (Lee et al., 2010). CPSF6/CFIm68 is a pre-  51 
mRNA splicing factor that is a member of the SR-protein family (Ruegsegger et al., 1996) and 
bears a noncanonical C-terminal RS/RD/RE domain spanning residues 526-588 (Figure 2.2). 
Other discernible structural features are an N-terminal RNA recognition motif  and a central 
proline rich domain (Figure 2.2) that is predicted to be devoid of secondary structure. 
 
Figure 2.2 A schematic of CPSF6. Domains identified so far important for CPSF6 function have been 
highlighted.  The  N-terminal  CPSF6  domain  spanning  83-157  aa,  highlighted  in  light  blue,  has  been 
demonstrated to mediate intermolecular interactions with CPSF5, another splicing factor CPSF6 forms 
heterodimers  with,  mediating  their  joint  nuclear  localization  (Yang  et  al.,  2011).  The  central  9-mer 
peptide sequence spanning 314-322 aa, highlighted in orange, is buried within a predictably nonstructured 
proline-rich region and mediates CA-recognition (Lee et al., 2012), as confirmed in a co-crystal with 
HIV-1  CA-NTD  (Price  et  al.,  2012),  revealing  a  novel  surface  binding  pocket  on  CA-NTD  that 
CPSF6/CPSF6-358  presumably  buries  itself  into.  The  C-terminal  RS  domain  spanning  527-588  aa, 
harbors many RS/RD/RE repeats and is predicted to be responsible for TNPO3 binding.  
 
CPSF6 is found in the nucleus, whereas the restrictive form, CPSF6-358 resides in the 
cytoplasm (Lee et al., 2010). The susceptibility of HIV-1 to CPSF6-358-mediated restriction was 
mapped to CA, because a resistant virus that evolved during passage in CPSF6-358 expressing 
cells harbored a single point mutation in CA, N74D, which is found in a well conserved surface   52 
pocket on primate lentiviral CAs (Lee et al., 2010; Price et al,. 2012). In fact, N74 and adjoining 
CA residues are invariant among known HIV-1 isolates (Lee et al., 2010). A co-crystal structure 
of CA-NTD and a 15-mer peptide within the central proline-rich domain corresponding to 313-
327 aa of CPSF6 was solved, identifying a direct interaction between the two. The CA contact 
points in the structure were N57, Q67, K70, N74, A105, T107 and S109, all grouping together on 
the CA-NTD (Figure 1.9C) in a surface pocket that faces the interhexameric space described in 
Chapter 1; D.ii.1.  
 
B.iii.  Preintegrative steps of HIV-1 infection are subject to modulation by CypA, a  
CA interacting protein   
As described in D.ii.1, pinpointing the specific role of CypA in HIV-1 infection has been 
difficult. In lymphocyte-derived cell lines with low CypA concentrations, CypA seems to have a 
positive  effect  on  HIV-1,  possibly  by  increasing  incoming  core  stability  for  a  critical  time 
window, whereas in cell lines such as HeLa cells or lymphocyte derived cell lines with high 
CypA content (Yin et al., 1998; Ylinen et al., 2009), it may reversibly impede infection by 
several HIV-1 CA mutants such as E45A, A92E, G94D, T54A/N57A and Q63A/Q67A, which 
can be relieved by CsA treatment (Song et al., 2007; Qi et al., 2008). Other studies highlighted 
the dual nature of CypA modulation on incoming RTC/PICs even with WT HIV-1 pointing to a 
possible positive effect on reverse transcription although a cell type-dependent, CypA-related 
dominant restriction at the stage of nuclear import (Song et al., 2007; Yamashita et al., 2009) had 
the potential to override such enhancement (De Iaco et al., 2014). CypA exerts an effect as early 
as at the stage of uncoating, causing early capsid disassembly as evidenced in the case of CA 
A92E (Li et al., 2009), but it also has downstream effects on integration site targeting (Schaller   53 
et  al.,  2011).  These  functional  observations  with  mostly  CA  mutants  in  cell-type  dependent 
experimental  conditions  resulted  in  a  rather  complicated  picture.  Depending  on  the  time  of 
uncoating CypA may or may not be stably associated with the RTC/PIC, and such observations 
may be downstream effects of CypA modulation rather than due to a structural, stable CypA:CA 
interaction.  
One other complication has been a lack of a quaternary understanding of how CypA 
interacts with the viral core, as all structural characterization efforts to date have focused on 
individual  CypA:CA-NTD  interactions without  questioning  how  the  surface  topology  of  the 
hexagonal lattice with several CA hexamers, each displaying a CypA binding  loop in close 
proximity to each other, might add to the picture.        54 
C.  Materials and Methods                 
 
  Cells, viruses, and infections. HeLa, HEK293T, HeLa-T4 (Maddon et al., 1986), GHOST 
(Mörner et al., 1999) and MAGI (Chackerian et al., 1997) cell lines and its derivatives were 
cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine 
serum  (FBS),  100  IU/ml  penicillin,  and  100  μg/ml  streptomycin.  For  cell  cycle  arrest 
experiments, HeLa cells were growth-arrested by incubation in complete medium containing 2 
g/ml aphidicolin (Sigma) for 24 h, and maintained in this concentration of the drug during the 
infection.  HeLa  cells  stably  transduced  with  empty  lentiviral  vector  pLKO.1  or  pLKO.1 
expressing  TNPO3-specific  short  hairpin  RNA  (shRNA)  (GGCGCACAGAAATTATAGAA) 
were additionally grown in 1 μg/ml puromycin. HeLa-T4 cells were transfected with 100 nM 
TNPO3-directed  CGACAUUGCAGCUCGUGUA  or  mismatched  control 
CGCCUAUGUAGCUCGUGUA  (changes  are  underlined)  siRNA  by  using  RNAiMax  or 
Oligofectamine.  
Viral inocula used in Figures 2.3-5 were pseudotyped with the vesicular stomatitis virus 
G glycoprotein (VSV-G). The virus-specific molecular clones used were as follows: pBH2 and 
pBS-BC4MGppt  for  bovine  immunodeficiency  virus  (BIV)  (obtained  from  Michael  Kaleko, 
Advanced  Vision  Therapies),  pEV53  and  an  equine  infectious  anemia  virus  (EIAV)-green 
fluorescence protein (GFP) transfer vector for EIAV (gifts from John Olsen, University of North 
Carolina), pNL4-3env-GFP for HIV-1 (kindly provided by Dana Gabuzda, Dana-Farber Cancer 
Institute), pRCAS-GFP for  Rous sarcoma virus (RSV) (Addgene plasmid # 13878,  obtained 
from  Constance  Cepko  via  Addgene,  Cambridge,  MA),  pFP93  and  pGINSIN  for  feline 
immunodeficiency virus (FIV) (gifts from Eric Poeschla, Mayo Clinic), pFB-hrGFP (obtained 
from  Joseph  Sodroski,  DFCI)  and  pCG-GagPol  (provided  by  Richard  Mulligan,  Harvard   55 
Medical  School)  for  MLV.  Simian  immunodeficiency  virus  (SIV)-based 
pSIVmac239ΔnefΔenvEGFP (donated by J. Sodroski) was derived from pSIVΔnefEGFP (a kind 
gift from Ronald Desrosiers, Harvard Medical School) as follows. Env sequences were deleted 
by first changing the ATG start codon to TCC to create a BspE1 site. The 1.1-kb fragment 
between this and the native BspE1 site at position 8013 (GenBank accession # M33262.1) was 
excised, leaving Tat, Rev, and the Rev-responsive element intact.  
The MLV-based retroviral vector, MIGR1, encoding a mouse thymus derived  cDNA 
library was used for  the cDNA overexpression screen mentioned in  D.ii. The MLV  vectors 
MIGR1, MX, and LPCX were used to generate stable cell lines. All HIV-1 reporter vectors 
encoding  fluorescent  proteins  or  firefly  luciferase  were  NL4-3  derived.  Reporter  particles 
incorporated VSV-G, murine amphotropic Env, or HIV-1 Env glycoproteins. HIV-1, HIV-2, and 
SIV replication competent virus isolates, as listed in Figure 2.6, were also used in infection 
assays. Mouse and human CPSF6 cDNAs were purchased from Open Biosystems and Origene, 
respectively. Antibodies were from Abcam.  
Viral vector particles were generated by transfecting 293T cells in 10-cm plates with 10 
μg total of various ratios of virus production plasmids together with  the  VSV-G expression 
vector pMD.G using Fugene 6. Cells were washed at 16 h after transfection, and supernatants 
collected 28 to 72 h thereafter were clarified by centrifugation, filtered through 0.45 μm filters, 
and concentrated by ultracentrifugation at 53,000 × g for 2 h at 4 °C. HIV-1 CA p24 ELISA 
assay (Beckman Coulter) was performed per the manufacturer's recommendations. Infectious 
titers for luciferase- or Tat- expressing vectors were determined with GHOST cells.  
GFP reporter virus infections were conducted in triplicate in 48-well plates. Cells were 
replenished with fresh medium following 16 h of virus absorption, and the percentage of positive   56 
cells was determined at 48 h postinfection by using a FACsCanto flow cytometer equipped with 
FACSDIVA software. Inocula were adjusted to yield ~30 to 40% GFP-positive cells in control 
samples,  with  all  infections  scoring  between  5  and  60%  positive.  For  single-cycle  viral 
infections, infection was measured by firefly luciferase activity (Promega) or fluorescence by 
FACS 2-3 days later.  
Env-deleted  MHIV  chimera  plasmids  MHIV-mMA12CA-Luc,  MHIV-mMA12-Luc, 
MHIV-mIN-Luc,  and  MHIV-mMA12CA/mIN-Luc  as  well  as  parental  HIV-1LAI-based 
pLaiΔenvLuc2  were  generous  gifts  from  Michael  Emerman  and  Masahiro  Yamashita 
(Yamashita et al., 2004). Viruses were generated by co-transfecting 293T cells with pCG-VSV-
G using Fugene 6. Supernatants collected at 36 and 60 h posttransfection were pooled and spin 
concentrated as described above. Single-round MLV-Luc was produced as described previously 
(Shun  et  al  2007a).  Cells  infected  in  duplicate in  12-well  plates  for  12  h  were  rinsed  with 
phosphate-buffered saline and replenished with fresh medium. At 2 days postinfection, resulting 
levels of luciferase activity in cell extracts were normalized to corresponding levels of total 
protein as described previously (Shun et al, 2007a). Inocula were adjusted such that control cells 
yielded 1 × 103 to 1.2 × 104 relative light units (RLU)/μg.  
Western blotting. Cells were lysed with radioimmunoprecipitation assay buffer (20 mM 
HEPES [pH 7.5], 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% sodium dodecyl 
sulfate,  0.5  M  EDTA,  protease  inhibitors)  at  the  time  of  infection.  Following  protein 
concentration determinations by Bradford assay, 50 μg or various dilutions were fractionated 
through  10  to  20%  Tris-glycine  gels.  Proteins  transferred  onto  a  polyvinylidene  fluoride 
membrane were blotted with a 1:100 dilution of mouse anti-TNPO3 antibody (Abcam), followed 
by a 1:10,000 dilution of rabbit anti-mouse horseradish peroxidase (HRP)-conjugated secondary   57 
antibody (Dako). HRP-conjugated anti-β-actin antibody (1:10,000 dilution; Abcam) was used to 
control for gel loading.  
Recombinant protein purification. All INs were studied as His6-tagged fusion proteins; 
expression  and  purification  were  performed  essentially  as  previously  described  (Dar  et  al., 
2009). Briefly, shaker flasks of E. coli strain BL21 or its PC2 derivative were grown in LB 
medium at 28 °C to an A600 of 0.6 to 0.8 prior to induction with 0.4 mM isopropyl-thio-β-d-
galactopyranoside (IPTG) for 4 h, after which cells were harvested and lysed by sonication in 
buffer  A  {1  M  NaCl,  7.5  mM  3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-
propanesulfonate  (CHAPS),  0.5  mM  phenylmethanesulfonyl  fluoride,  25  mM  Tris-HCl  [pH 
7.4]}. Lysates were clarified by centrifugation at 40,000 × g for 30 min at 4 °C and incubated 
with 2 ml Ni-nitrilioacetate (NTA) agarose beads (Qiagen, Valencia, CA) for 3 h at 4 °C in 
buffer A containing 25 mM imidazole. After extensive washing, bound protein was eluted with 
buffer A-200 mM imidazole. IN-containing fractions diluted with 4 volumes of 7.5 mM CHAPS-
50 mM Tris-HCl [pH 7.4] were injected into a 1-ml HiTrap heparin column (GE Healthcare), 
and bound proteins were eluted with a linear gradient of 0.25 to 1 M NaCl in 7.5 mM CHAPS-50 
mM Tris-HCl [pH 7.4]. MLV IN was further purified by gel filtration on a Superdex-200 column 
in buffer A, whereas Mason-Pfizer monkey virus (MPMV) IN was purified using just Ni-NTA 
beads. IN proteins concentrated by ultrafiltration using Amicon ultracentrifugal filters with a 
10,000-molecular-weight  cutoff  (Millipore)  were  dialyzed  against  buffer  A-10%  (wt/vol) 
glycerol, flash-frozen in liquid N2, and stored at −80 °C. 
BL21 cells transformed with pGEX6P3-TNPO3 were grown at 37 °C to an A600 of 0.35 
to 0.45 prior to 4 h of induction with 0.4 mM IPTG. Bacteria were harvested and lysed by 
sonication in cold buffer B (150 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol [DTT], 50 mM   58 
Tris-HCl  [pH  7.4]).  The  crude  extract,  incubated  with  25  U/ml  Benzonase  nuclease  (EMD 
Biosciences) for 30 min at 25 °C to degrade bulk E. coli DNA, was clarified by centrifugation at 
40,000  ×  g  for  30  min  at  4  °C,  and  the  supernatant  was  incubated  with  2  ml  glutathione-
Sepharose beads (GE Healthcare) for 3 h at 4 °C. After washing in excess buffer B, a 50% gel 
slurry was incubated with 20 U PreScission protease (GE Healthcare) at 4 °C for 16 to 24 h to 
remove the GST tag. Flowthrough and wash fractions containing tagless TNPO3 were pooled, 
concentrated,  flash-frozen  in  liquid  N2,  and  stored  at  −80  °C.  Recombinant  Glutathione S-
transferase (GST) protein was purified following bacterial expression as previously described 
(Cherepanov et al., 2004). 
GST  pulldown  assays.  GST-TNPO3  protein  concentrations  were  determined  by 
densitometric scans of Coomassie-R250 stained gel images relative to bovine serum albumin 
(BSA) standard curves. GST-TNPO3 (12 μg, which corresponded to 0.46 μM during binding) or 
control GST (12 μg) absorbed onto  glutathione-Sepharose beads (30-μl  settled volume) was 
resuspended in 200 μl of PD buffer (150 mM NaCl, 5 mM MgCl2, 5 mM DTT, 0.1% Nonidet 
P40, 25 mM Tris-HCl [pH 7.4]) containing 10 μg BSA. IN (0.4 μM) was added, and the mixture 
was gently rocked for 3 h at 4 °C. After aspiration of the supernatant, the settled were beads 
resuspended in 600 μl PD buffer were allowed to sediment without centrifugation. The wash was 
repeated twice, and bound proteins were eluted in Laemmli sample buffer containing 50 mM 
EDTA-50 mM DTT. IN pulldown was confirmed in some experiments by blotting with a 1:1,000 
dilution of HRP-conjugated anti-His6 antibody (Clontech, Mountain View, CA). 
Ni-NTA pulldown assays. INs were adsorbed onto Ni-NTA agarose beads in NTA-PD 
buffer (150 mM NaCl, 2 mM MgCl2, 25 mM imidazole, 0.1% Nonidet P40, 50 mM Tris-HCl 
[pH 7.4]). Beads (25-μl settled volume containing 0.4 μM IN) resuspended in 300 μl NTA-PD   59 
buffer containing 10 μg of BSA were incubated without (input controls) or with 0.4 μM TNPO3 
for 3 h at 4 °C. Following supernatant aspiration, beads washed three times in ice-cold NTA-PD 
buffer were boiled in Laemmli sample buffer as described above. IN proteins were detected by 
staining with Coomassie-R250, whereas TNPO3 was detected by Western blotting.  
Viral DNA Quantitation by qPCR  (Figure 2.6). Cells challenged with DNaseI-treated 
HIV-1 vectors were lysed at different time points. As a control, a reverse transcription inhibitor 
[(150 nM efavirenz (EFV)] was added at the time of infection. Total DNA was extracted using 
the QIAmp Blood Mini Kit (Qiagen) and assayed by qPCR using Platinum qPCR SuperMix-
UDG (Invitrogen) with primers and conditions as previously described (Julias et al., 2001). For 
quantification of PCR products, duplicate samples of serial dilutions of plasmid DNAs containing 
the target sequences were used to generate a standard curve.  
High Molecular Weight HIV-1 CA-NC Complex Binding Assay. Recombinant wild-type 
and  N74D  HIV-1  CA-NC  were  expressed  in  bacteria,  purified,  and  assembled  in  vitro  as 
described  previously  for  wild-type  HIV-1  CA-NC  (Ganser  et  al,  1999).  Lysates  containing 
CPSF6-358-HA, CPSF6-300-HA, or rhTRIM5ʱ-HA were obtained from transiently transfected 
293T cells via successive freeze/thaws in hypotonic buffer. CA-NC complexes were mixed with 
cell  extracts  for  1  hr at  room temperature  before  ultracentrifugation through  a  70%  sucrose 
cushion (Stremlau et al., 2006). HA-tagged proteins were detected by Western blotting using 
HRP-conjugated anti-HA, whereas CA-NC was detected by Coomassie R-250 staining. 
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D.   Results  
D.i.  The requirement for TNPO3 maps to HIV-1 CA but not IN 
Original studies pointed to a functional role for TNPO3 in HIV-1 infection (Brass et al., 
2008; Koenig et al., 2008), possibly at nuclear import of the PIC (Christ et al., 2008).  The 
gammaretrovirus MLV, in contrast, had no dependence on this karyopherin, and biochemical 
studies showed that MLV IN failed to interact with recombinant TNPO3 under conditions where 
HIV-1 IN interaction was evident (Christ et al., 2008). To test the model that TNPO3 might be a 
lentiviral-specific factor that serves an IN-mediated function in lentiviral infection, such as PIC 
nuclear  import,  we  set  out  to  test  additional  lentiviral  and  non-lentiviral  vectors  for  their 
dependence on TNPO3 in HeLa-T4 cells. Our expanded set of lentiviral vectors included SIV, 
BIV, EIAV, and FIV, as well as the ʱ-retrovirus RSV. Recombinantly expressed and purified 
INs  of  these  retroviruses,  together  with  those  of  HIV-2  and  β-retroviral  MPMV,  were 
simultaneously assayed for TNPO3 binding. A high percentage of homology (≥98%, not shown) 
among TNPO3 proteins of the respective species was considered safe to allow the assessment of 
TNPO3 dependence in HeLa cells.  
Our results did not support the previously proposed model that TNPO3 interacts with 
lentiviral specific INs to mediate nuclear import of the PIC.  Not all lentiviruses tested were 
dependent  on  TNPO3  under  the  assay  conditions,  and  several  non-lentiviral  INs  also  had 
observable affinities to recombinant TNPO3 (D.i.1). Additionally, a functional assay employing 
MLV/HIV (MHIV) gag-pol chimerae identified the viral determinant of TNPO3 dependence as 
CA rather than IN (D.i.2).  
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D.i.1.  TNPO3 : retroviral IN binding profiles do not reflect the dependency of 
  respective retroviruses on TNPO3   
Infections  were  staged  to  yield  ~30  to  40%  transduction  of  target  HeLa  cells, 
corresponding to an MOI of ~0.35 to 0.5. TNPO3 expression was then knocked down both stably 
(by  means  of  a  pLKO.1-shRNA  vector)  yielding  an  approximate  7-  to  10-fold reduction  in 
TNPO3  protein  levels  compared  to  control  cells  (Figure.  2.3A)  or  transiently  (by  means  of 
siTNPO3  transfection)  yielding  a  stronger,  14-  to  20-fold  decrease in  protein levels  (Figure 
2.3C). Infectivities were assessed by GFP expression in infected cells as driven from retroviral 
vectors. As seen in Figure 2.3B and Figure 2.3D, various retroviruses displayed a wide range of 
sensitivity to TNPO3 knockdown, which did not correlate with the lentiviral- or nonlentiviral 
origin of the respective vectors. Replicating previously published results, HIV-1 infectivity was 
significantly  impaired  by  stable  TNPO3  knockdown,  whereas  MLV  was  unaffected  (Figure 
2.3B). RSV, an ʱ-retrovirus, mimicked MLV. SIV, BIV, and EIAV exhibited considerable ~6.9-
fold, 1.6-fold, and 1.9-fold infection defects, respectively, whereas infectivity of the lentiviral 
FIV vector was not impaired upon TNPO3 depletion (Figure 2.3B). The transient and stronger 
knockdown  achieved  with  siTNPO3  treatment  of  HeLa-T4  cells  replicated  the  defects  in 
infectivity profiles of the vectors tested (cf. Figures 2.3B, D). Primate lentiviral SIV was the 
most  affected  and  thus  the  most  dependent  on  TNPO3  under  both  stable  and  transient 
knockdown conditions, whereas another lentivirus, FIV, only had a mild TNPO3 dependence in 
either condition. The overall order of TNPO3 dependency of the tested viruses was accordingly: 
SIV > HIV-1 > BIV and EIAV > MLV, RSV, and FIV. 
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Figure  2.3  Retroviral  infectivity  profiles  of  TNPO3  knockdown  cells.  (A)  TNPO3  levels  in  shRNA 
transduced cells were reduced 7- to 10-fold (lane 7) as revealed by the comparison to a gradient dilution 
of control cells (lane 1-6); β-actin served as a gel loading control. (B) Infectivity defects incurred by viral 
vectors  upon  stable  TNPO3  knockdown  as  shown  by  mean  percentages  compared  to  empty  control 
shRNA transduced cells (n=5; ± standard errors of the means [SEM]) (C) Western blotting showing the 
levels of TNPO3 depletion in transiently knocked down HeLa-T4 cells: Comparison of mock (lane 1) or 
mismatch control transfected (lanes 2 to 7) cells with siTNPO3-treated cell (lane 8) revealed a 14- to 20-
fold decrease in steady state TNPO3 levels. (D) Infectivities (n=4; ± SEM) of indicated retroviral vectors, 
expressed as percent infectivity in TNPO3 knockdown cells compared to mismatch siRNA-transfected 
controls. Statistical significance values shown in (B) and (D) were calculated by using a Student's two-
sided t test. Asterisks directly above bars indicate differences between knockdown and control cells for a 
given virus, whereas asterisks above dotted lines indicate differences between indicated viruses. ***, P < 
0.0001; **, P < 0.001; *, P < 0.01. This particular dataset was generated by Kenneth Matreyek (Krishnan 
et al., 2010a). 
 
To test whether the sensitivities of each retrovirus to TNPO3 knockdown correlated with 
the  ability  of  their  respective  INs  to  bind  recombinant  TNPO3,  we  carried  out  reciprocal 
pulldown assays with either His6-tagged IN or GST-tagged TNPO3 proteins immobilized onto   63 
beads. Initially, GST-TNPO3 was assayed for its ability to bind soluble IN. Replicating earlier 
observations, HIV-1 IN was pulled down by GST-TNPO3 (Figure 2.4A, cf. lane 7 to lane 6; 
HIV-1 IN=32kD). Contrary to data from the previous report, however (Christ et al., 2008), MLV 
IN bound GST-TNPO3 readily as well (lane 8). GST-TNPO3 recovered SIV IN (lane 9) at levels 
similar to that of HIV-1 IN, whereas EIAV IN was not pulled down under these conditions (lane 
10;  deeper  inspection  by  Western  blotting  revealed  a  low-level  EIAV  IN  binding  to  GST-
TNPO3,  data not shown). GST alone  did not pull down any  of the  IN proteins, confirming 
specificity of the binding to TNPO3 (Figure 2.4A, lanes 12 to 17). 
Reciprocal pulldowns employed His6-tagged IN proteins immobilized on Ni-NTA beads 
and assessed their ability to capture tag-free TNPO3 (Figure 2.4B). Similar results were obtained 
compared to Figure 2.4A: HIV-1 and MLV IN had the highest recovery of TNPO3, while SIV 
and EIAV did less so, and FIV IN bound TNPO3 better in the Ni-NTA assay than in the GST 
pulldown assay (cf. Figure 2.5B, lanes 7-11 to Figure 2.5A, lanes 7-11). The lack of TNPO3 
recovery on empty Ni-NTA beads validated the specificity of the interactions detected (lane 12). 
Additional  IN  proteins  (of  which  the  respective  retroviral  vectors  were  not  tested  in  the 
infectivity assays) from HIV-2, BIV, RSV also displayed detectable TNPO3 binding, whereas 
MPMV IN failed to do so (lanes 19 to 24). Overall, our data revealed a lack of lentiviral specifity 
for the ability of TNPO3 to bind INs; TNPO3 readily bound INs derived from both γ- and ʱ-
retroviruses in addition to lentiviruses. Control Ni-NTA pulldowns of LEDGF/p75 confirmed the 
conformational integrity of each His6-tagged IN tested in the pull downs (data not shown).   64 
 
 
Figure 2.4 Pulldown analyses of IN-TNPO3 binding. (A) GST pulldowns. Lanes 1 to 5 contained 10% of 
input IN protein. Proteins bound to GST-TNPO3 (lanes 6 to 11) or GST (lanes 12 to 17) immobilized on 
Glutathione Sepharose beads were recovered by boiling and visualized by Coomaassie staining. Samples 
6 and 12 served as negative controls by omitting IN from binding reactions. (B) Reciprocal pulldowns 
with Ni-NTA bound INs: mock pulldowns (lanes 1-5 and 13-17) or TNPO3-pulldowns are shown (lanes 
7-12 and 19-24) Eluted proteins were detected by Western blotting (top) or Coomassie R-250 staining 
(bottom). Input levels of TNPO3 were analyzed in lanes 6 and 18. Lanes 12 and 24 are negative controls. 
Molecular  weight  markers  depicted  to  the  side  of  the  gels.  This  particular  dataset  was  generated  by 
Lavanya Krishnan (Krishnan et al., 2010a). 
 
  To assess TNPO3:IN binding more quantitatively and with higher sensitivity, surface 
plasmon resonance measurements were carried out with chip-immobilized TNPO3 and soluble 
INs. The data obtained confirmed the lentiviral nonspecificity of the interaction as revealed by 
binding affinities of respective INs ranking from strongest to weakest: FIV, HIV-1, and BIV > 
SIV and MLV > EIAV (data not shown).      65 




Figure 2.5 Infectivity profiles of MHIV chimera viruses versus HIV-1 and MLV. (A) Schematics of 
HIV-1 (white), MLV (gray), and chimera viral Gag and Pol proteins. NC, nucleocapsid; PR, protease; 
RT, reverse transcriptase; RH, RNase H. (B) Results of two independent experiments (means ± SEM) 
expressed as the percent infectivity on TNPO3-depleted compared to control cells. Student's two-sided t 
test comparisons of these values revealed significance parameters (***, P < 0.001; **, P < 0.01; *, P < 
0.05). In contrast, relative MHIV-mMA12 and MHIV-mIN titers did not significantly differ (P > 0.05) 
from the HIV-1 value. 
 
  Our  findings  indicated  that  IN-TNPO3  binding  affinities  did  not  correlate  with  the 
respective retroviral dependencies on TNPO3 during infection. We therefore sought to determine 
other viral factors that might contribute to the phenotype. As TNPO3 knockdown preferentially 
inhibited infection by HIV-1 over MLV (Figure 2.3B, D), previously described MHIV chimera 
viruses  (Yamashita  et  al.,  2007),  which  swap  various  parts  of  MLV  gag-pol  for  the 
corresponding ones in HIV-1 (Figure 2.5A), were investigated. As described in Chapter 1; D.ii.1, 
these hybrid constructs were previously used to highlight a dominant role for  HIV-1 CA in   66 
conferring infectivity on growth-arrested cells. The following chimera viruses were utilized in 
our studies: MHIV-mMA12CA, where MLV MA, p12, and CA replaced HIV-1 MA and CA 
(p12 is specific to MLV); MHIV-mMA12, harboring MLV MA and p12 in place of HIV-1 MA; 
MHIV-mIN, where MLV IN replaced the HIV-1 protein; and MHIV-mMA12CA/mIN, where 
MLV Gag and IN determinants were combined in the same construct (Figure 2.5A). Parental 
luciferase reporter viruses were VSV-G pseudotyped alongside the chimerae, and the resulting 
infectivities in HeLa cells stably knocked down for TNPO3 were expressed as percentages of 
control cell infection levels. 
  Replacing  HIV-1  MA  and  CA  with  the  corresponding  MLV  determinants  strikingly 
rendered the MHIV-mMA12CA chimera insensitive to TNPO3 knockdown. Swapping the CA of 
this virus back to the HIV-1 protein, however, resensitized MHIV-mMA12 to the knockdown, 
highlighting a role for CA in determining TNPO3 dependency during HIV-1 infection (Figure 
2.5B). The MHIV-mIN chimera, which harbored MLV IN alongside HIV-1 Gag determinants, 
was accordingly sensitive to the knockdown. Moreover, the combined MHIV-mMA12CA/mIN 
chimera virus behaved in a TNPO3-independent manner (Figure 2.5B). Thus, all viruses that 
harbored HIV-1 CA depended on TNPO3 for  optimal infectivity regardless of whether they 
carried HIV-1 or MLV IN, pinpointing HIV-1 CA as the viral determinant of TNPO3 function. 
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D.ii.  CPSF6-358 is an HIV-1 restriction factor that targets HIV-1 CA 
 
D.ii.1.  CPSF6-358, a primate lentiviral specific restriction factor of PIC nuclear 




Figure 2.6 CPSF6-358 restricts primate lentiviruses at the nuclear import step and can be overcome by 
CA  N74D  (A)  Infection  of  HeLa  cells  expressing  mCPSF6-358  with  HIV-RFP/VSV-G  and  MLV-
RFP/VSV-G vectors. Infectivity was quantified by FACS for the expression of red fluorescent protein 
(RFP). (B) mCPSF6-358 readily inhibits replication competent primate lentiviruses under single-cycle 
conditions using MAGI cells expressing CCR5. VSV-G pseudotyped MLV expressing HIV-1 Tat was 
used as a control. (C) qPCR profiling of HIV-1 DNA species. 293T cells expressing control mCPSF6 or 
mCPSF6-358 were infected with VSV-G pseudotyped HIV or integration deficient HIV/D116N IN and 
whole  cell  lysates  were  probed  at  different  time  points  post-infection  to  quantify  viral  reverse 
transcription  products  (ERT,  not  shown;  LRT,  shown)  and  2-LTR  circles.  (D)  HIV-1  CA  N74D 
efficiently infects nondividing HeLa cells arrested with aphidicolin and infection is resistant to mCPSF6-
358 restriction as opposed to WT HIV-1. Control infections are carried out in cycling HeLa and HeLa-
mCPSF6-358 cells with MLV. All viruses  are pseudotyped with VSV-G. This particular dataset  was 
generated by the KewalRamani laboratory (Lee et al., 2010). 
 
In a joint study with the KewalRamani Lab, a mouse thymic cDNA expression library 
was screened in NIH3T3.hCycT1 cells (Michel et al., 2009) to identify factors that limit the   68 
infection of VSV-G pseudotyped HIV-1. From this we identified mouse CPSF6-358 (mCPSF6-
358), a C-terminal truncation product of the cellular nuclear splicing factor CPSF6 that only 
harbors the N-terminal 358 amino acids (Lee et al., 2010). The parental protein, mCPSF6, did 
not show a restrictive phenotype upon overexpression. A similarly truncated human CPSF6-358 
also restricted HIV-1 infection (data not shown). mCPSF6 was shown to localize to the nucleus, 
whereas mCPSF6-358 and other restrictive CPSF6 species were enriched in the cytoplasm as 
assessed by nucleocytoplasmic fractionation followed by immunoblotting in NIH3T3.hCycT1 
cells (data not shown). To confirm the specificity of the restriction, control and mCPSF6-358-
expressing  HeLa  cells  were  challenged  with  VSV-G  pseudotyped  HIV-RFP  or  MLV-RFP 
(Figure 2.6A). HIV-1, but not MLV infection, was strongly impaired by mCPSF6-358.  
To  further  characterize  the  retroviral  specificity  of  the  restriction  several  primate 
lentiviruses were assayed for  their susceptibility  to mCPSF6-358 interference in control and 
mCPSF6-358-expressing  MAGI-Hi5  cells.  Different  strains  of  replication  competent  HIV-1 
(HIV-1LAI, HIV-1YU-2, HIV-1JR-CSF) and HIV-2, SIVmac239 or SIVmne cl.8 were all susceptible to 
mCPSF6-358 mediated restriction displaying approximately 10-fold or greater infectivity defects 
(Figure 2.6B). Even stronger infectivitry defects were observed in continuous replication assays 
such that over the course of three weeks or longer, HIV-1NL4-3, HIV-1NL4-AD8, HIV-1YU-2, and 
HIV-1JR-CSF did not replicate to detectable levels in HUT-R5- mCPSF6-358 cells as opposed to 
parental control HUT-R5 cells (data not shown). 
Quantification of vDNA species by quantitative PCR (qPCR) revealed that the mCPSF6-
358 block impaired HIV-1 at a step post reverse transcription (as implied by unaffected kinetics 
and steady state levels of LRT levels), whereas overexpression of the full length mCPSF6 had no 
effect (Figure 2.6C). However, the accumulation of the 2-LTR circular form of vDNA, a dead-  69 
end form produced in the nucleus, was reduced upon mCPSF6-358 expression, even in the case 
of  HIVIN/D116N (an integration deficient IN active site mutant) that normally generates elevated 
levels of 2-LTRs due to accumulation of unintegrated vDNA species inside the nucleus (Figure 
2.6C).  In vitro integration assays with isolated PICs from  either control  NIH3T3.hCycT1 or 
NIH3T3.hCycT1-mCPSF6-358 cells revealed no defect to integration competence, mapping the 
infectivity defect at a pre-integration and post/at-nuclear import step (data not shown). 
To further confirm the nuclear import defect imposed by mCPSF6-358 restriction, control 
HeLa cells and HeLa cells expressing mCPSF6-358 were challenged with VSV-G pseudotyped 
HIV-1  both  under  cycling  and  aphidicolin-treated,  growth-arrested  non-mitotic  conditions. 
Aphidicolin is an inhibitor of DNA polymerase ʱ and δ that results in cell cycle arrest at the 
G1/S phase (Ikegami et al., 1978; Goscin et al., 1982). Growth arrest intensified the mCPSF6-
358 HIV-1 infectivity defect more than one order of magnitude bringing it down to a ~70-fold 
decrease when compared to untreated parental HeLa cells (Figure 2.6D). MLV, a γ-retrovirus 
that depends on mitosis to gain access to target nucleus (Roe et al, 1993) served as a negative 
control; its already decimated infectivity in growth-arrested cells was unaffected by mCPSF6-
358 overexpression.  
In a parallel viral evolution assay, replication-competent HIV-1NL4-3/BaL was passaged in 
HUT-R5.mCPSF6-358 cells and gave rise to a single point CA mutant, N74D, which rendered 
the virus completely resistant to mCPSF6-358 restriction with no observable fitness cost in these 
cells (data not shown).  Introducing the mutation into  HIVNLdE and infecting  growth-arrested 
HeLa cells with VSV-G pseudotyped HIVNLdE CA N74D then revealed that this CA mutant virus 
was still unaffected by the combination of cell-cycle arrest and mCPSF6-358 expression (Figure 
2.6D).    70 
D.ii.2.  CPSF6-358 is a novel CA-interacting protein, and CA N74D abolishes this 
  interaction  
  The ability of the N74D mutant to evade mCPSF6-358 restriction suggested that this 
antiviral protein might directly target viral CA. To assay for an interaction of CPSF6-358 to CA, 
we employed the high molecular weight (HMW) CA-NC ‘tube’ binding assay, where in vitro 
reconstituted tubular CA-NC assemblies are used to recapitulate the surface configuration of the 
CA hexagonal lattice (Ganser et al., 1999). The HMW CA-NC complexes can then be incubated 
with  target  factors  either  in  the  form  of  ectopically  expressed  or  recombinant  proteins. 
Ultracentrifugation through a sucrose cushion then separates CA-binding partners from the rest 
of the mixture by allowing their co-pelleting with the CA-NC tubes (Stremlau et al., 2006).  
  We  assembled  WT  and  N74D  CA-NC  complexes  in  vitro.  Pre-assembled complexes 
were  then  incubated  with  293T  cell  lysates  transfected  with  human  CPSF6-358;  the  non-
restrictive larger deletion variant, CPSF6-300; or rhTRIM5ʱ which served as positive control. As 
shown previously (Stremlau et al., 2006), WT CA-NC complexes pellet rhesus rhTRIM5ʱ, a 
known CA interactor, under these conditions (Figure 2.7, right panel) (interestingly, N74D CA-
NC complexes more efficiently precipitated rhTRIM5ʱ - about two-fold - than wild-type CA-NC 
complexes in four separate trials). Non-restrictive CPSF6-300 pelleted with WT and N74D CA-
NC complexes at an equal efficiency (Figure 2.7, middle panel). By contrast, CPSF6-358 co-
purified more efficiently with WT vs. N74D CA-NC cores (Figure 2.7, left panel), at an average 
difference of 3.9-fold over four trials (data not shown), revealing a mechanistic explanation to 
N74D evasion of CPSF6-358 restriction.   71 
 
 
Figure 2.7 CPSF6-358 is a novel CA-binding protein and N74D inhibits binding. Enhanced binding of 
CPSF6-358 to WT CA-NC complexes. Recombinant WT and N74D CA-NC complexes were incubated 
with lysates from 293T cells transfected with HA-tagged constructs expressing CPSF6-300, CPSF6-358, 
or  rhTRIM5ʱ.  Mixtures  were  then  layered  on  top  of  a  70%  sucrose  cushion  followed  by 
ultracentrifugation. Top panels are Western blots using anti-HA; bottom panels are Coomassie R-250 
stains  of  pelleted  material.  Lanes  1  and  5  depict  lysate  inputs  that  were  not  subjected  to 
ultracentrifugation. Lanes 2 and 6 are pelleted material in the absence of CA-NC complexes. Recovery of 
HA-tagged  proteins  in  pellet  fractions  following  coincubation  with  CA-NC  complexes  (50% of  total 
loaded) relative to input samples (10% of total loaded) was measured by densitometry. 
 
 
D.ii.3.  CPSF6-358 restriction and TNPO3-requirement have different cell cycle 
  dependencies  
  Following the observation that mCPSF6-358 restricted HIV-1 infection at the stage of 
nuclear import and a single point mutant of HIV-1 CA, N74D, could overcome this restriction 
with no apparent fitness cost in HeLa cells (Figure 2.6D untreated cells, WT vs N74D), the two 
viruses were assayed for their dependence on several karyopherins, including TNPO3 (Figure 
2.8), that may have functional importance for HIV-1 PIC nuclear import.   72 
 
 
Figure 2.8 Cell growth arrest does not increase the dependency of WT HIV-1 on TNPO3. HeLa cells that 
contain only the empty vector or cells that express mCPSF6-358 and HeLa cells transduced with control 
shRNA vector or TNPO3 shRNA were infected with either WT HIV-1 or N74D mutant vectors that 
express  a  luciferase  reporter  (HIVNLdE-luc/VSV-G  or  HIVNLdE  CA  N74D-luc/VSV-G,  respectively).  Cell 
lysates were measured for luciferase activity 48 h after infection. Luciferase values reflect averages of 
duplicate infections with standard deviations. The data in the right panel were from cells treated with 
aphidicolin. This particular dataset was generated by the KewalRamani laboratory (Lee et al., 2010). 
       
  HeLa cells stably depleted of TNPO3 were similar to mCPSF6-358 expressing cells in 
that both types of cells were about 10-fold less susceptible to infection by WT HIV-1 than were 
control cell lines during normal growth (Figure 2.8, left panel). Infection by N74D HIV-1 was 
not only unimpaired upon mCPSF6-358 expression, but also upon TNPO3 depletion, indicating 
that CA N74D rendered HIV-1 not only mCPSF6-358 resistant but TNPO3 independent, as well. 
Upon aphidicolin-induced growth arrest in the same set of cells (Figure 2.8, right panel), the 
mCPSF6-358 restriction and TNPO3 knockdown phenotypes differed, however. As previously 
observed  in  Figure  2.6D,  nondividing  cells  that  express  mCPSF6-358  strongly  restricted 
infection by WT HIV-1 (~ two orders of magnitude) but not by N74D HIV-1. In contrast, the 
HIV-1 infectivity defect in TNPO3-depleted cells remained similar upon growth arrest. Thus, the 
dependence on TNPO3 in  HIV-1 infection was the same in  dividing and nondividing cells, 
whereas  HIV-1  was  differentially  more  vulnerable  to  mCPSF6-358  in  nondividing  cells.   73 
Additional  karyopherins  such  as  Nup153  and  Nup155  were  also  tested  in  similar  assays, 
revealing differential NUP requirements for N74D and WT HIV-1 (data not shown).  
 
D.iii.  HIV-1 N74D has increased sensitivity to CsA and lowered binding to CypA 
 
 
Figure 2.9 HIV-1 N74D CA has increased sensitivity to CsA and shows reduced binding to CypA. (A) 
OMK or HeLa cells incubated with or without 2.5 μM CsA were infected with different volumes of VSV-
G pseudotyped WT or N74D HIV-1-RFP 48 h before FACS analysis. (B) HeLa cells were infected with 
VSV-G pseudotyped WT or N74D, G94D, N74D/G94D, G89V, and N74D/G89V  HIV-1-luc with or 
without 2.5 μM CsA for 48 h before bioluminescence analysis.  Infectivity data are presented both in 
absolute counts per second (left) and as normalized percentages based on WT infectivity without CsA 
treatment (right). (C) WT, N74D, and P90A CA-NC complexes were incubated with 293T cell extracts 
expressing HA-tagged CypA. HA-CypA in the pellet is detected by immunoblotting, whereas CA-NC 
pellet amounts are visualized by Coomassie R-250 staining. Image is representative of two independent 
experiments. Panels A and B were generated by the KewalRamani laboratory (Lee et al., 2010). 
  
Owl monkey kidney (OMK) cells express a Trim5 restriction factor variant, TrimCyp 
that recognizes incoming capsids via its C-terminal Cyp domain (Sayah et al., 2004). N74D   74 
impairs CPSF6-358 recognition without causing gross changes in the capsid core as observed by 
normal levels of rhesus TRIM5ʱ restriction in HeLa cells (data not shown). To test for changes 
in CypA recognition, N74D HIV-1 sensitivity to TRIMCyp was assayed (Figure 2.9A). N74D, 
which bears no fitness cost to HIV-1 in HeLa cells, was restricted in OMK cells similar to WT 
HIV-1 over a titration curve; however, it was 2- to 5-fold less susceptible overall (solid data 
points), suggestive of decreased binding to TRIMCyp. Notably, when these cells were treated 
with CsA,  ablating interaction between  CA and  both TrimCyp and CypA alike (empty data 
points), WT HIV-1 infection increased to a greater extent  (20- to 600-fold over the titration 
curve) than N74D HIV-1 (5-to 50-fold). Parallel infections in HeLa cells, where there is no 
TRIMCyp expression but CypA, revealed that whereas WT HIV-1 was virtually unaffected by 
CsA  treatment,  N74D  HIV-1  infectivity  decreased  up  to  3-fold,  suggestive  of  an  increased 
dependence on normal levels of CypA.  
To better characterize its lowered sensitivity to TrimCyp, higher sensitivity to CsA and 
increased requirement for CypA, N74D was assessed alongside other CA mutant viruses with 
known CypA dependence. G89V that abolishes CypA binding and G94D that renders HIV-1 
CsA-dependence were tested in presence and absence of CsA (Figure 2.9B). As expected, G89V 
rendered  HIV-1  insensitive  to  CsA  in  absence  of  CypA  binding  with  or  without  the  N74D 
mutation compared to WT HIV-1. Confirming the previous observation in Figure 2.9A, N74D 
HIV-1 infectivity was decreased and,  in line with the literature (Aberham et al., 1996), the 
infectivity of G94D HIV-1 was increased upon CsA treatment. Combining N74D with G94D led 
to a complete relief of the CypA-dependent restriction of G94D, and the resulting double mutant 
was as dependent on CypA / as sensitive to CsA as N74D was by itself.    75 
To test for a biochemical basis to why N74D has an increased dependence on CypA that 
can even override the CypA-dependent restriction of G94D, we employed the in vitro CA-NC 
binding assay to assess CypA binding to N74D  compared to WT CA (Figure 2.9C). In cell 
extracts, N74D bound 65 to 70% less CypA than WT CA-NC in two independent assays, P90A 
CA-NC served as a negative control. This result suggests that N74D HIV-1 cores in infected 
cells  may bind CypA  with less affinity, which may  render the virus more sensitive to  CsA 
treatment. 
Our  results  overall  pinpoint  to  CA  as  the  functional  target  of  two  novel  HIV-1 
determinants  in  infected  cells.  Corroborated  by  structural  efforts  from  independent  research 
efforts we have not only identified CPSF6 as a novel CA binding protein that may also regulate 
the previously established interaction between CA and CypA, but also a novel conserved surface 
pocket on capsid at the CA hexamer:hexamer interface. Our results emphasize the importance of 
evaluating biochemical and functional observations on CA binding proteins within the context of 
the quaternary capsid lattice, where different interactions may take place not only simultaneously 
but also cooperatively or in a coregulated manner.     
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E.  Discussion                 
E.i  The capsid cone displays a multifaceted surface regulating HIV-1 PIC nuclear 
   import where several host factors converge 
  Since TNPO3 and CPSF6 became players in the field of HIV-1 PIC nuclear import and 
preintegration trafficking, their functional role has been extensively studied. Price et al. (2012) 
solved  the  co-crystal  structure  of  CA-NTD:CPSF6313-327,  revealing  how  the  surface  pocket 
created by CA-NTD helix 3 and 4 present critical contact points to the CPSF6 15-mer (Figure 
1.9C: CA residues N57, Q67, K70, N74, A105, T107 and S109), and how N74D would thus 
abrogate binding to CPSF6 rendering the virus CPSF6-independent / CPSF6-358 resistant. It is 
noteworthy  that  at  the  time  of  our  publications  no  critical  function  could  be  ascribed  to 
endogenous CPSF6, as cellular depletion by RNAi failed to show either a negative or positive 
effect on HIV-1 infectivity in the cells tested. Modeling a CypA molecule onto this co-crystal 
structure  (see  Appendix  B),  which  is  projected  here  onto  the  hexamer:hexamer  interface  as 
resolved by Zhao et al., 2013 (Figure 1.9), reveals the context in which CPSF6313-327 would need 
to bind CA with regards to CypA (Figure 2.10).   77 
 
Figure 2.10 Structural modeling of CypA and CPSF6313-327 onto the hexameric lattice. The context of CA-
NTD:CypA  (PDB:  1AK4;  Gamble  et  al.,  1996)  aligned  with  CA-NTD2  (Appendix  A),  and  CA-
NTD:CPSF6313-327 (PDB: 4B4N; Price et al., 2012) aligned with CA-NTD3 of the CA hexamer:hexamer 
dimer described in Figure 1.9 (PDB: 1VU5) predicts a CypA molecule flexibly attached to the CA-NTD2 
CypA-loop  that  hypothetically  extends  over  the  CA-CTD:CA-CTD  dimer  bridging  the  CA 
interhexameric space. It may be reaching over to the adjacent CA-NTD1/3 wedge (please see Appendix A 
for a detailed discussion), which is also home to the surface pocket that CPSF6313-327  binds to. Though the 
ways of regulation between these three molecules might be myriad, and the joint configuration described 
herein  only  hypothetical,  the  model  nevertheless  provides  a  spatial  understanding  of  the  quaternary 
interaction surface that determines the fate of PIC nuclear import. (A) Top view. (B) Side view.   78 
Additional research efforts identified Coumermycin-A1 (C-A1; Vozzolo et al., 2010), a 
small molecule drug that was originally characterized to be a gyrase B inhibitor, blocked HIV-1 
infection at the step of integration as assessed by 2-LTR circle formation. Interestingly, however, 
when replication competent HIV-1 virus was subjected to a viral evolution assay under C-A1 
selection, the rescuant clone had acquired a single point mutation in HIV-1 CA, namely A105S, 
another residue lining the CPSF6-binding pocket. As was the case with N74D in our hands, the 
C-A1 resistant A105S was also proven to be insensitive to TNPO3 knockdown adding to the 
functional  relationship  between  TNPO3  and  CPSF6.  The  difference  in  the  infection  block; 
postnuclear in the case of C-A1 and at or before nuclear import in the case of CPSF6-358, is not 
well understood. We observed that TNPO3 dependence of HIV-1 is independent of cell cycle 
state (Figure 2.8) even though both N74D and A105S can override this dependence.  
A third restriction targeting HIV-1 CA was induced by another small molecule drug, PF-
3450074 (PF74; Blair et al., 2010). Mechanistic studies revealed that PF74 bound HIV-1 CA 
within the same surface pocket lined by helices 3 and 4 and that it acted by destabilizing the 
incoming viral capsid in the cytoplasm as revealed by fate-of-capsid assays (Shi et al., 2011), 
inducing  premature and  detrimental  uncoating.  A  viral  evolution  assay  under  drug  selection 
isolated a resistant clone, 5mut, with 5 missense mutations in CA, three of which (Q67H, K70R, 
T107N) are located near N74 and shared by the CPSF6 15mer as contact points as previously 
described (Price et al., 2012). Of the remaining two CA mutations (H87P, L111I) that were 
required to render the virus PF74 resistant,  H87P had been previosly described to cause reduced 
CypA  incorporation  into  progeny  virions  (Gatanaga  et  al.,  2006).  This  observation  was 
corroborated by the fact that CypA knockdown or CsA treatment rendered PF74 less potent,   79 
implying that by reducing its affinity to CypA, 5mut may have gained partial resistance to PF74 
(Shi et al., 2011).  
The overlap between binding sites for PF74 and CPSF6313-327 prompted us to look into 
whether  PF74  might  affect  the  CPSF6:CA  interaction.  We  confirmed  such  an  antagonistic 
relationship between PF74 and CPSF6/CPSF6-358 in HMW CA-NC binding assays (data not 
shown) in vitro. The fact that endogenous CPSF6 is nuclear and does not readily display an HIV-
1 infectivity phenotype, and also that PF74 impairs HIV-1 infection by accelerated uncoating 
presumably in the cytosol, prevented us from making a conclusive interpretation that CPSF6 may 
be the natural target of PF74 in infected cells. 
  As seen in the hypothetical structural model in Figure 2.10, where both CA-interactors 
CPSF6-313-327 and CypA are depicted on an A92E CA hexamer:hexamer interface (Zhou et al., 
2013),  CypA may  be  extending  over across the interhexameric space to CA-NTD1/3 of the 
adjacent CA-hexamer, potentially capping the surface pocket where CPSF6 is believed to bind 
CA (Price et al, 2012). A rather hypothetical structural configuration of one CypA molecule 
modeled onto a hexamer:hexamer dimer right above the interhexameric juncture thus displays 
further  secondary  interaction  possibilities  with  both  neighbouring  CA-NTDs  and  a  putative 
CPSF6 molecule binding the surface pocket generated by helices 3 and 4. Such intermolecular 
interactions at the surface of incoming RTC/PICs may explain how CypA can modulate core 
stability and how the quaternary capsid structure can coordinate different cellular nuclear import 
determinants.  One should note that at the time of these studies no function  was ascribed to 
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E.ii.  CA is a functional PIC component targeted by both TNPO3 and CPSF6-358 
Compositional analyses of cytoplasmic and nuclear HIV-1 RTCs had revealed that on the 
way  from  plasma  membrane  to  the  nucleus,  HIV-1  RTCs  shed  CA,  which  coincides  with 
increased reverse  transcription. However, (i) trace amounts of CA could still be detected in 
nuclear fractions (Miller et al., 1997), (ii) the detection limit for HIV-1 CA in early studies may 
have been limited (the intact viral capsid prior to uncoating is thought to be comprised of ~1056 
p24 CA molecules; Pornillos et al., 2011; Zhou et al., 2013) (iii) imaging studies detected co-
localization of p24 CA with de novo reverse transcripts pointing at a possibility that some CA 
may remain associated with HIV-1 RTCs (McDonald et al., 2002). Another group even observed 
intact HIV-1 capsid cores at the nuclear envelope upon infection (Arhel et al., 2007), and yet 
others reported evidence for nuclear presence of HIV-1 CA that is exported by means of TNPO3 
activity (Zhou et al., 2011)  
In this regard, the finding that CA plays a dominant role in nuclear import of the PIC, and 
that TNPO3, CPSF6 and CypA all converge on CA (at least functionally as revealed by CA 
mutant phenotypes) is critical. A biochemical basis to CPSF6:CA and CypA:CA interaction is 
evident,  and  our  observation  that  N74D,  a  CPSF6-358  binding  mutant,  also  affects  CypA 
interactions in cells - either due to intrinsic changes in CA structure or impaired CPSF6 binding - 
both functionally and biochemically suggests a link between these two factors. N74D, and thus 
CPSF6-binding, may modulate CypA binding to the extent that a CypA-dependent restriction 
can be alleviated as observed in the case of G94D. An alternative explanation could be intrinsic 
changes in the viral capsid core that affect such a restriction.  
Whether TNPO3 and its functional target CA are biochemically linked to each other, 
however, needs further elucidation. The observation that CA is a functional determinant of PIC   81 
nuclear import and exerts this function possibly via its interactions with cellular cofactors, raises 
the possibility that it may be a structural component of the PIC even past the nuclear barrier; or it 
may simply modulate and ‘imprint’ the PIC in a way with the aid of cofactors along the path, 
which determine the downstream fate of the PIC.  
The observation that integration site targeting is affected by TNPO3 KD and RanBP2 KD 
(Ocwieja et al., 2011), CsA treatment (Schaller et al., 2011), and also by CA mutations (Schaller 
et al., 2011) point to a critical role of CA in dictating postnuclear events, be it by its direct 
presence at or beyond NPCs, or by its ability to commit the HIV-1 PIC to differential nuclear 
import and targeting pathways via deterministic interactions that take place at the cytoplasmic 
side of the NPCs with downstream effects. 
  
E.iii.  Differences between TNPO3 and CPSF6-358 phenotypes   
   
  The  observation  that  the  infectivity  defect  upon  TNPO3  KD  and  CPSF6-358 
overexpression can both be bypassed by common CA mutants, yet respond differently to cell 
cyle arrest, point to a possibility that TNPO3 may also perform an additional function separate 
from the one that it may exert through CPSF6 and its direct interaction with CA. This function 
would be required for successful infection in cells regardless of their cell cycle state, bringing up 
the possibility that PIC nuclear ‘import’ may rather refer to PIC utilization of nuclear transport 
machinery which may involve physical transport or not through the NPCs. The fact that the virus 
can use alternative import pathways as shown by altered dependencies of WT versus CA mutant 
viruses on nuclear import factors (Lee et al., 2010) and by altered  integration site targeting 
phenotypes, TNPO3 may simply be playing a licensing role, in that it commits HIV-1 PIC to one 
or the other delivery lines that is not only used in the postmitotic phase. Yet another explanation   82 
is  that  pharmacologically  induced  cell-cyle  arrest  may  result  in  additional  mislocalized  – 
spatially  and/or  temporarily  –  CPSF6-interacting  HIV-1  dependency  factors,  that  may  be 
specifically  getting  sequestered  by  the  ectopic  overexpression  of  CPSF6-358  differentially 
compared to under conditions of TNPO3 knockdown.     
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A.  Abstract                     
 
HIV-1 infection is dependent on  the β-karyopherin  TNPO3, which is responsible for 
nuclear transport of SR proteins involved in mRNA splicing. Characterizing the infection block 
in  cells  depleted  for  TNPO3  has  yielded  disparate  findings.  Some  groups  have  reported 
significant reductions in the formation of viral DNA 2-LTR circles, which is indicative of a 
block  in  the  nuclear  import  of  the  PIC,  whereas  others  found  no  effect  on  2-LTR  circle 
formation. CPSF6 is an SR protein that contains a C-terminal RS/RD/RE domain. We showed 
previously that expression of a C-terminal truncation mutant of CPSF6, CPSF6-358, which is 
missing the RS/RD/RE domain, restricted HIV-1 infection at the step of nuclear import without 
affecting the intrinsic activity of the PIC to integrate into a target plasmid DNA in vitro. We also 
showed that a single point mutation in CA, N74D, overcame CPSF6-358 restriction and TNPO3 
dependency  during  HIV-1  infection,  and  diminished  the  binding  of  CPSF6-358  protein  to 
recombinant  CA-NC  tubes  that  mimic  the  surface  structure  of  intact  viral  cores.  Although 
TNPO3 also binds CA-NC tubes, the N74D change does not alter this interaction. We expanded 
the size of our panel of HIV-1 CA mutant viruses in both infectivity and biochemical binding 
assays and correlated their sensitivity to CPSF6-358 restriction and dependence on TNPO3 with 
the ability  of  the  respective  CA-NC  tubes  to  bind  the two  factors.  The  correlation  between 
TNPO3 dependency and sensitivity to CPSF6-358 mediated restriction of several HIV-1 CA 
mutant viruses, the lack of correlation between TNPO3 dependency and TNPO3 binding to CA-
NC as opposed to CPSF6-358 sensitivity and CA-NC binding within this panel, combined with 
the observation that the RS domain is missing from CPSF6-358 prompted us to test for a direct 
interaction between CPSF6 and TNPO3 to explain the functional link between these two factors 
and HIV-1 CA. We show specific binding between recombinant TNPO3 and the RS domain of   85 
CPSF6  and  also  mapped  this  interaction  to  subdomains  of  CPSF6.RS.  The  interaction  is 
downmodulated by RanQ69L-GTP, suggesting that CPSF6 is a bona fide import substrate of 
TNPO3. Our results are in accordance with a model where the functional link between TNPO3 
and HIV-1 CA is based on the ability of TNPO3 to interact with and shuttle CPSF6, which can 
restrict HIV-1 infection by direct targeting of CA.  
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B.   Introduction                     
   
B.i.   The role of TNPO3 in HIV-1 infection        
  
After the identification of TNPO3 as a positive factor for HIV-1 replication (Brass et al., 
2008; Christ et al., 2008; Koenig et al., 2008), the field could not immediately resolve the issue 
at which stage TNPO3 acted in the HIV-1 replication cycle. One camp proposed a role in nuclear 
import of the PIC, as determined by quantitative imaging of fluorescently labeled PICs (Christ et 
al., 2008) and reduced 2-LTR levels upon TNPO3 knockdown (Schaller et al., 2011; Logue et 
al.,  2011;  De  Iaco  et  al.,  2013),  whereas  others  assigned  TNPO3  a  postnuclear  role,  again 
primarily relying on 2-LTR data (Koenig et al., 2008; De Iaco et al., 2011; Cribier et al., 2011; 
Zhou et al,. 2011; Valle-Casuso et al., 2012), and also on vDNA distribution in fractionated cells 
(Zhou et al,. 2011).  The discrepancy in 2-LTR quantification by independent research groups 
was most recently attributed to the selection of nonspecific qPCR primers unable to differentiate 
between bona fide 2-LTR circles and heterogenous autointegration products that may still bear 2 
LTR sequences in close enough proximity to allow qPCR amplification (De Iaco et al., 2013). 
Careful  modification  of  primers  and  sequencing-based  characterization  of  qPCR  amplicons 
resolved this confounding phenomenon and revealed a true reduction in 2-LTR formation upon 
TNPO3 knockdown, which strongly supported a role for TNPO3 in PIC nuclear import (De Iaco 
et al., 2013) even though the 2-LTR defect was not as strong as the infectivity defect under the 
conditions tested. 
The  identification  of  CA  as  the  functional  determinant  of  TNPO3  dependency  of  a 
retrovirus  (Chapter  1;  D.i.2,  D.ii.1)  prompted  to  investigate  the  biochemical  basis  for  this 
functional link. One study could not detect a biochemical interaction between tubular assembles 
of HIV-1 CA and TNPO3 under conditions where CypA served as a positive control (Larue et   87 
al.,  2012);  whereas  an  independent  study  reported  binding  to  HIV-1  WT  CA-NC  HMW 
complexes under conditions where HIV-1 N74D CA-NC displayed a modest ~1.5-fold reduced 
binding compared to WT CA-NC. This was proposed as the biochemical basis for the relative 
TNPO3 independence of N74D HIV-1, albeit with the caveat that TNPO3 knockdown caused an 
8-fold infectivity defect in the case of WT HIV-1 (Valle-Casuso et al., 2012). Such opposing 
observations led us to systematically assess a panel of CA mutants with varying dependencies on 
TNPO3 for their ability to bind TNPO3 in the context of CA-NC. 
 
 
B.ii.  Molecular details of the partial CPSF6:CA interface 
 
The  highly  non-structured  central  proline-rich  domain  complicates  quantitative 
purification and structural determination of the full length CPSF6. Previous efforts solved the 
atomic structure of CPSF6  N13-235 in a heterotetrameric complex with a truncated form of 
CPSF5 composed of one CPSF5 dimer and two CPSF6 monomers (Yang et al., 2011). Research 
on CPSF6-358, however, instead focused on a central stretch of amino acids spanning 314-322 
aa, which was shown to be responsible for the restriction of HIV-1 as revealed by functional 
mapping  upon  deletion  and  alanine-scanning  mutagenesis  (Lee  et  al.,  2012).  Based  on  this 
finding, a co-crystal structure of CA-NTD and CPSF6313-327 was solved, revealing critical contact 
points between the two molecules and the biochemical basis of interaction (Price et al., 2012). 
Specifically,  N57,  Q67,  K70,  N74,  A105,  T107  and  S109  were  critical  for  binding.  These 
residues line the surface pocket on CA generated by helices 3 and 4, and as previously explained 
they face the interhexameric space described in Chapter 1; D.ii.1 (Figure 1.9C). 
At the time of our studies, evidence for a role in HIV-1 replication had been scarce for 
endogenous CPSF6. Exceptions to this were functional studies providing indirect evidence for a   88 
possible  coordination  between  CPSF6  and  CypA  as  revealed  by  the  ability  of  CPSF6-358-
resistant CA mutations also rescuing a CypA-mediated restriction several CA mutants are subject 
to: CA N74D/G94D (Ambrose et al,. 2012); CA A92E/A105T and CA R132K/A105T (Qi et al., 
2008), and CA T54A/A105T (Yang et al., 2007; Qi et al., 2008) are rescued from their respective 
CypA-sensitive, cell cycle-dependent phenotypes characteristic of CA G94D, A92E, R132K and 
T54A. Both N74D and A105T render HIV-1 CPSF6-358 resistant (De Iaco et al., 2013) and both 
residues are shown to mediate contact between CPSF6313-327 and CA (Price et al., 2012). We had 
previously shown that N74D reduced binding to CPSF6-358 in Figure 2.7 (Lee et al., 2010). An 
opposite effect, namely a role for CypA in CPSF6-358 mediated restriction, however, has not 
been observed. 
These findings are suggestive of endogenous CPSF6 having a potential role in the cell-
cycle dependent restriction of some HIV-1 CA mutants. This prompted us to screen a panel of 
HIV-1 CA mutants for their sensitivity to CPSF6-358 and compare these results to their ability to 
bind CPSF6-358 and full length CPSF6. We also wanted to test whether these interactions were 
subject to modulation by CypA, as probed by CsA treatment.  
 
B.iii.  Nucleocytoplasmic localization of CPSF6 species affects their restriction 
 
  phenotype       
It was originally observed that the restrictive ability of ectopically expressed CPSF6 and 
CPSF6-358 species may correlate with their nucleocytoplasmic localization (Lee et al., 2010). 
Independent research efforts gathered further evidence to support this claim. It was shown that 
engineering a full length CPSF6 construct with an NES, which forced cytoplasmic localization 
upon this normally nuclear protein, conferred upon this construct the ability to restrict HIV-1   89 
infection in a CA N74-dependent fashion (De Iaco et al., 2013). The same group also showed 
that redirecting the normally cytoplasmic CPSF6-358 into the nucleus by means of an SV40 NLS 
counteracted CPSF6-358 restriction. 
 
B.iv.  CPSF6, an SR protein, is potential cargo for TNPO3 
  The CPSF6.RS domain (spanning amino acids 526-588) is noncanonical in that it harbors 
RD/RE requences besides RS dipeptides that have been shown to require phosphorylation for 
recognition by TNPO3. RD/RE on the other hand, may already mimic such a phosphorylation 
event due to the negative charge carried by Asp and Glu carboxyl side chains.  
The  presence  of  a  C-terminal  RS-domain  in  nuclear  CPSF6  and  the  lack  thereof  in 
cytoplasmic  CPSF6-358 that restricts HIV-1 at the stage of nuclear import by targeting CA 
directly;  the  observation  that  depleting  the  SR-protein  transporter  TNPO3  impairs  HIV-1 
infectivity possibly at the stage of nuclear import in a CA-dependent fashion; and the overlap 
between CPSF6-358 resistance and TNPO3 independence of several CA mutants all together 
strongly imply a model where TNPO3 may simply be responsible for determining the cellular 
localization  of  the  CPSF6  species.  Such  regulation  may  be  disrupted  upon  inhibiting 
transporter:cargo recognition either through TNPO3 knockdown or removal of the RS-domain, 
as in the case of CPSF6-358. 
Evidence for such a model is already present in the literature. It was shown that TNPO3 
knockdown  relocalizes  endogenous  CPSF6  from  the  nucleoplasm  into  the  cytoplasm  in 
transformed fibroblasts, albeit partially (De Iaco et al., 2013). Further support came from double 
knockdown  studies  where  the  infectivity  defect  incurred  upon  WT  HIV-1  due  to  TNPO3 
depletion could be rescued by depleting endogenous CPSF6 (De Iaco et al., 2013). This result is   90 
also supportive of the model, where the infectivity defect WT HIV-1 encounters upon TNPO3 
knockdown may be due to cytoplasmically relocalized CPSF6, whose depletion then relieves the 
CA-targeting restriction.   
 
 
C.  Materials and Methods                 
 
  Cells,  viruses  and  infections.  HeLa,  HEK293T  and  their  derivative  cell  lines  were 
cultured  in  DMEM  supplemented  with  10%  FBS,  100  IU/ml  penicillin  and  100  μg/ml 
streptomycin.  For infection experiments with the CypA active site inhibitor  CsA, cells were 
treated  with  4  µM  CsA  during  the  course  of  infection.  For  infectivity  assays,  HeLa  and 
HEK293T cells stably transduced with empty lentiviral vector pLKO.1 or pLKO.1 expressing 
TNPO3-specific  shRNA  (GGCGCACAGAAATTATAGAA),  and  HeLa  and  HEK293T  cells 
stably transduced with empty lentiviral vector pLKO.1 or pLKO.1 expressing CPSF6-358-HA, 
were additionally grown in 1 μg/ml puromycin. HEK293T cells were transfected with pCP-HA-
TNPO3, pLKO.1-CPSF6-HA or pLKO.1-CPSF6-358-HA using Lipofectamine (Invitrogen), and 
cultured for 2 days prior to lysis to be used in HMW CA-NC binding assays. 
  Single round viral vector particles were generated by transfecting HEK293T cells in 10-
cm plates with 6 μg pCMV cells in GagPol (HXB2; Parolin et al., 1996) packaging plasmid, 3 μg 
HIV-1 transfer vector pHI.Luc (Nakajima et al., 2001), 1 μg pRev, and 1 μg VSV-G expression 
vector pCG-VSV-G using Fugene 6 as previously described (Hofmann et al., 1999). Cells were 
washed 16 h after transfection, and supernatants collected twice, once at 24 h and once at 48 h 
posttransfection. Viral supernatants were clarified by centrifugation, filtered through 0.45 μm 
filters, and titered via 32P RT assay.    91 
Plasmid  construction.  HIV-1  CA  mutants  were  generated  by  Quick  Lightning 
(Stratagene) site directed mutagenesis (SDM) of the pCMVe agene) sGagPol (HXB2) packaging 
plasmid. Human TNPO3 sequence was subcloned between BglII and XhoI sites of pCPHA-NLS 
(Cherepanov et al., 2004), generating pCP-HA-TNPO3. The GST-CPSF6.RS441-588 expression 
plasmid was obtained by subcloning a  DNA fragment encoding residues 441-588 of human 
CPSF6  between  BamHI  and  EcoRI  sites  of  pGEX6P3  (GE  Healthcare).  GST-CPSF6.RS  C-
terminal  truncations  were  generated  by  introducing  in-frame  stop  codons  after  the  coding 
sequence of CPSF6 residues 526, 540, 553 and 568 SDM of pGEX6P3-CPSF6.RS441-588. GST-
CPSF6.RS  N-terminal  truncations  were  generated  by  introducing  internal  deletions  within 
pGEX6P3-CPSF6.RS441-588  by  SDM  using  internal  deletion  primers  that  omitted  the  coding 
sequences for CPSF6.RS441-526, CPSF6.RS441-553, and CPSF6.RS441-568, respectively. pGEX6P3-
CPSF6.RS∆541-553  and  pGEX6P3-CPSF6.RS∆541-568  were  generated  similarly  by  SDM. 
pGEX6P3-CPSF6.RS541-568  fusion  construct  was  generated  by  subcloning  a  DNA  fragment 
encoding residues 541-568 of human CPSF6 between BamHI and EcoRI sites of pGEX6P3. All 
constructs were confirmed by sequence verification. 
The pET11a HIV-1 CA-NC expression vector was described previously (Ganser et al,. 
1999). pET11a HIV-1 CA-NC CA mutants were generated by SDM. The sequence encoding 
full-length human TNPO3 was cloned into the pET-SUMO vector (Invitrogen) generating pET-
His6-SUMO-TNPO3. The coding sequence of RanQ69L was subcloned in between the XmaI 
and XhoI sites of pCPH6P (Cherepanov, 2007) to generate pCP-His6-RanQ69L.  
Recombinant baculovirus expressing His6-CPSF6-358 was generated using the Bac-to-
Bac  system  (Invitrogen)  following  the  manufacturer's  instructions.  For  construction  of  the 
transfer vector, the CPSF6-358 region was amplified by PCR using primers that introduced an   92 
N-terminal His6-epitope into the construct in between 5’-EcoRI and a 3’-BamHI sites. The His6-
CPSF6-358 amplicon was then cloned into the EcoRI and BamHI sites of the pFAST-BAC-
DUAL vector according to the protocol of the manufacturer (Invitrogen), which also expresses 
RFP from its second promoter to aid with titering. After sequence confirmation, the pFAST-
BAC-DUAL-His6-CPSF6-358  vector  was  recombined  into  the  bacmid  by  transformation  of 
DH10 Bac cells (Invitrogen). Transformed bacterial colonies were grown by multiple antibiotic 
selection (50 mg/ml kanamycin, 7 mg/ml gentamicin, and 10 mg/ml tetracycline) and positive 
clones were identified by restriction digest and DNA sequencing.  
Recombinant protein purification. Rosetta2 (DE3) pLacI cells (Novagen), transformed 
with  pET-His6-SUMO-TNPO3,  were  grown  at  28  °C  in  Terrific  Broth  medium  (Melford) 
supplemented with 50 µg/ml kanamycin and 0.4% glycerol. Expression was induced with IPTG 
(0.01% final concentration) for 5 h at 25 °C. Bacteria, re-suspended in core buffer (25 mM Tris-
HCl [pH 7.4], 0.5 M NaCl) containing 1 mM PMSF and 1 mg/ml lysozyme, were disrupted by 
sonication. The lysates were pre-cleared by centrifugation at 13,000 rpm (SS-34 rotor) for 30 
min at 4 °C. The supernatants were incubated with Ni-NTA agarose (Qiagen) in the presence of 
20 mM imidazole. After extensive washing in core buffer containing 20 mM imidazole, the 
protein was eluted in core buffer with 200 mM imidazole. Following overnight incubation with 
SUMO  protease  to  remove  the  His6-SUMO  tag,  the  protein  was  captured  on  a  HiTrap  Q 
Sepharose column (GE Healthcare). The protein, eluted with a linear 0.1-1 M NaCl gradient, was 
further purified by size exclusion chromatography (Superdex 200, GE Healthcare) in 150 mM 
NaCl, 25 mM Tris-HCl [pH 7.4]. TNPO3 containing fractions were pooled, supplemented with 
10 mM DTT and 10% glycerol, concentrated to 3-8 mg/ml, snap frozen in liquid nitrogen and 
stored at -80 °C.   93 
An  overnight  culture  of  PC2  cells  (Cherepanov  2007)  transformed  with  pGEX6P3-
CPSF6.RS constructs was diluted 1:100 and grown to an A600 of 0.6 at 37 °C, followed by 1 mM 
IPTG induction for 4 h. Bacteria were harvested and lysed by sonication in buffer A (50 mM 
Tris-HCl [pH 7.4], 500 mM NaCl, 1 mM EDTA, 1 mM DTT). The lysate was treated with 25 
U/ml Benzonase nuclease (EMD Biosciences) for 30 min on ice prior to centrifugation at 40,000 
g for 30 min at 4 °C, and the supernatant was incubated with glutathione-Sepharose beads (GE 
Healthcare) for 2 h at 4 °C. The beads were washed extensively in buffer B (50 mM Tris-HCl 
[pH 7.4], 1 M NaCl, 1 mM EDTA, 1 mM DTT), resuspended in 50% bead slurry in the same 
buffer, and used in pulldown assays following total protein quantification by titration against 
BSA  standard  curves  visualized  by  Coomassie  R-250.  Recombinant  GST  was  purified  as 
previously described (Cherepanov et al., 2004). 
Recombinant  WT  and  9  mutant  (E45A,  K70R,  N74D,  G89V,  P90A,  A92E,  G94D, 
A105T, and A105S) HIV-1 CA-NC proteins were expressed in PC2 cells (Cherepanov 2007) and 
purified as described previously (Ganser et al., 1999; Lee et al., 2010), concentrated to 20 mg/ml 
and snap frozen in liquid nitrogen and stored at -80 °C. 
To make recombinant RanQ69L, PC2 cells were transformed with pCPH6P- RanQ69L 
and grown at 30 °C in LB medium supplemented with 120 µg/ml ampicillin to an A600 of 0.9-
1.0, after which the temperature was shifted to 25 °C and protein expression was induced with 
0.01% IPTG for 4 h. Bacterial pellets resuspended in ice-cold core buffer supplemented with 1 
mM  PMSF  were  disrupted  by  sonication,  and  the  lysates  were  cleared  by  centrifugation  at 
27,000 g for 30 min at 4 °C. Supernatants were incubated with NiNTA resin in the presence of 
20 mM imidazole; after extensive washing in core buffer containing 20 mM imidazole His6-
tagged proteins were eluted in core buffer supplemented with 200 mM imidazole. The proteins   94 
were further purified by gel filtration over a HiLoad 16/60 Superdex 200 column in 150 mM 
NaCl, 25 mM Tris-HCl [pH 7.4] and supplemented with 5 mM DTT. To charge RanQ69L with 
GTP, purified proteins were incubated on ice for 30 min in the presence of 10 mM EDTA and 2 
mM GTP, after which 25 mM MgCl2 was added. RanQ69LGTP complexes were supplemented 
with 10% glycerol, frozen in liquid nitrogen and stored at -80 °C. 
The bacmid expressing His6-CPSF6-358 was transfected into Spodoptera frugiperda 9 
(SF9) cells using Cellfectin II reagent (Invitrogen). Cells were incubated and passaged at 28 °C 
in SF-900 II serum-free insect cell medium (SFM-II, Invitrogen) for 3 days, and recombinant 
viruses were harvested (P1 viral stock). Following a viral plaque assay, as per the guidelines of 
the manufacturer (Invitrogen), three plaques (clones) were isolated and expanded by infecting 
SF21 cells. After culturing the cells for 3 days at  28 °C in SFM-II, the cells are lysed and 
subjected  to  Coomassie  R-250  staining  and  His6-immunoblotting  to  determine  the  highest 
expressor,  which  was  amplified  further  by  another  round  of  passaging.  The  P2  virus  was 
subjected to another round of clonal selection via viral plaque assays to  increase expression 
levels. The highest expressor was selected and amplified in SF21 cells (P3), and used for protein 
expression  and  purification.  His6-CPSF6-358  was  purified  by  Ni-NTA  followed  by  size 
exclusion chromatography, concentrated up to 0.180 mg/ml, dialyzed against 25 mM Tris-HCl 
[pH 7.4], 150 mM NaCl, 2 mM DTT, 0.02% sodium azide (v/v%), 10% glycerol (v/v%), snap 
frozen in liquid nitrogen and stored at -80 °C.  
In  vitro  assembly  of  TNPO3-RanQ69L-GTP.  TNPO3-RanQ69LGTP  complexes  were 
assembled by mixing TNPO3 with His6-RanQ69L-GTP at a 1:4 molar ratio and incubating the 
mixure for 1 h at 18 °C in binding buffer (BB: 150 mM NaCl, 25 mM Tris-HCl [pH 7.4]). The 
complex was then bound to a 1 ml HisTrap column (GE Healthcare) and eluted in 150 mM   95 
NaCl, 200 mM imidazole, 25 mM Tris-HCl [pH 7.4]. The tag was removed by incubation with 
His6-tagged human rhinovirus 3C protease. The protein was diluted 5-fold in BB and filtered 
through a HisTrap column. The protein was further purified by size exclusion chromatography 
on a HiLoad 16/60 Superdex 200 column operated in 150 mM NaCl, 25 mM Tris-HCl [pH 7.4].  
In  vitro  assembly  of  HMW  HIV-1  CA-NC  complexes.  HIV-1  CA-NC  particles  were 
assembled in vitro by diluting the CA-NC protein to a concentration of 10 mg/ml in 50 mM Tris-
HCl (pH 8.0), 0.5 M NaCl and 2 mg/ml DNA oligo-(TG)50. The mixture was incubated at 4 °C 
overnight and spun at 9000 g at for 5 min at 4 °C on a tabletop centrifuge. Pellets containing 
assembled  CA-NC  complexes  were  then  resuspended  in  assembly  buffer  (50 mM  Tris-HCl 
[pH 8.0], 0.5 M NaCl), diluted to an apparent concentration of 10 mg/ml based on OD280, and 
used in binding assays. 
 HMW CA-NC binding assays. HEK293T cells transiently transfected with CPSF6-358-
HA, CPSF6-HA, or HA-TNPO3 were lysed in hypotonic lysis buffer (10 mM Tris-HCl [pH 7.4], 
1.5 mM MgCl2, 10 mM KCl, 1 mM DTT) by successive freeze/thaws (in liquid nitrogen / 37 °C 
water bath) and diluted to 1 mg/ml total protein concentration as  determined by Bradford Assay 
(BioRad). The lysates were adjusted to contain 150 mM NaCl, and incubated with 5 µM WT or 
mutant  CA-NC  complexes  for  30  min  at  room  temperature  before  ultracentrifugation  (1  h; 
200,000 x g, 4 °C) through a 60% (HA-TNPO3, TNPO3) or 50% (CPSF6-358-HA, CPSF6-HA, 
His6-CPSF6-358)  sucrose  cushion  (Stremlau  et  al.,  2006).  Following  removal  of  the 
supernatants, the pellets were resuspended 2 x SDS Loading Buffer (SLB).  Input and pellet 
samples were subjected to HA immunoblotting (CPSF6-358-HA, CPSF6-HA, or HA-TNPO3), 
His6 immunoblotting (His6-CPSF6-358) or TNPO3 immunoblotting to detect binding proteins. 
Coomassie R-250 staining was performed to visualize CA-NC in the pellets. Band intensities   96 
were quantified by gel densitometry using  BioRad ChemieDoc and associated Image Lab  TM 
software.  
GST pulldown assays. Semi-purified GST-CPSF6.RS constructs, along with GST control, 
were immobilized on glutathione sepharose beads. Protein concentrations were determined by 
comparing gradient dilutions of loaded glutathione-sepharose beads to  BSA standard curves. 
Each binding reaction was set up to contain 1 µM bait protein. Settled beads (adjusted to 10 µl 
total)  loaded  with  GST-CPSF6.RS  constructs  were  incubated  with  1  µM  TNPO3  in  a  final 
volume of 100 µl buffer A (25 mM Tris-HCl [pH 7.4], 200 mM NaCl, 5 mM DTT, 0.1 mM 
EDTA, 0.5% CHAPS and protease inhibitors) containing 10 µg BSA. Following gentle rocking 
at 4 °C for 45 min the supernatant was removed from all samples and the beads were washed 
three times in 1 ml pulldown buffer (PDB; 25 mM Tris-HCl, [pH 7.4]), 200 mM NaCl, 5 mM 
DTT, 0.5% CHAPS). Bound proteins were eluted in 2 x SLB. Following SDS-PAGE, proteins in 
input and pulldown samples were visualized by Coomassie R-250 staining. Band intensities were 
quantified by gel densitometry using BioRad ChemieDoc and associated Image Lab TM software. 
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D.   Results 
D.i.  Correlation between TNPO3 dependence and CPSF6-358 sensitivity of a panel of 
  
  HIV-1 CA mutants 
 
We tested a panel of 9 HIV-1 CA mutants alongside WT HIV-1 for their dependence on 
TNPO3 and sensitivity to CPSF6-358 to assess how the two phenotypes might be related. Our 
panel  consisted  of  the  following  CA  mutants:  G89V  and  P90A  that  render  HIV-1  CypA-
independent due to mutations in the CypA binding site (G89V, P90A; Braaten et al., 1996), 
mutants C-terminal to the CypA-loop that render the virus CsA-dependent in HeLa cells (A92E, 
G94D; Aberham et al., 1996), mutants in the CPSF6 binding pocket that alleviate CPSF6-358 
sensitivity and presumably abrogate binding to CPSF6313-327 (K70R, N74D, A105T; Price et al., 
2012),  a  mutant  that  renders  HIV-1  resistant  to  the  integration  inhibitor  Coumermycin-A1 
(A105S; Vozzolo et al., 2010), and another CsA-dependent mutant that lies outside of both the 
CypA binding loop and and the CPSF6 binding pocket that renders the capsid core hyperstable 
(E45A; Forshey et al., 2002). Infection assays were carried out in stably transduced HeLa and 
HEK293T cells, yielding similar data (Figure 3.1) (results in HEK293T cells not shown), both in 
presence and absence of CsA, to assess a potential role of CypA  in utilizing TNPO3 and/or 
interacting with CPSF6.    98 
 
 
Figure 3.1 Infectivity profiles of HIV-1 CA WT and 9 mutants upon CPSF6-358 restriction and TNPO3 
KD.  Stably  transduced  empty  vector  HeLa-CTRL  vs  HeLa-TNPO3  KD  (upper  panel)  and  stably 
transduced empty vector HeLa-CTRL vs HeLa-CPSF6-358  cells (lower panel) were infected with RT 
matched inocula of single round HIV-1 vectors expressing luciferase; either in presence or absence of 4 
µM  CsA.  Bioluminescence  readings  were  taken  at  48  h  post  infection.  Results  of  two  independent 
experiments (mean ± standard error of the mean, SEM) are depicted as log10(relative light units/µg) per 
sample.  Mean  fold  inhibition  upon  CPSF6-358  restriction  /  TNPO3 depletion  in  presence  of  DMSO 
control; mean fold inhibition upon CPSF6-358 restriction / TNPO3 depletion in presence of 4 µM CsA; 
and the ratio of each is tabulated below each graph. (A) HeLa CTRL DMSO (white); HeLa CPSF6-358 
DMSO (black); HeLa CTRL 4 µM CsA (light grey); HeLa CPSF6-358 4 µM CsA (dark grey). (B) HeLa 
CTRL DMSO (white); HeLa TNPO3 KD DMSO (black); HeLa CTRL 4 µM CsA (light grey); HeLa 
TNPO3 KD 4 µM CsA (dark grey).    99 
 
 
Figure  3.2  Correlation  of  TNPO3  dependence  and  CPSF6-358  sensitivity  of  a  panel  of  HIV-1  CA 
mutants. Correlation between CPSF6-358 sensitivity and TNPO3 dependence in DMSO control (top left) 
and upon CsA treatment (top right). Correlation between CPSF6-358 sensitivity in DMSO control vs. 
CsA-treated  cells  (bottom  left;  K70R  is  omitted  from  the  analysis).  Correlation  between  TNPO3 
dependence in DMSO control vs. CsA-treated cells (bottom right). Graphs are plotted and Spearman’s 
rank correlation coefficients (rs) and the strength of significance (P) were calculated using Figure 3.1 
data. 
 
CPSF6-358 sensitivity and TNPO3 dependence correlated in DMSO-treated cells (Figure 
3.2; top left; Spearman’s rho coefficient, rs = 0.721, P<0.02), and in CsA-treated cells (Figure 
3.2; top right; rs = 0.842, P<0.01). TNPO3 dependence of HIV-1 was completely independent of 
CsA-treatment and CypA modulation under these conditions (Figure 3.2; bottom right; rs = 
0.964, P<0.0001). CPSF6-358 sensitivity in the absence and presence of CsA correlated less 
strongly, yet significantly (Figure 3.2; bottom left; rs = 0.717, P<0.05) when K70R was left out 
of calculation, which became significantly CPSF6-358 sensitive upon CsA treatment (Figure   100 
3.1).  
As seen in Figure 3.2, there is  a strong correlation between TNPO3 dependence and 
CPSF6-358  sensitivity  of  the  full  set  of  CA  mutants  both  under  DMSO-  and  CsA-treated 
conditions. CPSF6-358 restriction itself is independent of CsA treatment for all mutants except 
for K70R, which seems to reverse its CPSF6-358 sensitivity phenotype under drug treatment. As 
can be seen in Figure 3.1, K70R displays a severe infectivity defect in the HeLa cell line tested 
(10-100 fold) when compared to WT HIV-1. It has been reported previously that K70R may 
display a CypA-modulated stability defect (Li et al., 2009), and such defects may render the 
incoming quaternary capsid surface in a way that may affect  CPSF6-358 interactions  in  the 
cytosol. Additionally, further testing at equal MOIs rather than RT-matched conditions may be 
necessary to reveal the true phenotype of defective mutants such as E45A and K70R  
WT HIV-1 lost sensitivity to CPSF6-358 upon CsA treatment (Figure 3.2; cf. top left vs. 
top right), but was still restricted strongly. Mutation of CPSF6313-327 contact residues (K70R, 
N74D, A105T, and A105S) significantly conferred resistance to CPSF6-358 as did E45A, which 
lies outside of the CPSF6-CA interface, in the absence of CsA. These mutants also infected cells 
similarly regardless of TNPO3 depletion, except for HIV-1 CA K70R, whose dependence on 
TNPO3 was as strong as that of HIV-1 WT. All four CypA loop mutants displayed moderate 
CPSF6-358 sensitivity and TNPO3 dependence, albeit to a lesser extent compared to WT HIV-1. 
     101 
D.ii.  CPSF6-358 sensitivity of HIV-1 correlates with CA binding to CPSF6 
   




Figure 3.3 CPSF6-358 sensitivity of HIV-1 correlates with CA binding to CPSF6-HA. HMW CA-NC 
binding  assays  were  carried  out  with  the  panel  of  HIV-1  CA  mutants  to  test  their  ability  to  bind 
ectopically expressed CPSF6-HA in 293T cell extracts. (A) Top panel shows HA- immunoblot of CA-
bound CPSF6-HA and Coomassie R-250 stain of CA-NC pellets. (B) Mean % recovery of CPSF6-HA 
(+/-  SEM)  from  two  independent  experiments  were  graphed  and  (C)  correlated  with  CPSF6-358 
sensitivity (no CsA treatment) of each respective CA mutant vector from Figure 3.1. HIV-1 CA E45A 
was omitted from the calculations. 
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To gain insight into the determinants of CPSF6-358 sensitivity and TNPO3 dependency 
of HIV-1 CA mutants, we carried out HMW HIV-1 CA-NC tube binding assays that employ in 
vitro  assembled    HIV-1  CA  lattices  as  a  bait.  The  assay  -  as  opposed  to  monomeric  CA 
pulldowns - allows testing candidate cellular interactors as they would encounter the incoming 
quaternary capsid core in the cytosol. 
We  tested  both  ectopically  overexpressed  CPSF6  species  (CPSF6-HA,  Figure  3.3; 
CPSF6-358-HA, Figure 3.4) that were present abundantly in hypotonic cytoplasmic lysates (data 
not shown); and recombinant  His6-CPSF6-358,  obtained  via  baculoviral  expression in insect 
cells (Figure 3.5) in the absence of other cytoplasmic proteins.  
The ability of HIV-1 CA mutants to bind ectopically expressed CPSF6 species correlated 
strongly and significantly with the CPSF6-358 sensitivity of each respective mutant - with the 
caveat that the dresults for HIV-1 CA E45A had to be omitted in our analysis to reveal such a 
correlation  (CPSF6-HA:CA  rs=  0.833,  P<0.01,  Figure  3.3C;  CPSF6-358-HA:CA  rs=  0.8, 
P<0.01, Figure 3.4C). E45A is fully resistant to CPSF6-358 restriction (Figure 3.1) yet retains 
the ability to bind CPSF6 species in vitro, unlike the CPSF6-358 resistant HIV-1 CA mutants 
N74D, A105T and A105S (Figures 3.3, 4). E45A is also a severely defective CA mutant when it 
s absolute infectivity is compared to WT HIV-1 (Figure 3.1). Such gross defects complicate a 
comparative analysis, especially E45A is known to be an intrinsic stability mutant (Forshey et 
al., 2002), which may stem from large scale conformational changes at the CA hexamer:hexamer 
interspace, where CPSF6 interactions also take place. Thus in vitro binding assays looking at 
CPSF6-358/CPSF6 interactions with E45A within the context of a CA-NC construct as tested in 
out studies may not reflect the quaternary surface structure that is exposed in an infected cell, 
which led us to omit E45A in our statistical analysis.      103 
K70R, another CPSF6 resistant HIV-1 CA mutant, also retained the ability to bind both 
CPSF6 species in vitro under the experimental conditions tested. HIV-1 CA-NC binding profiles 
to CPSF6-HA and CPSF6-358-HA were strongly correlated (rs= 0.83, P<0.01; data not shown), 
supporting the notion that the major determinant of the CA:CPSF6 interaction is shared between 
CPSF6 and CPSF6-358 (Price et al., 2012).     104 




Figure 3.4 CPSF6-358 sensitivity of HIV-1 correlates with CA binding to CPSF6-358-HA. HMW CA-
NC binding assays were carried out with the panel of HIV-1 CA mutants to test their ability to bind 
ectopically expressed CPSF6-358-HA in 293T cell extracts. (A) Top panel shows a representative HA-
immunoblot of CA-bound CPSF6-358-HA and Coomassie R-250 stain of CA-NC pellets. (B) Mean % 
recovery  of  CPSF6-358-HA  (+/-  SEM)  from  two  independent  experiments  were  graphed  and  (C) 
correlated with CPSF6-358 sensitivity (in absence of CsA treatment) of each respective CA mutant vector 
from Figure 3.1. HIV-1 CA E45A was omitted from this analysis. 
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D.ii.3. CPSF6-358 sensitivity of HIV-1 correlates with CA binding to recombinant  
   
  His6-CPSF6-358   
 
To assess whether the direct interaction between HIV-1 CA and CPSF6 (Price et al., 
2012) and the binding phenotypes we observed in our assays could still be modulated by other 
cellular  factors,  we  assessed  binding  between  recombinant  His6-CPSF6-358  and  HIV-1 
assemblies (Figure 3.5). 
Similar  to  the  observations  with  cytoplasmic  CPSF6-HA  and  CPSF6-358-HA,  the 
CPSF6-358 sensitivities of HIV-1 CA mutant viruses mirrored their ability to bind recombinant 
His6-CPSF6-358  protein;  although  this  correlation  was  somewhat  weaker,  it  yet  still  gained 
statistical significance (rs= 0.7, P<0.05; cf. Figures 3.3, 4).  
One  immediate  observation  was  that  the  CypA-sensitive,  CsA-dependent  HIV-1  CA 
mutants, A92E and G94D, displayed reduced affinity to His6-CPSF6-358 when compared to 
when the protein was assayed as a cell lysate.  
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Figure 3.5 CPSF6-358 sensitivity of HIV-1 correlates with CA binding to recombinant His6-CPSF6-358. 
HMW CA-NC binding assays were carried out with the panel of HIV-1 CA mutants (5 µM) to test their 
ability  to  bind  recombinant  His6-CPSF6-358  (1  µM)  in  isotonic  buffer.  (A)  Top  panel  shows  a 
representative His6- immunoblot of CA-bound His6-CPSF6-358 and Coomassie R-250 stain of CA-NC 
pellets. (B) Mean % recovery of His6-CPSF6-358 (+/- SEM) from two independent experiments were 
graphed and (C) correlated with CPSF6-358 sensitivity (in absence of CsA treatment) of each respective 
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D.iii.  TNPO3 dependence of HIV-1 does not correlate with CA binding to TNPO3 
 
  Following our observations that TNPO3 dependence and CPSF6-358 sensitivity of HIV-1 
CA mutants correlated and that CPSF6-358 sensitivity of HIV-1 CA mutants in turn strongly 
correlated with the ability of all but one  mutant to bind CPSF6, we  tested whether TNPO3 
interacted with. 
  We  detected  binding  between ectopically  expressed  HA-TNPO3  and  HIV-1  CA  WT 
(Figure 3.6A). This interaction, however, displayed no correlation with the dependence of the 
respective HIV-1 CA mutants on TNPO3 in infected cells (Figure 3.6C; rs=  -0.4, P=0.286) 
Similar results were obtained in binding assays using recombinant TNPO3 in isotonic buffer 
(data not shown).  
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Figure 3.6 TNPO3 dependence of HIV-1 does not correlate with CA binding to HA-TNPO3. HMW CA-
NC binding assays were carried out with the panel of HIV-1 CA mutants to test their ability to bind 
ectopically  expressed  HA-TNPO3  in  293T  cell  extracts.  (A)  Top  panel  shows  a  representative  HA-
immunoblot  of  CA-bound  HA-TNPO3  and  Coomassie  R-250  stain  of  CA-NC  pellets.  (B)  Mean  % 
recovery of HA-TNPO3 (+/- SEM) from two independent experiments were graphed but (C) lacked a 
correlation with TNPO3 dependence (in absence of CsA treatment) of each respective CA mutant vector 
(data from Figure 3.1). 
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D.iv.  CPSF6.RS is potential import cargo of TNPO3       
 
D.iv.1. TNPO3 binds CPSF6.RS directly and specifically       
 
 
Figure  3.7  TNPO3  binds  CPSF6.RS  directly  and  specifically.  (A)  The  primary  sequence  of  the  C-
terminal RS-domain of CPSF6. Canonical RS repeats, and non-canonical RD/RE repeats are highlighted 
in red and blue respectively. (B) GST-CPSF6441-588 can pull down recombinant TNPO3 out of solution. 
(C) Initial mapping studies with CPSF6.RS C-terminal truncations and recombinant TNPO3. Images are 
representative  of  two  independent  binding  assays.  In  each  case  total  protein  staining  is  done  with 
Coomassie R-250. 
 
The lack of correlation between TNPO3 dependence of HIV-1 CA mutants and their 
ability to bind TNPO3 prompted us to test the hypothesis that TNPO3 may exert its function in 
HIV-1 replication indirectly through an interaction with CPSF6, which is predicted to be an 
import cargo for TNPO3 in cells (Maertens et al., 2014).  
To assess whether there is direct binding between recombinant TNPO3 and CPSF6, as   110 
expected from a transporter:cargo pair, we set out to test for binding between these two factors. 
Extensive efforts to express and purify full length CPSF6 in quantitative amounts conducive for 
biochemical  analysis  failed  (bacterial  expression,  in  vitro  transcription  and  translation  and 
baculoviral expression  in insect  cells;  data  not  shown).  We  instead  decided to work  with  a 
truncation  construct,  GST-CPSF6.RS441-588,  that  harbors  the  putative  TNPO3  recognition 
domain, the C-terminal SR-rich CPSF6.RS, spanning CPSF6 residues 526-588 as predicted from 
primary sequence analysis (Figure 3.7A). The GST fusion protein GST-CPSF6.RS441-588 proved 
to be highly soluble and conducive to purification, thus this domain was used in pull down 
studies with recombinant TNPO3. 
As seen in Figure 3.7B, GST-CPSF6.RS441-588 pulled down recombinant TNPO3, whereas 
GST by itself did not, indicating the binding was specific to the CPSF6.RS441-588 domain. To 
determine the subdomains of CPSF6.RS that mediate binding, we designed consecutive CPSF6 
C-terminal truncation mutants and tested them in the pulldown assay side by side with GST-
CPSF6.RS441-588 (Figure 3.7.C, lane 1). Of the three CPSF6 truncation mutants that lacked the C-
terminal 20 aa (GST-CPSF6.RS441-568), 34 aa (GSTCPSF6.RS441-554) or 48 aa (CPSF6.RS441-540), 
(lanes  2-4);  GST-CPSF6.RS441-540  lost  binding  to  TNPO3  completely,  whereas  GST-
CPSF6.RS441-554 displayed reduced binding and GST-CPSF6.RS441-568 was unaffected. Thus one 
determinant of binding to TNPO3 was mapped to CPSF6 residues 540-554 aa, with residues 
spanning 554-568 aa playing a potential secondary role under these assay conditions.     111 
D.iv.2. TNPO3:CPSF6.RS binding is mediated may be mediated by multiple points of  
 




Figure 3.8 The extended CPSF6.RS mutagenesis scheme.  
 
  To fine-map the interaction between TNPO3 and GST-CPSF6.RS441-588 we expanded our 
set of CPSF6.RS mutants (Figure 3.8) to include a larger C-terminal deletion (CPSF6.RS441-526, 
#8), internal RS domain deletions (∆541-553, #5; ∆541-568, #6) and N-terminal deletions of 
CPSF6.RS  (CPSF6.RS527-588,  #2;  CPSF6.RS554-588,  #3;    CPSF6.RS569-588,  #4),  along  with  the 
internal 541-568 aa sequence  fused to GST  (CPSF6.RS541-568, #7)  that we had  preliminarily 
identified to be critical for binding in Figure 3.7. The results are shown in Figure 3.9.   112 
 
 
Figure 3.9 TNPO3:CPSF6.RS binding is mediated by multiple points of contact. GST.CPSF6.RS mutants 
were  individually  expressed  and  purified  while  immobilized  on  Glutathione  sepharose  beads.  GST 
pulldowns are carried out following incubation with equal amounts of TNPO3. TNPO3 was visualized by 
immunoblotting (upper panel), whereas GST-CPSF6.RS proteins were stained with Coomassie R-250 
(central panel). The amount of pulled down TNPO3 was normalized by the amount of GST.CPSF6.RS in 
each pulldown and graphed (lower panel). The images are representative of two independent experiments. 
The graph shows %recovery of TNPO3 (means +/- standard errors of the means) after normalization for 
the bead-immobilized GST-CPSF6.RS constructs in two independent experiments.  
 
  Surprisingly, all of the constructs tested  recovered TNPO3 at least as  much as GST-
CPSF6.RS441-588 (lane 12), except for GST-CPSF6.RS441-540 (lane 9). Extending the C-terminal 
truncations down to CPSF6 residue 526 (constructs #8-12 in Figure 3.8 & 3.9) revealed that in 
absence  of  the  540-568  aa  sequence,  GST-CPSF6.RS441-526  pulled  down  TNPO3  strongly,   113 
recovering all of TNPO3 used as input. GST-CPSF6.RS441-526 along with GST-CPSF6.RS554-588 
recovered the highest amounts of TNPO3, implying that both domains bear residues important 
for  TNPO3  binding.  The  8-10-fold  increased  recovery  of  TNPO3  by  GST-CPSF6.RS441-526 
compared  to  CPSF6.RS441-553,  CPSF6.RS441-568,  and  CPSF6.RS441-588,  together  with  the 
observation that CPSF6.RS554-588 also efficiently pulled down TNPO3, implied that CPSF6.RS 
residues spanning 527-553 aa may have a negative affect on TNPO3 binding in the context of 
this partial CPSF6 construct. 
  The N-terminal truncation mutant CPSF6.RS527-588 (construct #2 in Figure 3.8 & 3.9)l 
bound  TNPO3.  Larger  N-terminal  truncations  that  removed  residues  spanning  527-553 
(construct #3 in Figure 3.8 and 3.9) and 527-568 (construct #4 in Figure 3.8 and 3.9) also scored 
positive  for  binding  TNPO3  in  this  assay,  contradicting  our  previous  finding  that  residues 
spanning CPSF6.RS 540-568 aa constituted the major binding site to TNPO3 (Figure 3.7). 
  Internal deletions of 540-554 and 540-568 (constructs #5, 6 in Figure 3.8 and 3.9) still 
bound TNPO3, implying that the residues within these deletion constructs were not essential to 
bind TNPO3. 
  Overall, CPSF6 residues 441-526 and 554-588 conferred binding to TNPO3, whereas 
CPSF6 residues 540-553 conferred a negative effect under these assay conditions.   
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D.v.  The TNPO3:CPSF6.RS interaction is modulated by RanQ69L-GTP  
   
 
Figure 3.10 Coincubation with RanQ69LGTP impairs TNPO3:CPSF6.RS domain interaction. Image is 
representative of two independent binding assays. Total protein staining is done with Coomassie R-250. 
 
High concentrations of intranuclear RanGTP disrupts transportin:import cargo complexes 
by binding to transportins competitively, which results in cargo release (Chapter 1, D.i; Figure 
1.8). To assess whether the specific binding we observed in vitro between TNPO3 and GST-
CPSF6.RS441-588 (Figure 3.7) constituted a bona fide transport:import cargo interaction between 
TNPO3 and the CPSF6.RS domain, we tested whether pre-formed stable TNPO3:RanQ69L-GTP 
complexes would impair this binding.  As seen in Figure 3.10, GST-CPSF6.RS441-588 was either 
incubated with TNPO3 alone (lane 1), the pre-formed TNPO3:RanQ69L-GTP complex (lane 2) 
or RanQ69L-GTP (lane 3). TNPO3 pulldown by GST-CPSF6.RS441-588 was completely inhibited 
upon coincubation with TNPO3:RanQ69L-GTP complexes compared to TNPO3 alone (cf. lanes 
4 and 5), suggesting that RanQ69L-GTP inhibited the interaction.henning     115 
E.  Discussion                 
As shown in D.i, Figure 3.2; TNPO3 dependency of HIV-1 CA mutants correlated with 
sensitivity  to  CPSF6-358.  Inhibiting  the  CA:CypA  interaction  pharmacologically  with  CsA 
flipped the CPSF6-358 sensitivity of HIV-1 CA K70R (i.e., from being resistant to sensitive). 
CPSF6-358 sensitivities of HIV-1 CA mutants correlated in both the absence and presence of 
CsA (Figure 3.2), implying that CypA modulation played little role in the CA:CPSF6 interaction 
under these conditions, except for K70R as mentioned above.  
All CypA loop mutants,  CA  G89V, P90A,  A92E and G94D, moderately  reduced the 
TNPO3 dependency and CPSF6-sensitivity of HIV-1. HIV-1 CA E45A proved to be an outlier in 
our studies due to its ability to bind CPSF6 as well as CA WT in vitro, yet this virus was not 
restricted in infectivity assays. A potential explanation of this phenomenon can be that CPSF6-
358 restriction relies on yet another factor in the cell  and that E45A cannot interact with it. 
Alternatively, intrinsic changes in core stability (Forshey et al., 2002) may affect interactions 
with  cellular  factors,  or  due  to  differential  blocks  in  its  replication  HIV-1  E45A  may  not 
encounter  CPSF6  inside  cells,  presumably  due  to  a  differential  uncoating  kinetics  that  may 
preclude  endogenous  CPSF6  species  from  coming  in  contact  with  the  quaternary  CA 
hexamer:hexamer interface in a timely manner.  
  HIV-1 CA A92E and G94D displayed reduced binding to recombinant His6-CPSF6-358, 
which could imply that binding to ectopically expressed CPSF6 species may be enhanced by the 
CypA-dependent restriction these mutants encounter in infected cells. In preliminary assays, we 
did not observe an effect of CsA on the binding of CPSF6 to WT or K70A CA-NC. Use of CA 
double  mutants  such as  ones  that  combine  CPSF6  and  CypA-related  phenotypes  in  binding   116 
assays may enhance out understanding of whether there is functional interplay between CPSF6 
and CypA.  
  Our  mapping  studies  of  the  binding  between  TNPO3  and  CPSF6.RS  proved  to  be 
indeterminate (Figures 3.6-8). Confounding factors may have been the lack of full length CPSF6 
used in binding assays and that GST-CPSF6.RS441-588 may not have recapitulated the tertiary 
structure of the CPSF6.RS domain, either as part of CPSF6 itself, and/or as part of other cellular 
complexes CPSF6 may be found in (Yang et al., 2011). Anither plausible explanation may be the 
lack of phosphorylation of our binding construct, which is required for most cargo proteins such 
as ASF/SF2 to bind TNPO3 (Lai et a., 2000; Lai et al., 2001; Maertens et al., 2014). Indeed, it 
has  been  reported  that  phosphorylation  enhances  the  solubility  of  ASF/SF2  RRM2-RS  and 
CPSF6.RS domains (Maertens et al., 2014). Accordingly, the lack of phosphorylation may have 
resulted in nonspecific binding between TNPO3 and partially insoluble CPSF6.RS under our 
experimental  conditions.  An  alternative  explanation  could  be  that  partial  deletions  and 
truncations  may  be  disrupting  the  tertiary  protein  structure  within the  CPSF6.RS  domain to 
different extents, confounding our analysis. Our results could, however, also imply that TNPO3 
binding may be modulated negatively and positively by multiple points of contact on CPSF6.RS, 
rather than by a defined set of amino acids within a specific subdomain. Such multi-contact 
TNPO3:cargo binding has precedence in the literature. For example, the co-crystal structure of 
TNPO3:ASF/SF2  RRM2-RS  domain  revealed  multiple  residues  both  in  the  RS  and  RRM 
domains that play important roles in TNPO3 binding (Maertens et al., 2014). 
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E.i.   A potential role of TNPO3 in HIV-1 infection that is mediated by CPSF6 
   
The  finding  that  the  HIV-1  infectivity  defect  upon  TNPO3  depletion  can  largely  be 
alleviated  by  simultaneous  knockdown  of  endogenous  cytoplasmic  CPSF6  (De  Iaco.,  2013; 
Fricke et al., 2013) is strong evidence that the role TNPO3 plays in  the HIV-1 life cycle is 
mediated through cytoplasmic CPSF6; an intermediary factor that directly targets HIV-1 CA. 
The correlation between binding profiles of  HIV-1 CA mutants with CPSF6/CPSF6-358 and 
their respective sensitivities to CPSF6-358 (D.ii), but the lack thereof with TNPO3 and their 
respective  dependencies  on  TNPO3  (D.iii)  are  supportive  of  a  model  where  CPSF6  is  the 
biochemical  link  that ties TNPO3  functionally  to  HIV-1  CA.  The  observation  that TNPO3-
insensitive CA mutants (e.g. N74D, A105S, A105T) are actual CPSF6-binding mutants (Figures 
3.3-5) gives credence to this hypothesis. In this regard it seems that the binding we detected 
between TNPO3 and HIV-1 CA-NC is nonspecific.  
According to this model (Figure 3.11) TNPO3 and CPSF6 are bona fide transporter : 
nuclear import cargo partners, where TNPO3 exerts a positive effect on incoming HIV-1 virions 
by ensuring nuclear sequesteration of endogenous CPSF6. Cytosolic accumulation of CPSF6, be 
it either due to TNPO3 depletion of recognition RS domain removal, will then pose a restrictive 
phenotype at the stage of HIV-1 PIC nuclear import. Thus, the positive role of TNPO3 in HIV-1 
infection stems from its ability to sequester an otherwise nuclear HIV-1 capsid interactor that can 
become detrimental to HIV-1 infection upon untimely mislocalization to the cytosol. Our current 
understanding of TNPO3 strongly favors such a model, with the caveat that  (i) there are CA 
mutants such as K70R that are resistant to CPSF6-358 yet depend on TNPO3; and (ii) the cell 
cycle dependencies of TNPO3 and CPSF6-358 phenotypes are disparate (Chapter 2; D.iii). 
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Figure 3.11. The model depicting the role of TNPO3 in HIV-1 infection. TNPO3 recognizes (A) and 
binds CPSF6 via its RS domain in the cytosol (B), ferries it through the NPCs into the nucleus (C), where 
upon competitive RanGTP binding CPSF6 is then released into the nucleoplasm (D). CPSF6 cannot be 
shuttled into the nucleus when TNPO3 is depleted, and instead binds and restricts the incoming HIV-1 
capsid in the cytosol (E).  Truncation of the C-terminal RS domain prevents TNPO3 recognition and 
nuclear transport of CPSF6-358, which then instead binds and restricts the incoming HIV-1 capsid in the 
cytosol.   119 
E.ii.  Is there a tertiary complex between TNPO3, CPSF6, CypA and CA? 
 
  The in vitro evidence that CPSF6.RS is a specific binding partner of TNPO3 and that this 
binding is abrogated upon TNPO3:RanQ69L-GTP complex formation suggests that CPSF6 is a 
bona fide import cargo for TNPO3. As described in Chapter 1; D.i, the β-karyopherin TNPO3 is 
supposed to bind its import cargo, CPSF6, in the cytoplasm, ferry it across the NPC and once at 
the nuclear side of NPCs release it upon competitive RanGTP binding. Thus, even if it may be 
transitory mid-shuttling, a TNPO3:CPSF6 complex is expected to form on the cytosolic side of 
an NPC, where CPSF6 species can bind incoming HIV-1 capsids. It is currently not known, 
however, whether  binding to CA (mediated by CPSF6 residues 314-322 aa) and binding  to 
TNPO3 (mediated by the RS domain) can affect each other within the context of full length 
endogenous  CPSF6.  If  both  are  specific  in  vivo,  the  two  binding  events  may  be  mutually 
exclusive due to steric hindrance, cooperative, or independent. Unfortunately, the lack of access 
to quantitative amounts of recombinant CPSF6 species harboring both domains hindered our 
studies in this regard. 
   Cooperative  binding,  for  example,  could  explain  the  observation  that  ectopically 
expressed TNPO3 bound CA-NC complexes non-specifically (Figure 3.6), if it were mediated by 
residual amounts of CPSF6 present in cell lysates. Our finding that recombinant TNPO3 also 
displayed  similar nonspecificity when it comes  to binding CA-NC in absence  of cell lysate 
(results not shown), however, allows the alternative interpretation that the observed binding may 
be non-specific in nature and an artifact of the in vitro binding system, or that direct TNPO3 
binding may be mediated by an as yet to be described domain on HIV-1 CA. The strong genetic 
evidence obtained with present CA mutants that render HIV-1 TNPO3-independent and cluster 
around the CPSF6-binding pocket, suggest otherwise, however.   120 
  At first sight, the tertiary model presented in Chapter 2; E.i (Figure 2.10) is suggestive of 
possible  intermolecular  interactions  between  CPSF6  and  CypA  and  that  their  simultaneous 
binding to the capsid surface would require some coordination. The lack of conclusive evidence 
for such a link in our functional and biochemical assays, however, needs to be weighed carefully. 
In  vitro  binding  assays  employ  a  rather  high  concentration  of  HIV-1  CA-NC  complexes, 
potentially making it impossible to observe effects on e.g. cooperativity, due to the saturating 
levels of CA binding sites present. This may in turn prevent occupation of all CPSF6- and CypA 
binding sites, diminishing the probability of joint binding events. Similarly, in vivo, not all CA 
hexamer:hexamer  interfaces  may  be  occupied  by  cytoplasmic  binding  factors,  precluding 
cooperation or any other functional link. Observing such interaction may require all interactors 
involved in recombinant form to allow quantitative saturation of all binding sites.  
  Under our experimental conditions, we have not been able to observe an effect of CsA on 
CPSF6-binding to WT CA, implying that liberation of CypA-loops from endogenous levels of 
CypA in a cell extract does not affect ectopically expressed CPSF6 binding  to CA (data not 
shown; also addressed in Henning et al., 2014). This was also the case for the CA K70R mutant 
(results not shown), which in infectivity assays revealed a functional role of CypA, since CsA 
treatment / altered CypA binding modulated the infectivity of this particular virus (Figure 3.1). 
An  alternative  approach  could  be  to  saturate  CypA-loops  with  excess  recombinant  CypA. 
However,  (i) we have not been able to detect recombinant CypA binding to HMW CA-NC 
complexes efficiently (results not shown), and (ii) saturating CA tubes with recombinant CypA 
has been known to destabilize and induce their disassembly (Graettinger et al., 1999), which may 
thus require the use of CA A14C/E45C disulfide cross-linked stable CA tubes instead (Pornillos   121 
et al., 2009). Similarly, quantitative production of recombinant CPSF6 species bearing the CA 
interaction domain should enable reverse competition assays. 
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A.   The convergence of CPSF6 and CypA on the CA hexamer:hexamer interface 
    Since  the  atomic  structures  of  CA-NTD  (Gitti  et  al.,  1996)  and  the  CA-NTD:CypA 
(Gamble et al., 1996) complex were solved, investigators working on HIV-1 CA and its role in 
HIV-1 replication have used this monomeric structure as a reference base to map amino acid 
residues with aberrant biological phenotypes onto it. Even after the atomic structural of the CA 
hexameric unit was solved (Pornillos et al., 2009), functional and biochemical CA mutations 
were highlighted on a CA-NTD monomer or on a single CA-hexamer to aid with interpretations 
about how their structural context may tie in to their observed biology.  
   However, since CA was identified as the main structural component of the viral core in 
ultrastructural and immunoelectron microscopic studies of HIV-1 (Gelderblom et al., 1987), it 
has been known that the capsid core forms a conical topology within a virion, which was later 
revealed to be constructed by CA hexamer and pentamer interactions (Jin et al., 1999; Ganser et 
al., 1999). Accumulating structural data on full length CA (Ganser-Pornillos et al., 2007) and its 
oligomers (Pornillos et al., 2009; Pornillos et al., 2011) finally allowed full conical modeling of 
the capsid core (Figure 1.5; Pornillos et al., 2011), which was confirmed in atomic detail most 
recently (Zhao et al., 2013). 
   The  identification  of  cellular  factors  such  as  CypA,  TNPO3,  CPSF6,  Nup358  and 
Nup153 that enable CA-mediated functions emphasizes the need to understand their interaction 
interface with capsid, which presents a multimeric and multifaceted lattice to the cytosol. On the 
capsid, CA hexamers and biologically important CA residues are found within the context of 
other  CA  hexamers  and  their  surface  exposed  residues.  This  requires  a  superstructural 
understanding of their relative positions on capsid (Figure 1.9), and a superstructural projection 
of CA interactors (Figure 2.10); something the field had largely omitted so far.   124 
   We and others have shown, for example, that CPSF6 binds CA within a surface pocket 
defined by CA-NTD helices 3 and 4 (Lee et al., 2010; Price et al., 2012). It is only revealed 
within the context of a CA hexamer:hexamer interface, however, that the minimal CA binding 
portion, CPSF6313-327, finds itself within this interhexameric space, access to which may require 
coordination  with  CypA  and  neighboring  CA  molecules  (Figure  2.10).  Such  a  hypothetical 
coordination may explain our observation that the CPSF6 binding mutant N74D increases CsA-
sensitivity of HIV-1, as well, and that this may be a result of a decreased binding affinity to 
CypA (Figure 2.9; Ambrose et al 2012).  This model will be discussed in further detail under 
section E of this chapter.  
 
 
B.   A multiplicity of nuclear import/preintegration targeting pathways and their 
 
   potential roles of TNPO3, CPSF6 and CypA in pathway commitment   
   TNPO3, Nup358 (Ocwieja et al., 2011) and Nup153 (Koh et al., 2013) have been shown 
to reduce HIV-1 integration frequency in regions dense with transcriptional units (TUs). CA 
mutants N74D and N57A, which are CPSF6 and Nup153 binding mutants, respectively, also 
display reduced dependence on the aforementioned nuclear transport proteins, integrate not only 
in regions of low TUs but also of low gene density, showing some difference from the targeting 
phenotype  under  knockdown  conditions  listed  above  (Schaller  et  al.,  2011).  CypA  binding 
mutants (G89V, P90A) or CsA treatment of WT virus results in yet another different targeting 
phenotype,  namely  into  regions  with  higher  than  normal  gene  density  and  with  higher 
transcriptional activity (Schaller et al., 2011). Intriguingly, CsA treatment does not affect the 
targeting phenotype of N74D and N57A, in line with a model that these mutations lead to a 
different import/integration pathway than of WT HIV-1. Indeed, compared to WT HIV-1, N74D   125 
employs a different set of NPC components (Lee et al., 2010).  
    The N74D mutation confers resistance to CPSF6-358, reduces dependency on TNPO3, 
Nup358 and Nup153, all of which have been shown to interact with HIV-1 CA (Figure 2.7; Lee 
et al., 2010; Price et al., 2012;  Figure  3.6; Valle-Casuso et al., 2011; Schaller et al., 2011; 
Matreyek  et  al.,  2013)  (our  results  in  Figure  3.6,  however,  argue  for  such  binding  to  be 
nonspecific in the case of TNPO3). Biochemically, however, N74D has only been proven to 
have a direct negative effect on CPSF6 binding to CA, whereas the functional independence 
from Nup153 of this mutation did not manifest itself in the form of altered Nup153 binding to 
CA (Matreyek et al., 2013) or TNPO3 (Figure 3.6). Similar to CPSF6313-327 (Price et al., 2012), 
however, Nup153-CTD also binds the same CA surface pocket – and can compete with CPSF6 
binding - suggestive of a need to coordinate their interaction with the CA lattice on an incoming 
PIC. It is possible that the PIC may be handed over from one factor to another; overlapping 
binding sites, and cytoplasmic localization and local concentrations of each factor may ensure 
directionality of transport and temporal regulation. Alternatively, both factors may be able to 
bind an incoming capsid core at the same time, either intact or partially uncoated, in different 
pockets available on the quaternary CA hexamer lattice. 
   Similar  coordination  may  exist  between  soluble  CypA  in  the  cytosol  and  the  NPC 
component Nup358 that has a CTD homologous to CypA (Wu et al., 1995), which has been 
shown to bind CA-NTD (Bichel et al., 2013) akin to CypA. As discussed above, such shared 
binding may enable directionality and temporal regulation to  PIC transport to and across the 
NPC, where multiple exposed CypA loops may coordinate these events.   
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C.   Does the TNPO3:IN interaction play a role post-nuclear import ? 
   The HIV-1 infectivity defect observed upon TNPO3 depletion has been reproducibly 
around 5-20-fold in experimental systems tested so far (Brass et al., 2008; Christ et al., 2008; 
Krishnan et al., 2010a; Schaller et al., 2011; De Iaco et al., 2011; Valle-Casuso et al., 2012; Shah 
et al., 2013), and in the case of another primate lentivirus, SIV, the defect can be up to 20-fold. 
Additionally, the TNPO3 dependency of WT HIV-1 does not depend on the cell cycle state of 
target cells, as pharmacological induction of growth arrest at the stage of G2->S phase with 
aphidicolin does not render HIV-1 more sensitive to the depletion of the protein (Figure 2.8; 
Schaller et al., 2011). This may imply that the role TNPO3 plays in HIV-1 PIC nuclear import is 
independent of the cell cycle state, and that it can perform its function whether or not the nuclear 
envelope is intact. This may hint at (i) an integrative step common to both cell cycle arrested and 
cycling cells, or (ii) a role of the NPC that TNPO3 may regulate, such as nuclear import and 
licensing different integration site targeting pathways. CPSF6-358 restriction, on the other hand, 
is  accentuated  upon  growth  arrest,  which  may  be  reflective  of  the  expression  levels  of 
endogenous  CPSF6  that  is  released  upon  TNPO3  knockdown  vs.  ectopically  over-expressed 
CPSF6-358  that  readily  accumulates  in  the  cytosol.  Further  comparison  of  the  different 
phenotypes were discussed in Chapter 2; E.iii.  
   The initial controversy regarding whether TNPO3 depletion resulted in a 2-LTR circle 
formation (‘nuclear import’) defect was resolved by correcting for confounding autointegration 
events, which revealed an absolute 2-4-fold decrease (Chapter 3, B.i; De Iaco et al., 2013). This, 
however, is lower than the observed 5-20-fold infectivity defect caused by TNPO3 depletion in 
respective cell lines tested. Again, a potential explanation of this observation could be that there 
may be an independent component to TNPO3 function post-nuclear import, such as a role in   127 
integration as mediated by a TNPO3:IN interaction (Christ et al., 2008; Krishnan et al., 2010a) 
that may take place within the context of the intasome (Larue et al., 2012) once inside the 
nucleus. This additional role may then synergize with the nuclear import defect imposed by 
cytoplasmically  relocalized  endogenous  CPSF6  (Chapter  3;  E.i)  and  thus  result  in  higher 
infectivity defects observed across the board in TNPO3 depleted cells. Preliminary results from 
our  research  group  imply  that  recombinant  TNPO3  may  marginally  enhance  the  in  vitro 
integration activity of HIV-1 IN, yet this phenomenon awaits a more detailed study.  
 
D.  Timing of uncoating and nuclear import: Does the incoming capsid core 
    play a licensing role or a direct structural role? How far into the nucleus 
    might CA reach?    
   As described previously in Chapter 1; D.ii.1, it is generally accepted that uncoating, to an 
indeterminate extent, takes place in the cytosol when the HIV-1 core traverses the cytoplasm 
headed to the nucleus. This process is believed to be highly regulated  in a cell-type specific 
fashion both by positive stabilizing factors; e.g. PDZD8, CypA, CPSF6 (cell-type dependent; see 
below in  E)  and  negative  destabilizing factors; e.g. TRIM5ʱ,  possibly  Mx2, CypA (may be 
concentration dependent), and CPSF6 (described in detail in Chapter 1; D.ii.1-2). It has been 
reported that intact capsid cores could be detected on the cytosolic face of NPCs by electron 
microscopy  (Arhel  et  al.,  2007).  Employing  a  functional  assay  that  takes  advantage  of  the 
TRIMCyp sensitivity of the incoming capsid only when it displays the quaternary CA lattice 
(Hulme et al., 2014) was used as a surrogate for uncoating, and a half-life of about 40 min was 
calculated for uncoating, with the process going to completion by 2 h post infection (Hulme et 
al., 2011). On the other hand, fate-of-capsid assays that are used to quantify pelletable, intact   128 
incoming cores in infected cells readily detect CA+ high molecular weight complexes at 24 h 
post  infection  (Stremlau  et  al.,  2006).  These  findings  mark  the  extremes  of  the  generally 
accepted timeline of HIV-1 early phase events where uncoating is believed to happen around 6-8 
h  post  infection,  readying  the  PIC  for  nuclear  import.  It  is  also  worth  mentioning  that 
biochemical detection of HMW CA complexes may not be taken as functional evidence for 
being precursors to mature PICs, since  ~ 85% of  viral  particles entail non-infectious events 
(Thomas et al., 2007).  
   Additionally, the observation that CA can play a functional role in PIC nuclear import 
and integration site targeting (Ocwieja et al., 2011), as described earlier in C, may or may not be 
taken as evidence for a structural presence of CA in these processes when they actually take 
place. By ‘matching’ the incoming PIC with differential NPC components at the stage of import, 
CA and its interactors; e.g. CypA, CPSF6 (Schaller et al., 2011), Nup153 (Koh et al., 2013), may 
be functioning as master regulators of distinct PIC import pathways, which lead to different 
integration site targeting. As such, CA may perform a licensing function at a pre-import stage 
with farther reaching consequences at post-import steps - even if CA may not be physically there 
inside the nucleus. 
 
E.  The role of endogenous CPSF6 in HIV-1 infection      
   Initial studies on the protein could not ascribe any function to endogenous CPSF6 in 
HIV-1 replication, because depleting it via RNAi in experimental cell lines had neither a positive 
nor a negative effect on HIV-1 infectivity (Lee et al., 2010; De Iaco et al., 2013). Additionally, 
the CPSF6-binding mutant N74D (Figure 2.7; Lee et al., 2010) repeatedly displayed WT levels 
of infectivity, implying that loss of CPSF6 binding did not bear any discernable fitness cost to   129 
the virus (Lee et al., 2010; De Iaco et al., 2011; Schaller et al., 2011; Zhou et al., 2011; Price et 
al., 2012; Koh et al., 2013). This was challenged, however, upon finding that N74D replicated 
poorly in primary macrophages, and that it was blocked prior to reverse transcription in these 
cells (Schaller et al., 2011; Towers, 2011; Ambrose et al., 2012) along with the CypA binding 
mutant P90A. It is had been shown that CypA may increase the stability of incoming viral cores 
(Li et al., 2009; De Iaco et al., 2013; Fricke et al., 2013; Shah et al., 2013) and endogenous 
CPSF6 in macrophages may serve a similar function  potentially playing a role as an HIV-1 
dependency factor that promotes capsid core integrity and reverse transcription together with 
CypA.  
   In a similar vein we had shown that N74D displayed an impaired affinity to CypA and 
that it was rendered more susceptible to pharmacological inhibition by CsA, again lending 
support to the hypothesis that CPSF6 and CypA interactions with the incoming capsid core may 
be coregulated. Prior evidence for such coordination came indirectly as several CA mutants 
affected by a CypA-dependent cellular restriction at or after nuclear import could be rescued by 
introducing secondary mutations that we now know abrogate CPSF6 binding: CA N74D/G94D 
(Ambrose et al,. 2012), CA A92E/A105T and T54A/A105T (Yang et al., 2007; Qi et al., 2008) 
are  all  rescue  mutants that do not display the original  CypA-sensitive phenotype of  G94D, 
A92E, and T54A, respectively.  
   The  reciprocal  phenotypes,  i.e.  loss  of  CypA  binding  leading  to  the  rescue  of  the 
endogenous CPSF6-dependent restriction of a HIV-1 CA mutant was recently observed in a 
physiologically  relevant  HIV-1  mutant  (Henning  et  al.,  2014).  R132K  in  the  cytotoxic  T-
lymphocyte (CTL) response escape mutant HIV-1 CA R132K/L136M (RKLM) isolated in vivo 
from  human  leukocyte  antigen  (HLA)-B27+  individuals  –  the  R132K  mutation  prevents   130 
recognition  by  the  HLA-B27  allele,  which  is  part  of  the  human  major  histocompatibility 
complex class I (MHC I) (Goulder et al., 2001) – was known to be linked to a cell cycle arrest 
phenotype (Qi et al., 2008). In this recent study, it was revealed that the restriction imposed on 
CA  RKLM  can  be  lifted  upon  CPSF6  knockdown  as  well  as  introducing  CPSF6-binding 
mutations; N74D and A105T, but also by CsA treatment or CypA depletion (Henning et al., 
2014), again highlighting the functional significance of endogenous CPSF6. It is important to 
mention, however, that HIV-1 does not prefer this escape pathway in vivo; namely losing the 
ability to bind CPSF6, as evidenced by late CTL variants that can sustain high levels of viral 
replication that still bind CPSF6, can be restricted by CPSF6-358 in vitro (Henning et al., 2014). 
These  observations  point  to  a  second  and  positive  role  of  CPSF6,  yet  these  two  opposing 
functions have not been elucidated in detail. 
    Further  evidence  for  CPSF6  playing  a  positive  role  in  HIV-1  replication  was  again 
detected in macrophages (Rasaiyah et al., 2013). The investigators observed that endogenous 
CPSF6  may  be  acting  like  a  protective  cloak  against  an  interferon–induced  cytoplasmic 
restriction  in  macrophages  that  would  otherwise  attack  the  incoming  capsid  core  causing 
premature disassembly and impaired reverse transcription (as opposed to the impaired nuclear 
import reported by Lee et al., 2010). The CPSF6 isoform they claim to be studying however is 
different than the one tested in our assays (Figures 2.6-8, 3.1; Lee et al., 2010), which lacks the 
37 codon long exon 6 corresponding to residues 231-267 on CPSF6 that lie upstream of the CA 
binding  site  within  the  proline-rich  domain  (Figure  2.2).  It  is  interesting  to  note  that  an 
independent study confirmed this unique phenotypic difference (Hori et al., 2013), i.e. a block to 
reverse transcription vs. nuclear import of the PIC, determined by the absence or presence of 
exon 6.  Accordingly, further investigation into differential  cytoplasmic  pulldown partners of   131 
each individual CPSF6 isoforms, and of the 37 codon long exon 6 itself is warranted, along with 
studies looking for effects of potential minimal CPSF6 constructs that harbor exon6 and the CA-
binding  domain  of  CPSF6  (231-322  aa;  1-321  aa,  Fricke  et  al.,  2013).  As  opposed  to  our 
previous failed attempts at expressing and purifying full length CPSF6 quantitatively (data not 
shown), we currently have an optimized protocol that may allow us to study further the role of 
exon6 within the context of recombinant full length CPSF6.    
   CPSF6-358 impairs nuclear import of the HIV-1 PIC by directly binding and targeting 
CA (Lee et al., 2010; Lee et al., 2012; Price et al., 2012), and we have shown that full length 
CPSF6 also has the ability to interact with the CA lattice (Figure 3.3). Others have shown that 
CPSF6  may  play  a  role  in  stabilizing  the  incoming  capsid  since  ectopically  expressed,  and 
cytoplasmically  localized  CPSF6  (De  Iaco  et  al.,  2013)  and  recombinantly  expressed  and 
purified CPSF6 (1-321 aa; Fricke et al., 2013) seem to enhance pelletability of intact HMW 
capsid cores, evidenced by in vitro fate-of-capsid and CA-NC pelleting assays, respectively. Our 
observation that N74D CA-NC tubes, which do not bind CPSF6, reproducibly pellet less than 
WT CA-NC tubes (Figure 3.5) in absence of an otherwise stabilizing cellular extract (Guth et al., 
2014) is in line with this model, yet one cannot disregard the possibility that these mutations may 
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APPENDIX A  
THE CA HEXAMER:HEXAMER INTERFACE AS A POTENTIAL 
MULTIFACETED BINDING SITE FOR CYPA 
     164 
A.  Introduction 
 
  We carried out preliminary structural modeling in Chapters 2 and 3 in order to project the 
full study set of CA mutants onto the incoming virion capsid surface to get a better grip of 
how  they  might  relate  to each  other,  to  the multihexameric  surface configuration  of  the 
conical capsid and also to other CA binding factors, CypA and CPSF6. The observation that 
a CypA molecule modeled onto the CA hexamer:hexamer interface was in close proximity of 
adjacent CA molecules it does not interact via CypA-loops prompted us to carefully analyze 
this hypothetical interface. As a result, we came up with structural predictions about how a 
CypA molecule may be coordinated and stabilized on a quaternary capsid surface with the 
aid  of  novel  interactions  mediated  by  neighboring  surface  CypA  loops.  We  highlighted 
candidate CA and CypA residues that may play critical roles in this hypothetical interaction. 
Our predictions may have wider implications in that they provide a mechanistic explanation 
to the workings of several CypA-sensitive, CsA-dependent CA mutants present on CypA 
loops.  Such  multifaceted  coordination  of  CypA  in  between  two  CA  hexamers  may  also 
determine the mode of CPSF6 binding and other potential CA interacting proteins. 
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B.  Methods                 
 
    Modeling is carried out in PyMol (DeLano Scientific LLC®) using publicly available 
conical capsid structures and molecular CA hexamer structures described in Zhao et al, 2013 that 
used CA A92E mutant capsids for reference (PDB: 1VU5). The atomic structure of CypA was 
obtained  from  the  CypA:CA-NTD  crystal  structure  described  in  Gamble  et  al.,1996  (PDB: 
1AK4). 
    Two adjacent CA hexamers (1VU5_hijklm & 1VU5_uvwxyz) together with a CypA:CA 
NTD structure (1AK4_BC) were modeled by aligning the Cʱ backbone of 1AK4_C (CA-NTD, 
not shown) with the Cʱ backbone of 1VU5_i (CA-NTD2). Accordingly, CypA (1AK4_B) is 
modeled  onto  the  interhexameric  space  in  the  vicinity  of  two  neighboring  CA  molecules; 
1VU5_y (CA-NTD1) and 1VU5_z (CA-NTD3) of the adjacent CA-hexamer, 1VU5_uvwxyz.   
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C.   Results 
 
C.i.  Molecular modeling of CypA onto the CA hexamer:hexamer interface and  
the description of the hypothetical secondary CA : CypA interface 
 
 
Figure A.1 The CA-NTD2:CypA:CA-NTD1/3 interhexamer bridging model. CypA (1AK4_B) that is 
attached to CA-NTD2 (upon alignment) within the CA hexamer on the right (1VU5_hijklm) is in close 
proximity of CA-NTD1 (1VU5_y) and CA-NTD3 (1VU5_z) on the adjacent CA hexamer to the left 
(1VU5_uvwxyz).  (A)  Side  view  depicting  the  hypothetical  bridge.  (B)  Top  view  depicting  the 
hypothetical interface between CypA:CA-NTD1/3 
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In this particular model (Figure A.1), the two adjacent CA hexamers, 1VU5_hijklm & 
1VU5_uvwxyz  are  rather  planar  along  the  axis  of  the  viral  capsid  cone  and  thus  the 
interhexameric space is rather narrow allowing the modeled CypA molecule to bridge the two 
CA hexamers. A detailed view from the top of this hypothetical interface reveals how the CypA 
molecule (modeled as attached to CA-NTD2) is enclosed within the flexible surface loops of 
CA-NTD1  and  CA-NTD3  that  bear  biologically  significant  residues  with  CypA-related 
phenotypes (Figure A.2).  
 
 
Figure  A.2  The  CA-NTD2:CypA:CA-NTD1/3  interhexamer  bridging  model,  with  CA  residues 
responsible for CypA-related phenotypes highlighted. Top view. 
 
   168 
  The  model,  as  it  is,  depicts  a  static  configuration  of  all  the  individual  molecules  in 
relation  to  each  other.  The  proposed  secondary  interface,  in  actuality,  has  three  degrees  of 
freedom: (i) the flexible CypA-loop of CA-NTD2 (1VU5_i) that the CypA molecule is attached 
to, (ii) the flexible CypA-loop of CA-NTD1 (1VU5_y), and (ii) the flexible CypA-loop of CA-
NTD3 (1VU5_z) (Figure A.2). 
 
 
Figure  A.3  The  CA-NTD2:CypA:CA-NTD1/3  interhexamer    bridging  model,  with  potential  CypA 
residues  lining  the  secondary  CypA:CA  interface  highlighted.  Head  on  view  to  CypA  from  the 
perspective of the neighboring CA hexamer (CA-NTD1 & CA-NTD3). 
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  According to the model, previously identified CA-NTD surface loop residues A92, G94 
and N121, all of which can render HIV-1 CsA-dependent and CypA-sensitive upon mutation 
(A92E,  G94D,  N121K), surround the CypA molecule from the opposite side of where it is 
attached to the CA-NTD2 CypA loop (G89-P90) via its active site residue, F60 (Braaten et al., 
1997).  CA-NTD  H87  is  also  found  at  this  interface  (Figure  A.2),  which  upon  mutating  to 
H87P/Q can affect CypA incorporation into virions (Gatanaga et al., 2006).  
  Another  perspective  (Figure  A.3)  reveals  the  CypA  residues  facing  this  hypothetical 
interface.  CypA  residues  K28,  K31,  R37,  K44,  K76,  and  K91  are  highlighted  due  to  their 
potential for electrostatic interactions with the CypA-loop mutants A92E and G94D on CA-
NTD1 and CA-NTD3, taking into account the three degrees of structural freedom mentioned 
earlier. The most dramatic juxtaposition between CypA and the neighboring CA hexamer is 
where CypA K28 comes in close proximity of CA-NTD3 A92E (the ε-amino group of CypA 
K28 is ~ 4.6 Å from the γ carboxyl group of CA-NTD3 A92E) and where CypA R37 and K44 
approach CA-NTD1 A92E (the guanidine group of CypA R37 and the ε-amino group CypA K44 
are ~ 5.9 Å and ~ 4.6 Å away from CA-NTD1 A92E, respectively). Another CypA residue E34 
may swing close enough to CA N121, potentially enabling electrostatic interactions with N121K; 
another CypA-dependent mutant of CA.   
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D.  Discussion 
  As  mentioned  in  the  Introduction,  research  on  the  molecular  architecture  of  the 
supramolecular  CypA:capsid  structure  has  been  lagging  behind  our  understanding  of  the 
quaternary capsid structure. CypA has been a prominent yet elusive cellular factor regulating 
HIV-1  infection  via  its  interaction  with  CA  resulting  in  phenotypes  affecting  almost  all 
replicative steps leading up to provirus formation.  
  Given  the  known  conical  topology  of  the  HIV-1  capsid  coat  (Zhao  et  al.,  2013), 
interhexameric spacing and angles vary along different axes of the capsid cone. Thus, the model 
does neither propose that all interhexameric spacings along the cone can accommodate such a 
bridging,  nor  does  it  predict  that  such  a  secondary  interface  will  be  formed  by  all  CypA 
molecules attached to the core. But the capsid cone has a planar surface along its vertical axes 
(Figure 1.5) that minimizes the interhexameric spacing, and thus may support such bridging. 
From another perspective CypA is a cellular factor that may regulate core stability (Li et al., 
2009; Shah et al., 2013), and it is intuitive that core (supramolecular intermultimeric) stability 
might  be  modulated  by  strengthening  or  weakening  interhexameric  interactions  (CA-
NTD2:CypA:CA-NTD1/3) rather than CA-NTD2:CypA only (Figure A.2). 
  In  the  case  of  WT  HIV-1  capsid,  the  hypothetical  secondary  interface,  enabled  by 
neighboring flexible surface CypA loops, may aid interhexameric stability by hydrophobic or 
electrostatic  interactions  between  CypA  and  adjoining  CA-NTD1/3.  The  CypA  residues 
highlighted in Figure A.3 may or may not be responsible for such interactions, even though the 
revelation that CypA-dependent mutants face these basic residues makes it tempting to speculate 
so. Thus the model predicts that CypA is held in place in between two hexamers by its canonical 
interaction  with  the  CA-NTD2  CypA  loop  (G89-P90)  at  its  active  site  (F60),  and  by   171 
noncanonical - and probably weaker - interactions with the CypA loops of CA-NTD1/3 at its 
opposite end, independent from its active site. 
  It is worth emphasizing that while interpreting this hypothetical structure it was assumed 
that the reference CA A92E lattice and the positioning of the mutant CypA loops (Zhao et al., 




D.i.   Implications for CypA-sensitive, CsA-dependent HIV-1 CA mutants 
 
  The two more established CypA-sensitive, CsA-dependent mutants of the CypA loop; i.e. 
A92E and G94D, both carry a negative charge. Our current knowledge refutes the hypothesis 
that  these  may  be  loss-of  function  mutants  with  regards  to  CypA  binding.  The  alternative 
explanation, i.e. that the restricted phenotype of these mutants may be due to a gain of function 
such as CypA binding while under CsA selection (Aberham et al., 1996), has not been addressed. 
The negative charge on these two mutant residues prompted us to look for potential amino acids 
on CypA at this non-canonical interface, which  may enable electrostatic interactions.  In our 
static model, the ε-amino group of CypA K28 is in close proximity (~ 4.6 Å) of the γ carboxyl 
group of CA-NTD3 A92E; and the guanidine group of CypA R37 and the ε-amino group CypA 
K44 are ~ 5.9 Å and ~ 4.6 Å away from CA-NTD1 A92E, respectively. Though not as close, 
CypA  K31,  K76  and  K91  also  face  the  mutated  CA-NTD  CypA  loops  at  this  hypothetical 
interface. As mentioned before, CypA is attached to CA-NTD2 via a flexible CypA-loop, and 
both CA-NTD1 and CA-NTD3 CypA loops are flexible themselves, which may even allow 
closer spacing between CypA and the CA-NTD1/3 CypA loops.    172 
  Our working hypothesis is that by enabling electrostatic interactions these mutants may 
be stabilizing this hypothetical noncanonical interface to the detriment of HIV-1, since a rigid 
CypA bridge with both ends locked tight onto the hexameric lattice may cause aberrant stability 
or may limit exposure of CA surfaces beneath that may need to be utilized by other cellular 
cofactors (Figure A.2 & Figure 2.10). Similary, the recently identified CypA-sensitive, CsA-
dependent  phenotype of  CA N121K  (Takemura et al., 2013)  might  also  stem from such an 
additional interaction with CypA at this interface. A potential point of interaction could be CypA 
E34 in this case.  
  Thus the model suggests that the CsA-dependent phenotype of HIV CA mutants such as 
A92E, G94D, N121K may be due to the need of HIV-1 for a single flexible CA-NTD2:CypA 
hinge only but not a rigid CA-NTD2:CypA:CA-NTD1/3 bridge. In the presence of CsA, CypA 
binding  to  CA-NTD2  would  be  inhibited,  yet  the  aforementioned  CsA-dependent  mutations 
might  allow  continuing  CypA  association  with  the  capsid  core,  albeit  at  a  possibly  weaker 
interface.  
  Supporting this model, there are two reports of functional evidence for A92E conferring 
an ability for CA to interact with CypA even when the primary interaction at the CypA active 
site is inhibited: CA P90A/A92E, which harbors P90A (a CypA binding mutant) is actually 
sensitive to Cyp-mediated TRIMCyp restriction in OMK cells when compared to P90A mutant 
virus (Hatziioannou et al., 2004; Diaz-Griffero et al., 2006). In the absence of CsA however, 
CypA would be locked onto its place, to the detriment of these mutants. The weak interactions 
allowed by WT CA may aid HIV-1 infectivity, though they may not be enough to utilize CypA 
in the presence of CsA, when primary binding to CA-NTD2 is inhibited (Figure A.3). The model 
may not account for the phenotypes of all CypA-sensitive mutants: T54A (hypostable cores) and   173 
E45A (hyperstable cores) both face away from the CypA molecule spanning the CA-NTDs on 
the surface and their phenotype may be rather due to some intrinsic stability defect, which may 
indirectly affect PIC import and integration. 
 
D.ii.  Implications for other CA-binding proteins 
  As  shown  in  a  CA-NTD:CPSF6  15-mer  cocrystal,  and  then  modeled  onto  the 
hexamer:hexamer  interface  in  Figure  2.10,  CPSF6  is  believed  to  bind  CA-NTD  within  this 
surface  pocket  lined  by  helix  4  that  faces  the  interhexameric  space.  With  CypA  potentially 
capping this interspace and with CPSF6 being much larger than the pocket itself (and possibly 
having to bury the CA-interacting loop into this pocket from above), it is probable that access of 
CPSF6 may be modulated by the CypA cap. Alternatively, CypA and CPSF6 may modulate or 
require the presence/function of each, even though we have not yet been able to find strong 
evidence  suggestive  of  such  modulation  in  Chapter  3.  CypA  has  been  shown  to  modulate 
TRIM5ʱ recognition and activity (Stremlau et al., 2006b). This may stem from CypA having a 
stabilizing effect on the capsid lattice, whose superstructural integrity is required by TRIM5ʱ for 
recognition (Towers et al., 2003).    
  The observation that CA N74D/G94D (Ambrose et al,. 2012) and CA A92E/A105T and 
T54A/A105T  (Yang  et  al.,  2007)  are  rescued  from  their  respective  CsA-dependent,  CypA-
sensitive phenotypes (G94D, A92E, T54A) is further support that there may be a functional talk 
between  CPSF6  (both  N74D  and  A105T  render  HIV-1  CPSF6-358  resistant  by  impaired 
binding, De Iaco et al., 2013) and CypA, though the details of such interaction is currently 
beyond our understanding. However the observation that A92E can either be rescued by N74D (a 
CPSF6-binding mutant; De Iaco et al., 2013) or P90A (a CypA binding mutant; Li et al., 2009)   174 
in  HeLa  cells  hints  that  this  historically  labeled  CypA-dependent  restriction  may  rather  be 
CypA/CPSF6-dependence.  Structural  and  biochemical  efforts  trying  to  understand  this 
quaternary relationship on the CA hexamer:hexamer interface should be immensely informative 
to deepen our understanding.  
  It is noteworthy that RanBP2/Nup358, which has proposed roles in mediating HIV-1 PIC 
nuclear  entry  and  integration  site  targeting  (Zhang  et  al.,  2010;  Ocwieja  et  al.,  2011),  also 
harbors  a  C-terminal  Cyp  domain  (Wu  et  al.,  1995)  and  may  also  be  utilizing  such 
interhexameric bridging in its interaction with CA (Bichel et al., 2013). Additional cell type 
dependent cofactors (some of which may be harboring Cyp-domains themselves, Davis et al., 
2010) may also be modulating CPSF6 and CypA binding to CA, adding yet another layer of 
complexity. 
 
D.iii.  Future experiments proposed to test the model   
  Biochemical  assays  testing  for  interaction  would  be  most  informative.  The  proposed 
secondary  interface  on  a  CA  hexamer  can  be  produced  biochemically  as  a  stable  hexamer 
(Pornillos et al., 2009). One could then devise a binding assay between this construct and active 
site mutant CypA (F60A or R55A) wherein any binding to the CypA loop mediated by CypA 
active site would be precluded. The effect of proposed residues (C.i) on CA-NTD1/3 and CypA 
that  may  mediate  secondary  interactions  can  then  be  assayed.  Given  that  such  secondary 
interactions are strong enough, binding to mutant CA (A92E/G94D/N121K) may be detected 
even with an active site mutant of CypA (F60A). 
  Based  on  the  hypothesis  that  the  secondary  interface  may  be  strengthened/further 
stabilized in the case of A92E/G94D/N121K (gain of function/binding mutants), CypA binding   175 
to these mutant CA hexamers may be less/not affected by CsA. Alternatively, CypA residues 
highlighted in Figure A.3 (K28, K31, R37, K44, K76, K91) can be mutated to reverse charges 
and then tested for binding to CA mutants A92E/G94D; or in the case of E34 to N121K.  
  Alternative  structural  determination methods  such  as  3D  cryoEM  imaging  and  NMR 
studies  on  CypA:CA  complexes  may  shed  light  into  the  existence  of  such  a  noncanonical 
CypA:CA interaction. We set up a collaboration with Dr. Zhang (University of Pittsburgh – 
Department of Structural Biology) and Dr. Polenova (University of Delaware – Department of 
Chemistry and Biochemistry) to test the model employing these methods. Preliminary reports 
confirm the presence of such a novel noncanonical interaction between CypA and adjacent CA 
hexamer though the data awaits a careful analysis and independent confirmation and thus were 
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